

(19) **DANMARK**

(10) **DK/EP 2911687 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **A 61 K 38/36 (2006.01)** **A 61 K 48/00 (2006.01)** **C 12 N 15/86 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-05-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-02-13**
- (86) Europæisk ansøgning nr.: **13789223.8**
- (86) Europæisk indleveringsdag: **2013-10-25**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-09-02**
- (86) International ansøgning nr.: **EP2013072450**
- (87) Internationalt publikationsnr.: **WO2014064277**
- (30) Prioritet: **2012-10-26 WO PCT/EP2012/071297** **2013-07-03 WO PCT/EP2013/064054**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussel, Belgien**
- (72) Opfinder: **VANDENDRIESSCHE, Thierry, Tiensesteenweg 250, B-3360 Bierbeek, Belgien**
CHUAH, Marinee, Tiensesteenweg 250, B-3360 Bierbeek, Belgien
- (74) Fuldmægtig i Danmark: **HØIBERG P/S, Adelgade 12, 1304 København K, Danmark**
- (54) Benævnelse: **Vektor til levermålrettet gentterapi af hæmofili og fremgangsmåder og anvendelse deraf**
- (56) Fremdragne publikationer:
WO-A1-2009/130208
WO-A1-2011/005968
A. CANTORE ET AL: "Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice", BLOOD, vol. 120, no. 23, 4 October 2012 (2012-10-04), pages 4517-4520, XP055050690, ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-432591 cited in the application
SCHUETTRUMPF JOERG ET AL: "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 6, 15 March 2005 (2005-03-15), pages 2316-2323, XP002555907, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2004-08-2990 [retrieved on 2004-11-18] cited in the application
ZHIJIAN WU ET AL: "Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose", MOLECULAR THERAPY, vol. 16, no. 2, 1 February 2008 (2008-02-01), pages 280-289, XP055097643, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300355 cited in the application

DESCRIPTION

FIELD OF THE INVENTION

[0001] The invention relates to expression vectors for gene therapy with improved liver-specific expression capabilities, particularly for use as a gene therapy means for the treatment of hemophilia, more particularly for restoring coagulation factor IX (FIX) in liver-directed gene therapy of hemophilia B.

BACKGROUND OF THE INVENTION

[0002] Hemophilia B is an X-linked, recessive bleeding disorder caused by deficiency of clotting factor IX (FIX). The clinical presentation for hemophilia B is characterized by episodes of spontaneous and prolonged bleeding. There are an estimated 1 in 20,000 individuals who suffer from hemophilia B. Currently, hemophilia B is treated with protein replacement therapy using either plasma-derived or recombinant FIX. Although FIX protein replacement markedly improved the life expectancy of patients suffering from hemophilia, they are still at risk for severe bleeding episodes and chronic joint damage, since prophylactic treatment is restricted by the short half-life, the limited availability and the high cost of purified FIX, which can approach 100.000\$/patient/year. In addition, the use of plasma-derived factors obtained from contaminated blood sources increases the risk of viral transmission. Gene therapy offers the promise of a new method of treating hemophilia B, since the therapeutic window is relatively broad and levels slightly above 1% of normal physiologic levels are therapeutic. If successful, gene therapy could provide constant FIX synthesis which may lead to a cure for this disease. The different modalities for gene therapy of hemophilia have been extensively reviewed (Chuah et al., 2012a, 2012b, 2012c; VandenDriessche et al., 2012; High 2001, 2011; Matrai et al., 2010a, 2010b).

[0003] Hemophilia A is a serious bleeding disorder caused by a deficiency in, or complete absence of, the blood coagulation factor VIII (FVIII). The severity of hemophilia A and hemophilia B has been classified by the subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis into three forms, depending on respectively, the FVIII level and the FIX level: 1) severe form (FVIII or FIX level less than 0.01 international units (IU)/ml, i.e. less than 1% of normal FVIII or FIX level), 2) moderate form (FVIII or FIX level from 0.01 to 0.05 IU/ml, i.e. from 1 to 5% of normal FVIII or FIX level), and 3) mild form (FVIII or FIX level higher than 0.05 to 0.4 IU/ml, i.e. higher than 5 to 40% of normal FVIII or FIX level). Hemophilia A is the most common hereditary coagulation disorder with an incidence approaching approximately 1 in 5000 males.

[0004] Protein substitution therapy (PST) with purified or recombinant FVIII has significantly

improved the patients' quality of life. However, PST is not curative and patients are still at risk of developing potentially life-threatening hemorrhages and crippling joint inflammation. Unfortunately, many patients suffering from hemophilia A (up to 40%) develop neutralizing antibodies to FVIII (i.e. "inhibitors") following PST. These inhibitors complicate the management of bleeding episodes and can render further PST ineffective. These limitations of PST, justify the development of gene therapy as a potential alternative for hemophilia treatment. Furthermore, only a modest increase in FVIII plasma concentration is needed for therapeutic benefit, with levels of more than 1% of normal levels able to achieve markedly reduced rates of spontaneous bleeding and long-term arthropathy.

[0005] The liver is the main physiological site of FIX and FVIII synthesis and hence, hepatocytes are well suited target cells for hemophilia gene therapy. From this location, FIX protein can easily enter into the circulation. Moreover, the hepatic niche may favor the induction of immune tolerance towards the transgene product (Annoni et al., 2007; Follenzi et al., 2004; Brown et al., 2007; Herzog et al., 1999; Matrai et al., 2011; Matsui et al., 2009). Liver-directed gene therapy for hemophilia can be accomplished with different viral vectors including retroviral (Axelrod et al., 1990; Kay et al., 1992; VandenDriessche et al., 1999, Xu et al., 2003, 2005), lentiviral (Ward et al., 2011, Brown et al., 2007, Matrai et al., 2011), adeno-associated viral (AAV) (Herzog et al., 1999) and adenoviral vectors (Brown et al., 2004) (Ehrhardt & Kay, 2002). In particular, AAV is a naturally occurring replication defective non-pathogenic virus with a single stranded DNA genome. AAV vectors have a favorable safety profile and are capable of achieving persistent transgene expression. Long-term expression is predominantly mediated by episomally retained AAV genomes. More than 90% of the stably transduced vector genomes are extra-chromosomal, mostly organized as high-molecular-weight concatamers. Therefore, the risk of insertional oncogenesis is minimal, especially in the context of hemophilia gene therapy where no selective expansion of transduced cells is expected to occur. Nevertheless, oncogenic events have been reported following AAV-based gene transfer (Donsante et al., 2007) but it has been difficult to reproduce these findings in other model systems (Li et al., 2011). The major limitation of AAV vectors is the limited packaging capacity of the vector particles (i.e. approximately 4.7 kb), constraining the size of the transgene expression cassette to obtain functional vectors (Jiang et al., 2006). Several immunologically distinct AAV serotypes have been isolated from human and non-human primates (Gao et al., 2002, Gao et al. 2004), although most vectors for hemophilia gene therapy were initially derived from the most prevalent AAV serotype 2. The first clinical success of AAV-based gene therapy for congenital blindness underscores the potential of this gene transfer technology (Bainbridge et al., 2008).

[0006] AAV-mediated hepatic gene transfer is an attractive alternative for gene therapy of hemophilia for both liver and muscle-directed gene therapy (Herzog et al., 1997, 1999, 2002; Arruda et al., 2010; Fields et al., 2001; Buchlis et al., 2012; Jiang et al., 2006; Kay et al., 2000). Preclinical studies with the AAV vectors in murine and canine models of hemophilia or non-human primates have demonstrated persistent therapeutic expression, leading to partial or complete correction of the bleeding phenotype in the hemophilic models (Snyder et al., 1997, 1999; Wang et al., 1999, 2000; Mount et al., 2002; Nathwani et al., 2002). Particularly, hepatic

transduction conveniently induces immune tolerance to FIX that required induction of regulatory T cells (Tregs) (Mingozzi et al., 2003; Dobrzynski et al., 2006). Long-term correction of the hemophilia phenotype without inhibitor development was achieved in inhibitor-prone null mutation hemophilia B dogs treated with liver-directed AAV2-FIX gene therapy (Mount et al., 2002). In order to further reduce the vector dose, more potent FIX expression cassettes have been developed. This could be accomplished by using stronger promoter/enhancer elements, codon-optimized FIX or self-complementary, double-stranded AAV vectors (scAAV) that overcome one of the limiting steps in AAV transduction (i.e. single-stranded to double-stranded AAV conversion) (McCarty, 2001, 2003; Nathwani et al., 2002, 2006, 2011; Wu et al., 2008). More particularly, Wu et al. (2008) discloses optimized scAAV vectors for liver-directed gene delivery comprising a transthyretin (TTR) enhancer-promoter, an MVM intron, codon-optimized hFIX cDNA and a polyadenylation signal, resulting in increased transgene expression in the liver and a sustained correction of hemophilia B at low vector dose in mice. Wu et al. are however completely silent on the use of the Serpin enhancer and on mutated FIX containing a hyper-activating R338L mutation. Alternative AAV serotypes could be used (e.g. AAV8 or AAV5) that result in increased transduction into hepatocytes, improve intra-nuclear vector import and reduce the risk of T cell activation (Gao et al., 2002; Vandenberghe et al., 2006). Liver-directed gene therapy for hemophilia B with AAV8 or AAV9 is more efficient than when lentiviral vectors are used, at least in mice, and resulted in less inflammation (VandenDriessche et al., 2007, 2002). Furthermore, recent studies indicate that mutations of the surface-exposed tyrosine residues allow the vector particles to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation, which resulted in a 10-fold increase in hepatic expression of FIX in mice (Zhong et al., 2008).

[0007] These liver-directed preclinical studies paved the way toward the use of AAV vectors for clinical gene therapy in patients suffering from severe hemophilia B. Hepatic delivery of AAV-FIX vectors resulted in transient therapeutic FIX levels (maximum 12% of normal levels) in subjects receiving AAV-FIX by hepatic artery catheterization (Kay et al., 2000). However, the transduced hepatocytes were able to present AAV capsid-derived antigens in association with MHC class I to T cells (Manno et al., 2006; Mingozzi et al., 2007). Although antigen presentation was modest, it was sufficient to flag the transduced hepatocytes for T cell-mediated destruction. Recently, gene therapy for hemophilia made an important step forward (Nathwani et al., 2011; Commentary by VandenDriessche & Chuah, 2012). Subjects suffering from severe hemophilia B (<1% FIX) were injected intravenously with self-complementary (sc) AAV8 vectors expressing codon-optimized FIX from a liver-specific promoter. This AAV8 serotype exhibits reduced cross-reactivity with pre-existing anti-AAV2 antibodies. Interestingly, its uptake by dendritic cells may be reduced compared to conventional AAV2 vectors, resulting in reduced T cell activation (Vandenberghe et al., 2006). In mice, AAV8 allows for a substantial increase in hepatic transduction compared to AAV2, though this advantage may be lost in higher species, like dog, rhesus monkeys and man. Subjects received escalating doses of the scAAV8-FIX vector, with two participants per dose. All of the treated subjects expressed FIX above the therapeutic 1% threshold for several months after vector administration, yielding sustained variable expression levels (i.e. 2 to 11% of normal levels). The main difference with the previous liver-directed AAV trial is that for the first time sustained therapeutic FIX levels

could be achieved after gene therapy. Despite this progress, T-cell mediated clearance of AAV-transduced hepatocytes remains a concern consistent with elevated liver enzyme levels in some of the patients. Transient immune suppression using a short course of glucocorticoids was used in an attempt to limit this vector-specific immune response.

[0008] One of the significant limitations in the generation of efficient viral gene delivery systems for the treatment of hemophilia A by gene therapy is the large size of the FVIII cDNA. Previous viral vector-based gene therapy studies for hemophilia A typically relied on the use of small but weak promoters, required excessively high vector doses that were not clinically relevant or resulted in severely compromised vector titers. Several other *ad hoc* strategies were explored, such as the use of split or dual vector design to overcome the packaging constraints of AAV, but these approaches were overall relatively inefficient and raised additional immunogenicity concerns (reviewed in Petrus et al., 2010). It has been found that the FVIII B domain is dispensable for procoagulant activity. Consequently, FVIII constructs in which the B domain is deleted are used for gene transfer purposes since their smaller size is more easily incorporated into vectors. Furthermore, it has been shown that deletion of the B domain leads to a 17-fold increase in mRNA and primary translation product. FVIII wherein the B domain is deleted and replaced by a short 14-amino acid linker is currently produced as a recombinant product and marketed as Refacto® for clinical use (Wyeth Pharma) (Sandberg et al., 2001). Miao et al. (2004) added back a short B domain sequence to a B domain deleted FVIII, optimally 226 amino acids and retaining 6 sites for N-linked glycosylation, to improve secretion. McIntosh et al. (2013) replaced the 226 amino-acid spacer of Miao et al. with a 17 amino-acid peptide in which six glycosylation triplets from the B-domain were juxtaposed. Yet, production was still not sufficient for therapeutic purposes.

[0009] Non-viral vectors typically rely on a plasmid-based gene delivery system, where only the naked DNA is delivered, potentially in conjunction with physicochemical methods that facilitate transfection. Consequently, the non-viral approach maybe less immunogenic and potentially safer than viral vectors, though innate immune response may still occur. The non-viral gene transfer method is simple, but the efficiency is generally low compared to most viral vector-mediated gene transfer approaches. Efficient *in vivo* gene delivery of non-viral vectors remains a bottleneck. Typically, for hepatic gene delivery, plasmids are administered by hydrodynamic injection. In this case, a hydrodynamic pressure is generated by rapid injection of a large volume of DNA solution into the circulation, in order to deliver the gene of interest in the liver (Miao et al., 2000). Efforts are being made to adapt hydrodynamic injection towards a clinically relevant modality by reducing the volume of injection along with maintaining localized hydrodynamic pressure for gene transfer. Alternative approaches based on targetable nanoparticles are being explored to achieve target specific delivery of FIX into hepatocytes. Expression could be prolonged by removing bacterial backbone sequences which interfere with long term expression (i.e. mini-circle DNA) Finally, to increase the stability of FIX expression after non-viral transfection, transposons could be used that result in stable genomic transgene integration. We and others have shown that transposons could be used to obtain stable clotting factor expression following *in vivo* gene therapy (Yant et al., 2000; Mates, Chuah et al., 2009, VandenDriessche et al., 2009; Kren et al., 2009; Ohlfest et al., 2004).

[0010] An exemplary state of the art vector for liver-specific expression of FIX is described in WO2009/130208 and is composed of a single-stranded AAV vector that contains the TTR/Serp regulatory sequences driving a factor cDNA. A FIX first intron was included in the vector, together with a poly-adenylation signal. Using said improved vector yielded about 25-30% stable circulating factor IX. WO 2009/130208 does not teach nor suggest the inclusion of an MVM intron into the vector, nor the use of a codon-optimized human FIX gene containing a hyper-activating R338L mutation.

[0011] In order to translate viral-vector based gene therapy for hemophilia to the clinic, the safety concerns associated with administering large vector doses to the liver and the need for manufacturing large amounts of clinical-grade vector must be addressed. Increasing the potency (efficacy per dose) of gene transfer vectors is crucial towards achieving these goals. It would allow using lower doses to obtain therapeutic benefit, thus reducing potential toxicities and immune activation associated with in vivo administration, and easing manufacturing needs.

[0012] One way to increase potency is to engineer the transgene sequence itself to maximize expression and biological activity per vector copy. We have shown that FIX transgenes optimized for codon usage and carrying an R338L amino acid substitution associated with clotting hyperactivity and thrombophilia (Simioni et al., 2009), increase the efficacy of gene therapy using lentiviral vector up to 15-fold in hemophilia B mice, without detectable adverse effects, substantially reducing the dose requirement for reaching therapeutic efficacy and thus facilitating future scale up and its clinical translation (Cantore et al., 2012).

[0013] Also codon optimization of human factor VIII cDNAs leads to high-level expression. Significantly greater levels (up to a 44-fold increase and in excess of 200% normal human levels) of active FVIII protein were detected in the plasma of neonatal hemophilia A mice transduced with lentiviral vector expressing FVIII from a codon-optimized cDNA sequence, thereby successfully correcting the disease model (Ward et al., 2011). International patent application WO 2011/005968 discloses codon-optimized sequence of human blood clotting factor VIII, including codon-optimized B domain deleted human FVIII.

[0014] It is an object of the present invention to increase the efficiency and safety of liver-directed gene therapy for hemophilia B.

SUMMARY OF THE INVENTION

[0015] It is an object of the present invention to increase the efficiency and safety of liver-directed gene therapy for hemophilia B. The above objective is accomplished by providing an AAV-based vector comprising a nucleic acid expression cassette with a Serpin enhancer defined by SEQ ID NO:8 or a sequence having 95% identity to said sequence that enhance liver-directed gene expression, while retaining tissue specificity, in conjunction with the use of a human FIX gene containing a hyper-activating R338L mutation and a codon-optimized

transgene, a promoter, a minute virus of mice (MVM) intron and a transcriptional termination signal.

[0016] The resulting vector and nucleic acid expression cassette results in unexpectedly high expression levels of FIX in the liver, due to its unique combination of regulatory elements and the choice of vector type and transgene. The combined effect of these elements could not have been predicted. In WO2009/130208 for example, the given AAV-based vector yielded about 25-30% stable circulating factor IX. In the current application the new vector obtained 500-600% of stable circulating factor IX levels. This represents a more than 20-fold increase in FIX levels due to the unique combination of elements of the nucleic acid expression cassette and vector of the present invention. In particular, the inventors demonstrated in Example 7 that specific combinations of the Serpin enhancer (called "Serp" or "SerpEnh" herein) with codon-optimized hFIX transgene or the Serpin enhancer with transgene encoding hFIX containing the Padua mutation provide for synergistic effects on FIX activity. The highest hFIX activity was measured in mice hydrodynamically injected with a plasmid comprising the unique combination of the Serpin enhancer with a codon-optimized transgene encoding hFIX containing the Padua mutation. hFIX activity in these mice was up to 265-fold higher as compared to hFIX activity in mice injected with a corresponding hFIX plasmid without the Serpin enhancer, the codon-optimization and the Padua mutation. This increase in hFIX activity was shown to be synergistic.

[0017] The invention therefore provides the following aspects:

Aspect 1. A vector comprising a nucleic acid expression cassette comprising a Serpin enhancer defined by SEQ ID NO:8 or a sequence having 95% identity to said sequence, a promoter, a minute virus of mouse (MVM) intron, a codon-optimized coagulation factor IX containing a hyperactivating mutation, and a transcriptional termination signal, wherein the vector is a viral vector derived from an adeno-associated virus (AAV) and wherein said hyperactivating mutation is an R338L amino acid substitution.

Aspect 2. The vector according to aspect 1, wherein said promoter is derived from the transthyretin (TTR) promoter, preferably the minimal TTR promoter.

Aspect 3. The vector according to any one of aspects 1 or 2, wherein said transcriptional termination signal is derived from the bovine growth hormone polyadenylation signal or from the Simian virus 40 polyadenylation signal.

Aspect 4. The vector according to any one of aspects 1 to 3, wherein said vector is AAV serotype 9.

Aspect 5. The vector according to any one of aspects 1 to 4, wherein said vector is a single-stranded AAV, preferably single-stranded AAV serotype 9.

Aspect 6. The vector according to any one of aspects 1 to 5, having SEQ ID NO: 1 or 2.

Aspect 7. The vector according to any one of aspects 1 to 4, wherein said vector is a self-

complementary AAV, preferably self-complementary AAV serotype 9.

Aspect 8. A method to obtain levels of factor IX in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml plasma in a subject, comprising the transduction of the vector according to any one of aspects 1 to 5, 7 into a subject.

Aspect 9. The method according to aspect 8, wherein the transduction of the vector according to any one of aspects 1 to 5, 7 into the subject is done at a dose lower than 2×10^{11} vg/kg.

Aspect 10. The method according to aspect 8, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 100 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 to 5, 7 into the subject is done at a dose lower than or equal than 6×10^{11} vg/kg.

Aspect 11. The method according to aspect 8, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 50 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 to 5, 7 into the subject is done at a dose lower than or equal than 6×10^{11} vg/kg.

Aspect 12. The method according to aspect 8, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 200 mU/ml in a subject, wherein the transduction of the vector according to any one of aspects 1 to 5, 7 into the subject is done at a dose lower than or equal than 2×10^{12} vg/kg.

Aspect 13. The method according to aspect 8, used to obtain levels of factor IX in plasma equal to or higher than the therapeutic concentration of 150 mU/ml in a subject, wherein the transduction of the vector according to any one of claims 1 to 5, 7 into the subject is done at a dose lower than or equal than 2×10^{12} vg/kg.

Aspect 14. The method according to any one of aspects 8 to 13, wherein said transduction is by intravenous administration.

Aspect 15. The method according to any one of aspects 8 to 14, wherein said subject is a mammalian subject, preferably a human subject.

Aspect 16. A method for treating hemophilia B in a mammalian subject, comprising performing the method according to any one of aspects 8 to 15.

Aspect 17. The use of the vector according to any one of aspects 1 to 5, 7 for the manufacture of a medicament to treat hemophilia B.

Aspect 18. The vector according to any one of aspects 1 to 5, 7 for use in the treatment of hemophilia B.

Aspect 19. A pharmaceutical composition comprising a vector according to any one of aspects 1 to 5, 7 and a pharmaceutically acceptable carrier, optionally further comprising an active ingredient for treating hemophilia B.

Aspect 20. The pharmaceutical composition according to aspect 19 use in treating hemophilia B.

Aspect 21. The pharmaceutical composition for use according to aspect 20, or the vector for use according to aspect 18, wherein said treatment results in levels of factor IX in plasma of the treated subject that are equal to or higher than the therapeutic threshold concentration of 10 mU/ml plasma in a subject, preferably equal to or higher than the therapeutic concentration of 50 mU/ml plasma in a subject, more preferably equal to or higher than the therapeutic concentration of 100 mU/ml plasma in a subject, even more preferably equal to or higher than the therapeutic concentration of 150 mU/ml plasma in a subject and even more preferably equal to or higher than the therapeutic concentration of 200 mU/ml plasma in a subject.

Aspect 22. The pharmaceutical composition for use according to aspect 20 or 21, or the vector for use according to aspect 18 or 21, wherein said treatment comprises the transduction of the vector according to any one of aspects 1 to 5, 7 into the subject at a dose lower than or equal than 2×10^{12} vg/kg, preferably at a dose lower than or equal than 6×10^{11} vg/kg, more preferably at a dose lower than or equal than 2×10^{11} vg/kg.

BRIEF DESCRIPTION OF THE FIGURES

[0018] The present invention is illustrated by the following figures which are to be considered for illustrative purposes only and in no way limit the invention to the embodiments disclosed therein:

Figure 1 A) shows a schematic diagram of the AAV9-SerpEnh-TTRm-MVM-co-hFIX construct (pdsAAVsc SerpTTRmMVMF9coptpA) with indication where the liver-specific Serpin regulatory element ("Serp" or "SerpEnh") is inserted upstream of the transthyretin minimal promoter (TTRm). Abbreviations used are: ITR: viral inverted terminal repeat; mTTR: minimal transthyretin promoter; MVM: minute virus mouse; huFIXcoptMT: codon-optimized FIX; bGHpA: polyadenylation signal of bovine growth hormone; **B)** shows the sequence of the AAV9-SerpEnh-TTRm-MVM-co-hFIX construct (SEQ ID No. 1) and **C)** shows the sequence of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L construct (SEQ ID No. 2).

Figure 2 shows FIX activity after intravenous injection of AAV9-SerpEnh-TTRm-MVM-co-hFIX construct (pdsAAVsc SerpTTRmMVMF9coptpA) or AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L construct in FIX-deficient hemophilia B mice. AAV vectors expressing either the human codon-optimized FIX cDNA were designated as AAV-co-hFIX or the human codon-optimized FIX-R338L cDNA as AAV-co-padua-hFIX. hFIX activity levels were determined using a chromogenic activity assay on citrated plasma. Mice were injected with different vectors dose of the cognate self-complementary AAV9 vectors (10^9 vg, 5×10^9 vg, 2×10^{10} vg).

Figure 3 A) shows a schematic representation of the AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L vector. The expression cassette was packaged in a self-complimentary (sc) adeno-associated virus serotype 9 (AAV9), flanked by the 5' and 3' AAV inverted terminal repeats (ITR). The liver-specific minimal transthyretin (TTRm) promoter drives the codon-optimized human FIX with R338L mutation (co-hFIX-R338L) transgene. The hepatocyte-specific regulatory elements ("Serp" or "SerpEnh") are located upstream of the TTRm promoter. The minute virus of mouse mini-intron (MVM) intron and bovine growth hormone polyadenylation site (pA) are also indicated. **B)** shows a schematic representation of a control vector AAV9-SerpEnh-TTRm-MVM-co-hFIX, which is identical to the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector, but the transgene, codon-optimized hFIX, does not contain the R338L mutation. **C)** compares the R338L or Padua mutation in human FIX fragment (SEQ ID NO:23), making hFIX hyper-functional, with human FIX fragment (SEQ ID NO:24).

Figure 4. Evaluation of codon-optimized and hyper-functional FIX transgenes by AAV9 delivery in hemophilic mice. Mice were intravenously administered 1×10^9 vg/mouse (A,B), 5×10^9 vg/mouse (C,D) or 2×10^{10} vg/mouse (E,F) of AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L (indicated as cohFIX-R338L) or AAV9sc-SerpEnh-TTRm-MVM-co-hFIX (indicated as cohFIX) vector. hFIX activity (**A, C, E**) and hFIX protein (**B, D, F**) were measured by clotting activity using chromogenic FIX activity assays ($n = 3$) and by ELISA ($n = 3$), respectively, on plasma samples collected at the indicated times after AAV administration. (**G, H, I**) Hemophilic mice were intravenously administered 1×10^9 vg/mouse (G), 5×10^9 vg/mouse (H) or 2×10^{10} vg/mouse (I) of AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L ($n = 3$). For each dose, hFIX expression (hFIX protein) was compared to the corresponding FIX clotting activity. (**J**) D-dimer levels and hFIX activity were determined in mice injected with AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L (indicated as AAV cohFIX R338L) or AAV9sc-SerpEnh-TTRm-MVM-co-hFIX (indicated as AAV cohFIX) vector at the indicated doses and compared to non-injected control mice. D-dimer levels were determined by ELISA and hFIX activity was analyzed by chromogenic assay. The D-dimer positive control is shown. Results are presented as mean $\pm$ SEM. *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$ (t- test). (**K**) Analysis of immune tolerance induction in hemophilia B mice injected with 5×10^9 vg/mouse of AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L (indicated as cohFIX-R338L, $n=4$). FIX-specific antibodies were measured by ELISA at week 2 (w2), w4, w6 and w8 after immunization with hFIX protein, as indicated. The immunizations were initiated 2 weeks after vector administration. Immunized PBS-injected hemophilia B mice ($n=4$) were used as control.

Figure 5. Biodistribution and transduction efficiency in different organs of mice injected with AAV9sc-SerpEnh-TTRm-MVM-co-hFIX-R338L (indicated as cohFIX-R338L, $n = 3$) or AAV9sc-SerpEnh-TTRm-MVM-co-hFIX (indicated as cohFIX, $n = 3$). (**A, B**) AAV copy number relative to 100 ng of genomic DNA was determined for both constructs at a dose of 1×10^9 vg/mouse (A) and 5×10^9 vg/mouse (B). (**C, D**) Quantitative reverse transcriptase (qRT)-PCR analysis of hFIX mRNA levels in the different organs expressed relative to hFIX mRNA levels in the liver for both constructs at a dose of 1×10^9 vg/mouse (C) and 5×10^9 vg/mouse (D). GAPDH was used for normalization. Results are presented as mean $\pm$ SEM. *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$ (t-

test).

Figure 6 A) shows a schematic representation of AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA vector. The expression cassette was packaged in a single-stranded (ss) adeno-associated virus, flanked by the 5' and 3' AAV inverted terminal repeats (ITR). The liver-specific minimal transthyretin (TTRm) promoter regulates transcription of the human codon-optimized B-domain deleted FVIII cDNA (hFVIIIcopt). The Serpin enhancer ("Serp" or "SerpEnh") is cloned upstream of the TTRm promoter. The minute virus of mouse mini-intron (MVM) and SV40 polyadenylation site (pA) are indicated. **B)** shows a schematic of the AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA construct (AAVss-SerpTTRm-MVM-FVIIIcopt-sv40pA) with indication where the liver-specific Serpin enhancer ("Serp" or "SerpEnh") is inserted upstream of the transthyretin minimal promoter (TTRm). Abbreviations used are: ITR: viral inverted terminal repeat; MVM intron: minute virus mouse intron; FVIIIcopt: codon-optimized B domain deleted human FIX; SvpolyA: polyadenylation signal of SV40. **C)** shows the sequence of the AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt -sv40pA construct (SEQ ID NO: 6). The flanking inverted terminal repeat sequences are indicated in italics, the Serpin enhancer ("Serp" or "SerpEnh") in bold (72 bp), the minimal transthyretin promoter (TTRm) is underlined (202 bp), the mTTR/5' untranslated region is boxed (21 bp), the MVM intron is in italics and underlined (92bp), the codon-optimized B domain deleted hFVIII (hFVIIIcopt) underlined and in bold (4377 bp), and the SV40 polyadenylation sequence is in italics and bold and underlined (134 bp). **D)** Nucleotide sequence of codon-optimized B domain deleted FVIII (SEQ ID NO: 7). **E)** Nucleotide sequence of the Serpin enhancer ("Serp" or "SerpEnh") (SEQ ID NO: 8). **F)** Nucleotide sequence of the minimal transthyretin promoter (TTRm) (SEQ ID NO: 9). **G)** Nucleotide sequence of the minute virus mouse (MVM) intron (SEQ ID NO: 10). **H)** Nucleotide sequence of the SV40 polyadenylation signal (SV40polyA) (SEQ ID NO: 11).

Figure 7 shows FVIII expression levels in CB17.SCID mice in function of time (days) following intravenous injection with AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA (5×10^9 vg/mouse). FVIII levels were determined using a hFVIII-specific ELISA and are expressed as a percentage of normal levels (i.e. physiological level of human FVIII of 200 ng/ml or 1 IU/ml of FVIII in a normal individual) and in ng/ml plasma.

Figure 8 A) shows a schematic of the plasmid pcDNA3_mouseCO_hyPiggyBac_Transposase_MT encoding codon-optimized hyperactive PiggyBac (PB) transposase. **B)** Nucleotide sequence of the pcDNA3_mouseCO_hyPiggyBac_Transposase_MT plasmid (SEQ ID NO:12). **C)** shows a schematic of the PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4Z4 transposon. The liver-specific minimal transthyretin (TTRm) promoter is operably linked to the Serpin enhancer ("Serp" or "SerpEnh") to regulate transcription of the human codon-optimized B-domain deleted FVIII cDNA (FVIIIcopt). The minute virus of mouse mini-intron (MVM) and SV40 polyadenylation signal (SV40pA) are indicated. **D)** Nucleotide sequence of the PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4Z4 transposon (SEQ ID NO:13). **E)** schematically shows the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_bgpA transposon. Codon-optimized human FIX expression is driven from the liver-specific minimal transthyretin

(TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh"). The minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated. **F)** Nucleotide sequence of the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_bghpA transposon (SEQ ID NO:14). **G)** schematically shows the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_Padua_bghpA transposon. Codon-optimized human Padua FIX expression is driven from the liver-specific minimal transthyretin (TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh"). The minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated. **H)** Nucleotide sequence of the PB_micro_T_No_ins_TTRminSerpMVM_FIXco_Padua_bghpA transposon (SEQ ID NO: 15). **I)** shows the Sleeping Beauty (SB) transposon pT2BH_TTRminSerpMVM_hFIXco_bghpA transposon. Codon-optimized human FIX expression is driven from the liver-specific minimal transthyretin (TTRm) promoter operably linked to the Serpin enhancer ("Serp" or "SerpEnh"). The minute virus of mouse mini-intron (MVM) and bovine growth hormone polyadenylation signal (bghpA) are indicated. **J)** shows a schematic of the plasmid pCDNA3_CMVBGI_SBMAX_bghpA encoding the hyperactive SBmax transposase. **K)** Nucleotide sequence of the pCDNA3_CMVBGI_SBMAX_bghpA plasmid (SEQ ID NO:17).

Figure 9. FIX expression levels in hemophilia B mice treated by liver-directed gene therapy using hyperactive PB transposon expressing either codon-optimized FIX or the hyperactive codon-optimized FIX-R338L mutant. The amount of transposon (IRpBAC_{micro}) and transposase plasmid (hypBase) is indicated. Human FIX levels were determined using activity assays.

Figure 10. FVIII expression levels in SCID mice treated by liver-directed gene therapy using hyperactive PB transposon systems: 1 µg pcDNA3_mouseCO_hyPiggyBac_Transposase_MT plasmid (hyPB plasmid) + 5 µg PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4Z4 transposon (**A**); or 1 µg hyPB plasmid + 500 ng PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4Z4 transposon (**B**). (lines: with hyPB, broken lines: without hyPB control). Physiologic FVIII concentration (100% = 200 ng/ml plasma) is indicated. Human FVIII levels were detected by ELISA.

Figure 11. Comparison of Sleeping Beauty transposon and PiggyBac transposon for codon-optimized hFIX hepatic gene delivery. Sleeping Beauty transposon (pT2BH_TTRminSerpMVM_hFIXco_bghpA) and PiggyBac transposon (PB_micro_T_No_Ins_SerpTTRminMVM_hFIXco_BGHpA) were injected in immunodeficient (NOD SCID) mice along with plasmid encoding codon-optimized hyperactive PB transposase (pcDNA3_mouseCO_hyPiggyBac_Transposase_MT) or hyperactive SBmax transposase (pCDNA3_CMVBGI_SBMAX_bghpA), respectively using the doses as indicated. One month post-injection FIX plasma levels were determined in plasma by ELISA.

Figure 12. Evaluation of effect of cloning MVM intron into nucleic acid constructs on *in vivo* expression of transgenes. **(A)** Schematic representation of the piggyBac transposon encoding for a wild-type hFIX (denoted as pB_hFIXIA) The expression cassette is flanked by the wild-

type piggyBac transposon invert repeat (IRpBac). The liver-specific minimal transthyretin (TTRm) promoter drives the human FIX transgene comprising a truncated 1;4 kb hFIX intron A between exon 1 and the following exons 2-8. The hepatocyte-specific regulatory element ("Serp" or "SerpEnh") is located upstream of the TTRm promoter. Bovine growth hormone polyadenylation site (pA) is also indicated. **(B)** Schematic representation of the piggyBac transposon encoding for a codon-optimized hFIX (denoted as pB_hFIXco). The expression cassette is the same as pB_hFIXIA, except for the transgene. The hFIX transgene is codon-optimized (hFIXco) and contains no intron A. MVM intron is cloned upstream of the FIXco transgene. **(C)** Schematic representation of the mouse piggyBac transposase plasmid (denoted as mpBase). The mouse codon-optimized native piggyBac transposase (mpB) driven by the cytomegalovirus (CMV) promoter is cloned upstream of a β -globin intron (β GI). Bovine growth hormone polyadenylation site (bghpA) is also indicated. **(D)** Schematic representation of the empty control plasmid (denoted as empty) without a transposase gene. The plasmid contains a multiple cloning site (MCS) between the CMV promoter and the bghpA polyadenylation signal. **(E, F)** Hemophilia B mice were hydrodynamically injected with 10 μ g of transposon plasmids comprising wild-type hFIX transgene and truncated intron A (pB_hFIXIA, E) or codon-optimized hFIX transgene and MVM intron (pB_MVM-FIXco, F) in conjunction with 2 μ g of plasmids encoding mouse piggyBac transposase (+ mpBase, full lines) or an empty control plasmid (+ empty, dashed lines) hFIX antigen expression (black squares) and hFIX clotting activity (grey squares) were measured on plasma samples collected at the indicated times by ELISA and a chromogenic hFIX activity assay, respectively. Transposon copies per diploid genome **(G)** and hFIX mRNA levels **(H)** were measured by a quantitative RT-PCR method (qRT-PCR) at the end of the experiments from total RNA extracted from liver biopsies. hFIX mRNA levels relative to FIXIA mRNA levels are shown in H. The pB_hFIXco plasmid showed more than 57-fold expression of mRNA as compared to the pB_FIXIA plasmid. Results were presented as mean $\pm$ standard error of the mean. n.s. indicates not significant, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$ ($n = 3$ mice/group).

Figure 13. Comparison of nucleic acid expression cassettes comprising hFVIII transgene. **(A,B)** Predicted (a,b) and measured (c,d) hFVIII levels in mice hydrodynamically injected with, from left to right, (a) AAV9ss-TTRm-MVM-hFVIII-SV40pA plasmid, (b) AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA plasmid, (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA plasmid, or (d) AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid, at 2 μ g DNA (A) or 5 μ g DNA (B). **(C,D)** Bars showing from left to right, predicted hFVIII levels in mice hydrodynamically injected with (b) AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA plasmid; measured hFVIII levels in mice injected with (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA plasmid; sum of hFVIII levels predicted in mice injected with (b) and hFVIII levels measured in mice injected with (c); and hFVIII levels measured in mice transfected with (d) AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid. (C) shows the data for mice that were injected with 2 μ g DNA, (D) shows the data for mice that were injected with 5 μ g DNA.

Figure 14. Comparison of nucleic acid expression cassettes comprising hFIX transgene. **(A,B)** Bars showing from left to right, hFIX activity in mice hydrodynamically injected with (a) AAVsc-TTRm-MVM-hFIX-SV40pA plasmid; (b) AAVsc-SerpEnh-TTRm-MVM-hFIX-SV40pA plasmid; (c) AAVsc-TTRm-MVM-hFIXco-SV40pA plasmid; (b) and (c) calculated as the sum of hFIX

activity measured in mice injected with (b) and (c); and (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-SV40pA plasmid at day 2 (A) and day 6 (B) post-injection. **(C,D)** Bars showing from left to right, hFIX activity in mice hydrodynamically injected with (c) AAVsc-TTRm-MVM-hFIXco-SV40pA plasmid; (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-SV40pA plasmid; (e) AAVsc-TTRm-MVM-hFIXcoPadua-SV40pA plasmid; (d) and (e) calculated as the sum of hFIX activity measured in mice injected with (d) and (e); and (f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-SV40pA plasmid at day 2 (C) and day 6 (D) post-injection.

Figure 15. (A) Schematic representation of the piggyBac transposon pB_hFIXco/IR_{mut16} wherein the expression cassette is flanked by a wild-type piggyBac transposon inverted repeat (IRwt) and a piggybac transposon inverted repeat containing the indicated point mutations (IR_{mut16}). The liver-specific minimal transthyretin (TTRmin) promoter drives a codon-optimized hFIX (hFIXco). Minute virus of mouse (MVM) intron is cloned upstream of the FIXco transgene. The Serpin enhancer (denoted as HSH8) is located upstream of the TTRmin promoter. Bovine growth hormone polyadenylation site (pA) is also indicated. **(B)** Schematic representation of the piggybac transposon pB_hFIXco/IR_{micro}. The transposon is the same as pB_hFIXco/IR_{mut16}, except for the inverted repeats, which are micro inverted repeats (IR_{micro}). **(C)** Schematic representation of the piggybac transposon pB_hFIXco-R338L. The transposon is the same as pB_hFIXco/IR_{micro}, except for the transgene which is codon-optimized human FIX containing the Padua mutation (hFIXco-R338L). **(D)** Schematic representation of the hyperactive piggyBac transposase (hyPBBase) plasmid. The hyperactive piggyBac transposase (hyPBBase) driven by the cytomegalovirus (CMV) promoter is cloned upstream of a β -globin intron (β GI). The hyperactivating mutations are indicated. Bovine growth hormone polyadenylation site (bghpA) is also indicated. **(E)** Three months after transfection with pB transposons pB_hFIXIA, pB_hFIXco, or pB_hFIXco-R338L, mice were subjected to immunization with recombinant hFIX antigen and adjuvant. Anti-hFIX specific antibodies were measured by ELISA at week 2 (black) and week 4 (grey) post-immunization (p.i). PBS-injected hemophilia B mice that were immunized with recombinant hFIX and adjuvant were used as positive control. Results are presented as mean $\pm$ standard error of the mean. n.s. indicates not significant, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$ ($n = 3$ mice/group). **(F,G,H,I,J,K)** CB17/IcrTac/Prkdc^{scid} mice were hydrodynamically transfected with 500 ng (F,H,J) or 50 ng (G,I,K) of pB-hFIXco (F-K), pB-hFIXco/IR_{micro} (H,I; triangle) or pB-hFIXco/IR_{mut16} (J,K; triangle) transposon plasmids along with 1000 ng (F,H,J) or 100 ng (G,I,K) mPB (triangle F,G) or hyPB-expressing plasmid (F,G; square and H-K) or empty control plasmid (hatched lines). hFIX expression was measured on plasma samples collected at the indicated times by a specific ELISA assay. Results were presented as mean $\pm$ standard error of the mean. n.s. indicates not significant, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$ ($n = 3$ mice/group).

DETAILED DESCRIPTION OF THE INVENTION

[0019] The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes.

[0020] Where the term "comprising" is used in the present description and claims, it does not exclude other elements or steps. The term "comprising" also encompasses the more specific embodiments defined as "consisting of" and "consisting essentially of".

[0021] Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated. Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order.

[0022] It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

[0023] The following terms or definitions are provided to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, Plainsview, New York (1989); and Ausubel et al., *Current Protocols in Molecular Biology* (Supplement 47), John Wiley & Sons, New York (1999), for definitions and terms of the art.

[0024] The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.

[0025] The term "coagulation factor IX" has the meaning as known in the art. Synonyms of coagulation factor IX are "FIX" or "Christmas factor" or "F9" and can be used interchangeably. In particular, the term "coagulation factor IX" encompasses the human protein encoded by the mRNA sequence as defined in Genbank accession number NM_000133.

[0026] Preferably, said FIX is a mutated FIX, which is hyperactive or hyper-functional as compared to the wild type FIX. Modifying functional activity of human coagulation factor can be done by bioengineering e.g. by introduction of point mutations. By this approach a hyperactive R338A variant was reported, which showed a 3 fold increased clotting activity compared to the wild type human FIX in an *in vitro* activated partial thromboplastin time assay (APPT) (Chang et al., 1998) and a 2 to 6-fold higher specific activity in hemophilia B mice transduced with the mutant FIX gene (Schuettrumpf et al., 2005). Further exemplary FIX point-mutants or domain exchange mutants with even higher clotting activities have been described: FIX, with the EGF-

1 domain replaced with the EGF-1 domain from FVII, alone or in combination with a R338A point mutation (Brunetti-Pierri et al., 2009), the V86A/E277A/R338A triple mutant (Lin et al., 2010), the Y259F, K265T, and/or Y345T single, double or triple mutants (Milanov, et al., 2012), and the G190V point mutant (Kao et al., 2010). The FIX mutant may be the one described by Simioni et al., in 2009 and denominated as the "factor IX Padua" mutant, causing X-linked thrombophilia. Said mutant factor IX is hyperactive and carries an R338L amino acid substitution. The FIX transgene used in expression vector described herein may encode the human FIX protein, most preferably the FIX transgene encodes for the Padua mutant of the human FIX protein.

[0027] The term "coagulation factor VIII" has the meaning as known in the art. Synonyms of coagulation factor VIII are "FVIII" or "anti-hemophilic factor" or "AHF" and can be used interchangeably herein. The term "coagulation factor VIII" encompasses, for example, the human protein having the amino acid sequence as defined in Uniprot accession number P00451.

[0028] Said FVIII may be a FVIII wherein the B domain is deleted (i.e. B domain deleted FVIII, also referred to as BDD FVIII or FVIII Δ B herein). The term "B domain deleted FVIII" encompasses for example, but without limitation, FVIII mutants wherein whole or a part of the B domain is deleted and FVIII mutants wherein the B domain is replaced by a linker. Non-limiting examples of B domain deleted FVIII are described in Ward et al. (2011) and WO 2011/005968.

[0029] Said FVIII may be B domain deleted FVIII wherein the B domain is replaced by a linker having the following sequence: SFSQNPPVLTRHQR (SEQ ID NO: 16) (i.e. SQ FVIII as defined in Ward et al. (2011)). In particular, said FVIII may have SEQ ID NO:7 (i.e. codon-optimized B domain deleted human FVIII or hFVIIIcopt), as disclosed also in WO 2011/0059.

[0030] A "regulatory element" as used herein refers to transcriptional control elements, in particular non-coding cis-acting transcriptional control elements, capable of regulating and/or controlling transcription of a gene, in particular tissue-specific transcription of a gene. Regulatory elements comprise at least one transcription factor binding site (TFBS), more in particular at least one binding site for a tissue-specific transcription factor, most particularly at least one binding site for a liver-specific transcription factor. Typically, regulatory elements as used herein increase or enhance promoter-driven gene expression when compared to the transcription of the gene from the promoter alone, without the regulatory elements. Thus, regulatory elements particularly comprise enhancer sequences, although it is to be understood that the regulatory elements enhancing transcription are not limited to typical far upstream enhancer sequences, but may occur at any distance of the gene they regulate. Indeed, it is known in the art that sequences regulating transcription may be situated either upstream (e.g. in the promoter region) or downstream (e.g. in the 3'UTR) of the gene they regulate in vivo, and may be located in the immediate vicinity of the gene or further away. Of note, although regulatory elements as disclosed herein typically are naturally occurring sequences, combinations of (parts of) such regulatory elements or several copies of a regulatory element,

i.e. non-naturally occurring sequences, are themselves also envisaged as regulatory element. Regulatory elements as used herein may be part of a larger sequence involved in transcriptional control, e.g. part of a promoter sequence. However, regulatory elements alone are typically not sufficient to initiate transcription, but require a promoter to this end.

[0031] The regulatory elements contained in the nucleic acid expression cassettes and vectors disclosed herein are preferably liver-specific. Non-limiting examples of liver-specific regulatory elements are disclosed in WO 2009/130208.

[0032] The regulatory element in the nucleic acid expression cassettes and vectors disclosed herein is preferably a liver-specific regulatory element derived from the serpin gene promotor. Said regulatory element comprises the sequence as defined in SEQ ID NO:8, a sequence having at least 85%, preferably at least 90%, more preferably at least 95%, such as 96%, 97%, 98% or 99%, identity to said sequence, or a functional fragment thereof. Said regulatory element is herein referred to as "the Serpin enhancer", "SerpEnh", or "Serp".

[0033] The regulatory element in the nucleic acid expression cassettes and vectors disclosed herein can consist of the sequence defined by SEQ ID NO:8 (i.e. the Serpin enhancer, also called "SerpEnh", or "Serp" herein).

[0034] 'Liver-specific expression', as used in the application, refers to the preferential or predominant expression of a (trans)gene (as RNA and/or polypeptide) in the liver as compared to other tissues. At least 50% of the (trans)gene expression may occur within the liver. More particularly, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% of the (trans)gene expression may occur within the liver. Liver-specific expression may entail that there is no 'leakage' of expressed gene product to other organs, such as spleen, muscle, heart and/or lung. The same applies mutatis mutandis for hepatocyte-specific expression, which may be considered as a particular form of liver-specific expression. Throughout the application, where liver-specific is mentioned in the context of expression, hepatocyte-specific expression is also explicitly envisaged. Similarly, where tissue-specific expression is used in the application, cell-type specific expression of the cell type(s) predominantly making up the tissue is also envisaged.

[0035] The term "functional fragment" as used in the application refers to fragments of the sequences disclosed herein that retain the capability of regulating liver-specific expression, i.e. they still confer tissue specificity and they are capable of regulating expression of a (trans)gene in the same way (although possibly not to the same extent) as the sequence from which they are derived. Fragments comprise at least 10 contiguous nucleotides from the sequence from which they are derived. In further particular embodiments, fragments comprise at least 15, at least 20, at least 25, at least 30, at least 35 or at least 40 contiguous nucleotides from the sequence from which they are derived.

[0036] As used herein, the term "nucleic acid expression cassette" refers to nucleic acid molecules that include one or more transcriptional control elements (such as, but not limited to

promoters, enhancers and/or regulatory elements, polyadenylation sequences, and introns) that direct (trans)gene expression in one or more desired cell types, tissues or organs. Typically, they will also contain the FIX transgene or the FVIII transgene as defined herein.

[0037] The term "operably linked" as used herein refers to the arrangement of various nucleic acid molecule elements relative to each such that the elements are functionally connected and are able to interact with each other. Such elements may include, without limitation, a promoter, an enhancer and/or a regulatory element, a polyadenylation sequence, one or more introns and/or exons, and a coding sequence of a gene of interest to be expressed (i.e., the transgene). The nucleic acid sequence elements, when properly oriented or operably linked, act together to modulate the activity of one another, and ultimately may affect the level of expression of the transgene. By modulate is meant increasing, decreasing, or maintaining the level of activity of a particular element. The position of each element relative to other elements may be expressed in terms of the 5' terminus and the 3' terminus of each element, and the distance between any particular elements may be referenced by the number of intervening nucleotides, or base pairs, between the elements.

[0038] As used in the application, the term "promoter" refers to nucleic acid sequences that regulate, either directly or indirectly, the transcription of corresponding nucleic acid coding sequences to which they are operably linked (e.g. a transgene or endogenous gene). A promoter may function alone to regulate transcription or may act in concert with one or more other regulatory sequences (e.g. enhancers or silencers). In the context of the present application, a promoter is typically operably linked to regulatory elements to regulate transcription of a transgene.

[0039] When a regulatory element as described herein is operably linked to both a promoter and a transgene, the regulatory element can (1) confer a significant degree of liver specific expression in vivo (and/or in hepatocytes/ hepatic cell lines in vitro) of the transgene, and/or (2) can increase the level of expression of the transgene in the liver (and/or in hepatocytes/hepatocyte cell lines in vitro).

[0040] The promoter contained in the nucleic acid expression cassettes and vectors disclosed herein may be a liver-specific promoter. In particular, the liver-specific promoter may be from the transthyretin (TTR) gene. More particularly, the TTR promoter may be a minimal promoter (also referred to as TTRm, mTTR or TRRmin herein), most particularly the minimal TTR promoter as defined in SEQ ID NO: 9.

[0041] The promoter in the nucleic acid expression cassettes and vectors disclosed herein may be a minimal promoter.

[0042] A 'minimal promoter' as used herein is part of a full-size promoter still capable of driving expression, but lacking at least part of the sequence that contributes to regulating (e.g. tissue-specific) expression. This definition covers both promoters from which (tissue-specific) regulatory elements have been deleted- that are capable of driving expression of a gene but

have lost their ability to express that gene in a tissue-specific fashion and promoters from which (tissue-specific) regulatory elements have been deleted that are capable of driving (possibly decreased) expression of a gene but have not necessarily lost their ability to express that gene in a tissue-specific fashion. Minimal promoters have been extensively documented in the art, a non-limiting list of minimal promoters is provided in the specification.

[0043] Typically, the nucleic acid expression cassette in the expression vector described herein comprises a plasmid origin, a promoter and/or enhancer, a (trans)gene, a transcription terminator, and a selection gene.

[0044] The nucleic acid expression cassette in the expression vector described herein may comprise the following elements:

- a plasmid origin such as the f1 origin,
- an Inverted Terminal Repeat sequence (ITR), sometimes mutated,
- an enhancer, preferably the Serpin enhancer ("Serp" or "SerpEnh"),
- a promoter, preferably the minimal TTR promoter (TTRm),
- the MVM intron,
- a (trans)gene, preferably a codon-optimized transgene
- a transcription terminator, preferably a polyadenylation signal such as the bGHpA,
- an Inverted Terminal Repeat sequence (ITR),
- a selection gene (e.g. an antibiotic resistance gene such as an ampicillin resistance gene), and
- a plasmid origin such as the pBR322 origin.

[0045] The cloning of the MVM intron into a nucleic acid expression cassette described herein was shown to unexpectedly high expression levels of the transgene operably linked thereto.

[0046] For example, said nucleic acid expression cassette in the expression vector comprises the following elements (cf. Figure 1):

- an plasmid origin such as the f1 origin,
- an Inverted Terminal Repeat sequence (ITR), sometimes mutated,
- an enhancer, preferably the Serpin enhancer ("Serp" or "SerpEnh"),
- a promoter, preferably the minimal TTR promoter (TTRm),
- an intron sequence, preferably the MVM intron,
- a (trans)gene, preferably the FIX encoding gene, or its Padua mutant form,
- a transcription terminator, preferably a polyadenylation signal such as the bGHpA,
- an Inverted Terminal Repeat sequence (ITR),
- a selection gene (e.g. an antibiotic resistance gene such as an ampicillin resistance gene), and
- a plasmid origin such as the pBR322 origin.

[0047] The combination of said elements results in an unexpectedly high expression level of FIX and in particular of the Padua mutant thereof in the liver of subjects. Preferably, the vector is an adeno-associated virus-derived vector, in combination with the Padua-mutant FIX gene.

[0048] In another example, said nucleic acid expression cassette in the vector comprises the following elements:

- a plasmid origin, such as the f1 Origin,
- an Inverted Terminal Repeat sequence (ITR), optionally mutated,
- a liver-specific regulatory element, preferably the Serpin enhancer,
- a promoter, preferably the minimal TTR promoter,
- an intron sequence, preferably the MVM intron,
- a (trans)gene, preferably codon-optimized factor VIII cDNA, even more preferably codon-optimized B domain deleted factor VIII cDNA,
- a transcription terminator, preferably a polyadenylation signal such as the Simian vacuolating virus 40 or Simian virus 40 (SV40) polyadenylation signal,
- an Inverted Terminal Repeat sequence (ITR),
- a selection gene (e.g. an antibiotic resistance gene such as an ampicillin resistance gene), and
- a plasmid origin, such as the pBR322 origin.

[0049] The combination of said elements results in an unexpectedly high expression level of FVIII specifically in the liver of subjects. Preferably, the vector is an adeno-associated virus(AAV)-derived vector in combination with codon-optimized B domain deleted FVIII cDNA.

[0050] For example, said nucleic acid expression cassette in the vectors disclosed herein comprises:

- a liver-specific regulatory element, preferably the Serpin enhancer,
- a promoter, preferably the minimal TTR promoter,
- the MVM intron
- a (trans)gene, preferably a codon-optimized transgene
- a transcription terminator, preferably a polyadenylation signal such as the bovine growth hormone polyadenylation signal.

[0051] In another example, said nucleic acid expression cassette in the vectors disclosed herein comprises:

- a liver-specific regulatory element, preferably the Serpin enhancer,
- a promoter, preferably the minimal TTR promoter,

- an intron sequence, preferably the MVM intron,
- a (trans)gene, preferably codon-optimized factor IX cDNA, even more preferably codon-optimized factor IX Padua cDNA,
- a transcription terminator, preferably a polyadenylation signal such as the bovine growth hormone polyadenylation signal,

[0052] In yet another example, said nucleic acid expression cassette in the vectors disclosed herein comprises:

- a liver-specific regulatory element, preferably the Serpin enhancer,
- a promoter, preferably the minimal TTR promoter,
- an intron sequence, preferably the MVM intron,
- a (trans)gene, preferably codon-optimized factor VIII cDNA, even more preferably codon-optimized B domain deleted factor VIII cDNA,
- a transcription terminator, preferably a polyadenylation signal such as the Simian vacuolating virus 40 or Simian virus 40 (SV40) polyadenylation signal,

[0053] The term "transgene" or "(trans)gene" as used herein refers to particular nucleic acid sequences encoding a polypeptide or a portion of a polypeptide to be expressed in a cell into which the nucleic acid sequence is inserted. However, it is also possible that transgenes are expressed as RNA, typically to lower the amount of a particular polypeptide in a cell into which the nucleic acid sequence is inserted. These RNA molecules include but are not limited to molecules that exert their function through RNA interference (shRNA, RNAi), micro-RNA regulation (miR), catalytic RNA, antisense RNA, RNA aptamers, etc. How the nucleic acid sequence is introduced into a cell is not essential to the invention, it may for instance be through integration in the genome or as an episomal plasmid. Of note, expression of the transgene may be restricted to a subset of the cells into which the nucleic acid sequence is inserted. The term 'transgene' is meant to include (1) a nucleic acid sequence that is not naturally found in the cell (i.e., a heterologous nucleic acid sequence); (2) a nucleic acid sequence that is a mutant form of a nucleic acid sequence naturally found in the cell into which it has been introduced ; (3) a nucleic acid sequence that serves to add additional copies of the same (i.e., homologous) or a similar nucleic acid sequence naturally occurring in the cell into which it has been introduced ; or (4) a silent naturally occurring or homologous nucleic acid sequence whose expression is induced in the cell into which it has been introduced. By 'mutant form' is meant a nucleic acid sequence that contains one or more nucleotides that are different from the wild-type or naturally occurring sequence, i.e., the mutant nucleic acid sequence contains one or more nucleotide substitutions, deletions, and/or insertions. In some cases, the transgene may also include a sequence encoding a leader peptide or signal sequence such that the transgene product will be secreted from the cell.

[0054] The term 'vector' as used in the application refers to nucleic acid molecules, usually

double- stranded DNA, which may have inserted into it another nucleic acid molecule (the insert nucleic acid molecule) such as, but not limited to, a cDNA molecule. The vector is used to transport the insert nucleic acid molecule into a suitable host cell. A vector may contain the necessary elements that permit transcribing the insert nucleic acid molecule, and, optionally, translating the transcript into a polypeptide. The insert nucleic acid molecule may be derived from the host cell, or may be derived from a different cell or organism. Once in the host cell, the vector can replicate independently of, or coincidental with, the host chromosomal DNA, and several copies of the vector and its inserted nucleic acid molecule may be generated.

[0055] The term "vector" may thus also be defined as a gene delivery vehicle that facilitates gene transfer into a target cell. This definition includes both non-viral and viral vectors. Non-viral vectors include but are not limited to cationic lipids, liposomes, nanoparticles, PEG, PEI, etc. Viral vectors are derived from viruses including but not limited to: retrovirus, lentivirus, adeno- associated virus, adenovirus, herpesvirus, hepatitis virus or the like. Typically, but not necessarily, viral vectors are replication-deficient as they have lost the ability to propagate in a given cell since viral genes essential for replication have been eliminated from the viral vector. However, some viral vectors can also be adapted to replicate specifically in a given cell, such as e.g. a cancer cell, and are typically used to trigger the (cancer) cell-specific (onco)lysis.

[0056] Preferred vectors are derived from adeno-associated virus, adenovirus, retroviruses and Antiviruses. Alternatively, gene delivery systems can be used to combine viral and non-viral components, such as nanoparticles or virosomes (Yamada et al., 2003). Retroviruses and Antiviruses are RNA viruses that have the ability to insert their genes into host cell chromosomes after infection. Retroviral and lentiviral vectors have been developed that lack the genes encoding viral proteins, but retain the ability to infect cells and insert their genes into the chromosomes of the target cell (Miller, 1990; Naldini et al., 1996, VandenDriessche et al., 1999). The difference between a lentiviral and a classical Moloney-murine leukemia-virus (MLV) based retroviral vector is that lentiviral vectors can transduce both dividing and non-dividing cells whereas MLV-based retroviral vectors can only transduce dividing cells.

[0057] Adenoviral vectors are designed to be administered directly to a living subject. Unlike retroviral vectors, most of the adenoviral vector genomes do not integrate into the chromosome of the host cell. Instead, genes introduced into cells using adenoviral vectors are maintained in the nucleus as an extrachromosomal element (episome) that persists for an extended period of time. Adenoviral vectors will transduce dividing and nondividing cells in many different tissues in vivo including airway epithelial cells, endothelial cells, hepatocytes and various tumors (Trapnell, 1993; Chuah et al., 2003). Another viral vector is derived from the herpes simplex virus, a large, double-stranded DNA virus. Recombinant forms of the vaccinia virus, another dsDNA virus, can accommodate large inserts and are generated by homologous recombination.

[0058] Adeno-associated virus (AAV) is a small ssDNA virus which infects humans and some other primate species, not known to cause disease and consequently causing only a very mild immune response. AAV can infect both dividing and non-dividing cells and may incorporate its

genome into that of the host cell. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, although the cloning capacity of the vector is relatively limited. Preferably, the vector used is therefore derived from adeno-associated virus (i.e. AAV vector).

[0059] Different serotypes of AAVs have been isolated and characterized, such as, for example AAV serotype 2, AAV serotype 5, AAV serotype 8, and AAV serotype 9, and all AAV serotypes are contemplated herein. Preferably, the vector used is AAV serotype 9.

[0060] The AAV vectors disclosed herein may be single-stranded (i.e. ssAAV vectors) or self-complementary (i.e. scAAV vectors). In particular, AAV vectors that comprise a FIX transgene as disclosed herein are preferably self-complementary, and AAV vectors that comprise a FVIII transgene as disclosed herein are preferably single-stranded. With the term "self-complementary AAV" is meant herein a recombinant AAV-derived vector wherein the coding region has been designed to form an intra-molecular double-stranded DNA template.

[0061] Gene therapy with adeno-associated viral vectors disclosed herein was shown to induce immune tolerance towards the transgene comprised in the vector.

[0062] The vector can also be a transposon-based vector. Preferably, said transposon-based vectors are derived from Sleeping Beauty (SB) or PiggyBac (PB). A preferred SB transposon has been described in Ivics et al. (1997).

[0063] Said transposon-based vectors may comprise the nucleic acid expression cassettes disclosed herein.

[0064] Said transposon-based vectors can be PiggyBac-based transposons. Such vectors are safe in that they do not enhance the tumorigenic risk. Furthermore, liver-directed gene therapy with these vectors was shown to induce immune tolerance towards the transgene, in particular hFIX, comprised in the vector.

[0065] Said PiggyBac-based vectors may comprise micro inverted repeats, preferably inverted repeats having SEQ ID NO:29 and SEQ ID NO:30. With "micro inverted repeats" is meant herein inverted repeats wherein the majority of the native sequence has been removed. Exemplary micro inverted repeats have been described in Meir et al. (2011. BMC Biotechnology 11:28) and are characterized by the sequences ttaaccctagaaagataatcatattgtgacgtacgttaaagataatcatgcgtaaaattgacgcatg (SEQ ID NO:29) and gcatgcgtcaattttacgcagactatcttctaggggttaa (SEQ ID NO:30). Such micro inverted repeats advantageously increase the expression level of the transgene comprised in the vector.

[0066] For example, said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, the codon-optimized human FIX Padua mutant, and the bovine growth hormone polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:15. Said

transposon-based vector may further comprise micro inverted repeats.

[0067] In another example, said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, codon-optimized human FIX cDNA, and the bovine growth hormone polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:14. Said transposon-based vector may further comprise micro inverted repeats.

[0068] In another example, said transposon-based vector is a PiggyBac-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, a codon-optimized human B domain deleted FVIII cDNA, and the SV40 polyadenylation signal, such as, e.g., the transposon defined by SEQ ID NO:13. Said transposon-based vector may further comprises micro inverted repeats.

[0069] In yet another example, said transposon-based vector is a Sleeping Beauty-based transposon comprising the Serpin enhancer, the minimal transthyretin promoter, the minute virus of mouse intron, codon-optimized human FIX cDNA, and the bovine growth hormone polyadenylation signal (Fig. 8I).

[0070] The transposon-based vectors disclosed herein are preferably administered in combination with a vector encoding a transposase for gene therapy. For example, the PiggyBac-derived transposon-based vector can be administered with wild-type PiggyBac transposase (Pbase) or mouse codon-optimized PiggyBac transposase (mPBase) Preferably, said transposases are hyperactive transposases, such as, for example, SBmax transposase and hyperactive PB (hyPB) transposase containing seven amino acid substitutions (I30V, S103P, G165S, M282V, S509G, N538K, N570S) as described in Yusa et al. (2011).

[0071] Transposon/transposase constructs can be delivered by hydrodynamic injection or using non-viral nanoparticles to transfect hepatocytes.

[0072] The nucleic acid regulatory elements, the nucleic acid expression cassettes and the vectors described herein can be used in gene therapy. Gene therapy protocols, intended to achieve therapeutic gene product expression in target cells, *in vitro*, but also particularly *in vivo*, have been extensively described in the art. These include, but are not limited to, intramuscular injection of plasmid DNA (naked or in liposomes), interstitial injection, instillation in airways, application to endothelium, intra-hepatic parenchyme, and intravenous or intra-arterial administration (e.g. intra-hepatic artery, intra-hepatic vein). Various devices have been developed for enhancing the availability of DNA to the target cell. A simple approach is to contact the target cell physically with catheters or implantable materials containing DNA. Another approach is to utilize needle-free, jet injection devices which project a column of liquid directly into the target tissue under high pressure. These delivery paradigms can also be used to deliver viral vectors. Another approach to targeted gene delivery is the use of molecular conjugates, which consist of protein or synthetic ligands to which a nucleic acid-or DNA-binding agent has been attached for the specific targeting of nucleic acids to cells (Cristiano et

al., 1993).

[0073] In particular, the use of the nucleic acid regulatory elements, nucleic acid expression cassettes or vectors as described herein is envisaged for gene therapy of liver cells. More particularly, the use of the regulatory elements, expression cassettes or vectors is for gene therapy *in vivo*. Even more particularly, the use is for a method of gene therapy to treat hemophilia, in particular to treat hemophilia B or hemophilia A.

[0074] Gene transfer into mammalian hepatocytes has been performed using both *ex vivo* and *in vivo* procedures. The *ex vivo* approach requires harvesting of the liver cells, *in vitro* transduction with long-term expression vectors, and reintroduction of the transduced hepatocytes into the portal circulation (Kay et al., 1992; Chowdhury et al., 1991). *In vivo* targeting has been done by injecting DNA or viral vectors into the liver parenchyma, hepatic artery, or portal vein, as well as via transcriptional targeting (Kuriyama et al., 1991; Kistner et al., 1996). Recent methods also include intraportal delivery of naked DNA (Budker et al., 1996) and hydrodynamic tail vein transfection (Liu et al., 1999; Zhang et al., 1999).

[0075] Methods for expressing a protein in liver cells are provided herein, comprising the steps of introducing in liver cells the nucleic acid expression cassette (or a vector) as described herein and expressing the transgene protein product in the liver cells. These methods may be performed both *in vitro* and *in vivo*.

[0076] Methods of gene therapy for a subject in need thereof are also provided, comprising the steps of introducing in the liver of the subject a nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and expressing a therapeutic amount of the therapeutic protein in the liver. The method may further comprise the steps of introducing in the liver of the subject a vector comprising the nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and expressing a therapeutic amount of the therapeutic protein in the liver. For example, the therapeutic protein encoded by the transgene in the nucleic acid expression cassette is factor IX, and the method is a method for treating hemophilia B. By expressing factor IX in the liver via gene therapy, hemophilia B can be treated (Snyder et al., 1999).

[0077] In another example, the therapeutic protein encoded by the transgene in the nucleic acid expression cassette is factor VIII, and the method is a method for treating hemophilia A.

[0078] Except when noted differently, the terms "subject" or "patient" are used interchangeably and refer to animals, preferably vertebrates, more preferably mammals, and specifically includes human patients and non-human mammals. "mammalian" subjects include, but are not limited to, humans, domestic animals, commercial animals, farm animals, zoo animals, sport animals, pet and experimental animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orang-utans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer

and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on. Accordingly, "subject" or "patient" as used herein means any mammalian patient or subject to which the compositions described herein can be administered. Preferred patients or subjects are human subjects.

[0079] As used herein, the terms "treat" or "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of proliferative disease, e.g., cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilised (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0080] As used herein, a phrase such as "a subject in need of treatment" includes subjects, such as mammalian subjects, that would benefit from treatment of a given condition, such as, hemophilia B. Such subjects will typically include, without limitation, those that have been diagnosed with the condition, those prone to have or develop the said condition and/or those in whom the condition is to be prevented.

[0081] The term "therapeutically effective amount" refers to an amount of a compound or pharmaceutical composition effective to treat a disease or disorder in a subject, i.e., to obtain a desired local or systemic effect and performance. The term may imply that levels of factor IX in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml (milli-units per milliliter) plasma, 50mU/ml plasma, 100mU/ml plasma, 150mU/ml or 200mU/ml plasma in a subject can be obtained by transduction or transfection of the vector described herein into a subject. Due to the very high efficiency of the vector and nucleic acid expression cassette described herein, this high physiological level of factor IX in the subject can be obtained even by administering relatively low doses of vector. The term can also imply that levels of factor VIII in plasma equal to or higher than the therapeutic threshold concentration of 10mU/ml (milli-units per milliliter) plasma, 50mU/ml plasma, 100mU/ml plasma, 150mU/ml plasma, 200mU/ml plasma or higher can be obtained by transduction or transfection of any of the vectors disclosed herein into a subject. Due to the very high efficiency of the vectors and nucleic acid expression cassettes disclosed herein, these high physiological levels of factor VIII in the subject can be obtained even by administering relatively low doses of vector. The term thus refers to the quantity of compound or pharmaceutical composition that elicits the biological or medicinal response in a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the hemophilia being treated. In particular, these terms refer to the quantity of compound or pharmaceutical composition which is necessary to prevent, cure, ameliorate, or at least minimize the clinical impairment, symptoms, or complications associated with hemophilia, in particular hemophilia B or hemophila A, in either a single or multiple dose.

[0082] In particular, the transduction of the vector defined herein into the subject can be done at a dose lower than 2×10^{11} vg/kg (viral genomes per kilogram) to obtain a physiological factor IX level of 10mU/ml plasma or of 50mU/ml plasma in a subject.

[0083] Alternatively, if a level of factor IX of 100 mU/ml plasma needs to be reached in a subject, the transduction of the vector defined herein into the subject can be done at a dose lower than or equal to 6×10^{11} vg/kg.

[0084] Further, if a level of factor IX equal to 150 mU/ml plasma or higher needs to be reached, the transduction of the vector defined herein into the subject can be done at a dose lower than or equal than 2×10^{12} vg/kg. A level of factor IX of 200 mU/ml plasma or higher can be reached in a subject, when the transduction of the vector defined herein into the subject is done at a dose lower than or equal to 2×10^{12} vg/kg.

[0085] The transduction of the vector defined herein into the subject can be done at a dose lower than or equal to 2×10^{12} vg/kg (viral genomes per kilogram), such as lower than or equal to 1×10^{12} vg/kg, 5×10^{11} vg/kg, 2.5×10^{11} vg/kg, 1×10^{11} vg/kg, 5×10^{10} vg/kg, 1×10^{10} vg/kg, 5×10^9 vg/kg, or 1×10^9 vg/kg preferably at a dose lower than or equal to 2.5×10^{11} vg/kg, to obtain a physiological factor VIII level of 10 mU/ml plasma, 50 mU/ml plasma, 100 mU/ml plasma, 150 mU/ml plasma, 200 mU/ml plasma, or higher in a subject.

[0086] For hemophilia therapy, efficacy of the treatment can, for example, be measured by assessing the hemophilia-caused bleeding in the subject. In vitro tests such as, but not limited to the in vitro activated partial thromboplastin time assay (APPT), test factor IX chromogenic activity assays, blood clotting times, factor IX or human factor VIII-specific ELISAs are also available. Any other tests for assessing the efficacy of the treatment known in the art can of course be used.

[0087] The compound or the pharmaceutical composition described herein may be used alone or in combination with any of the know hemophilia therapies, such as the administration of recombinant or purified clotting factors. The compound or the pharmaceutical composition described herein can thus be administered alone or in combination with one or more active compounds. The latter can be administered before, after or simultaneously with the administration of the said agent(s).

[0088] Further disclosed herein are pharmaceutical preparations which comprise a therapeutically effective amount of the expression vector as defined herein, and a pharmaceutically acceptable carrier, i.e., one or more pharmaceutically acceptable carrier substances and/or additives, e.g., buffers, carriers, excipients, stabilisers, etc. The term "pharmaceutically acceptable" as used herein is consistent with the art and means compatible with the other ingredients of a pharmaceutical composition and not deleterious to the recipient thereof. The term "pharmaceutically acceptable salts" as used herein means an inorganic acid

addition salt such as hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate, tartrate, and citrate. Examples of pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of pharmaceutically acceptable ammonium salts are ammonium salt and tetramethylammonium salt. Examples of pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine. Examples of pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine. The pharmaceutical composition described herein can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion. Other suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods. The pharmaceutical composition can be prepared in a manner known per se to one of skill in the art. For this purpose, the expression vector as defined herein, one or more solid or liquid pharmaceutically acceptable excipients and, if desired, in combination with other pharmaceutical active compounds, are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human medicine or veterinary medicine.

[0089] A pharmaceutical composition is provided herein comprising a nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and a pharmaceutically acceptable carrier. The pharmaceutical composition may comprise a vector containing the nucleic acid expression cassette containing a transgene encoding a therapeutic protein, and a pharmaceutically acceptable carrier. For example, the transgene encodes factor IX and the pharmaceutical composition is for treating hemophilia B or the transgene encodes factor VIII and the pharmaceutical composition is for treating hemophilia A.

[0090] The use of the nucleic acid expression cassette, its regulatory elements and the vector components as disclosed herein for the manufacture of these pharmaceutical compositions for use in treating hemophilia, preferably hemophilia B or hemophilia A, is also envisaged.

[0091] The following examples are provided to better illustrate particular embodiments, and they should not be considered limiting the application. The application is limited only by the claims.

EXAMPLES

Example 1: In vivo validation of liver-specific regulatory enhancer sequences expressing hyper-active FIX via AAV vector gene delivery.

Materials and methods

Vector construction

[0092] AAV-based vectors were constructed that express either the codon-optimized factor IX or the codon-optimized factor IX with the Padua R338L mutation from the TTRm promoter operably linked to the Serpin regulatory sequence. The Serpin regulatory sequence has been identified and described under patent application WO2009/130208.

[0093] An intron and poly-A sequence were also provided. The full sequence of the construct containing the codon-optimized factor IX is given in SEQ ID No.1 (Fig. 1B) and the construct containing the codon-optimized factor IX with the Padua R338L mutation in SEQ ID No.2 (Fig. 1C). The vectors were constructed by conventional cloning and DNA synthesis. A schematic overview of the AAV vector containing the codon-optimized huFIX is shown in Fig. 1A. The vector with the Padua R338L is identical except for the specific R338L mutation that results in FIX hyper-activity.

Cell lines and culture conditions

[0094] 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine (Gln), 100 IU/ml penicillin, 100 µg/ml streptomycin and 10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Merelbeke, Belgium).

AAV vector production

[0095] As an example, the AAV serotype 9 viral vector was chosen to package the construct, known to be a promising vector for gene therapy (Vandendriessche et al. 2007). AAV vectors expressing human FIX were produced at high-titer by calcium phosphate transfection according to the manufacturer's instruction (Calcium phosphate transfection kit, Invitrogen) of 293 cells with AAV2-vector DNA (26 µg/10 cm dish), an adenoviral helper plasmid (52 µg/10 cm dish) and AAV helper plasmids expressing Rep2 and Cap9 (26 µg/10 cm dish) for production of AAV9 serotypes, as described in Gao et al. (2002), Mingozzi et al. (2003) and Gehrke (2003).

[0096] Two days post-transfection, cells were lysed by successive freeze-thaw cycles and sonication. Lysates were treated with benzonase (Merck) and deoxycholate (Sigma-Aldrich)

and subsequently subjected to three successive rounds of cesium chloride density ultracentrifugation. The fractions containing the AAV particles were concentrated using an Amicon filter (Millipore) and washed with PBS 1mM MgCl₂. Vector genome titers were determined by quantitative polymerase chain reaction (qPCR) using TaqMan® probes and primers specific for the polyadenylation signal (forward primer: 5'GCCTTCTAGTTGCCAGCCAT (SEQ ID No.3), probe: 5'TGTTTGCCCCTCCCCCGTGC (SEQ ID No.4), reverse primer: 5'GGCACCTTCCAGGGTCAAG (SEQ ID No.5)).

Animal studies

[0097] Animal procedures were approved by the animal Ethical Commission of the VUB. Animals were housed under Biosafety Level II conditions. Mice were injected with the AAV9 vectors as described in Vandendriessche et al. (2007). Briefly, 10⁹ vg, 5x10⁹ vg, 2x10¹⁰ vg (vector genomes = vg) were injected (i.v.) into the tail vein of adult hemophilia B mice (3 mice/group). Blood was collected by retro-orbital bleeds under general anesthesia. Human FIX expression was determined in citrated mouse plasma using a chromogenic FIX activity assay, according to the manufacturer (Hyphen Biomed, Neuville-sur-Oise, France) using serially diluted hFIX standards for calibration.

Results

[0098] AAV vectors expressing either the human codon-optimized FIX cDNA (designated as AAV-co-hFIX in Fig. 2) or the human codon-optimized FIX-R338L cDNA (designated as AAV-co-padua-hFIX in Fig. 2) from a chimeric liver-specific promoter (SerpEnh/TTRm) were injected into FIX-deficient hemophilic mice that suffered from hemophilia B. A dose-response was observed and the AAV vector expressing the codon-optimized FIX-R338L yielded significantly higher FIX activity than the codon-optimized FIX control without the hyper-activating mutation. Remarkably, the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector reached therapeutic FIX levels at a relatively low dose (>50% of normal FIX levels at 1x10⁹ gc/mouse, >250% of normal FIX levels at 5x10⁹ gc/mouse and >700% of normal FIX levels at 2x10¹⁰ gc/mouse after 5 days), which underscores its potency. These levels typically increase more than 2-fold to stable levels in subsequent weeks, reaching respectively approximately >100%, >500% and >1400% FIX at doses of respectively, 1x10⁹ gc/mouse, 5x10⁹ gc/mouse and 2x10¹⁰ gc/mouse. These levels were still increasing in subsequent days following vector injection. Hence, this new vector produced unprecedented, high levels of human IX and can be used at much lower doses than described in the art to cure hemophilia B in a clinically relevant animal model.

Example 2: Enhanced, liver-specific expression of FIX via AAV vector gene delivery.

Materials and methods***Vector constructs***

[0099] A FIX construct comprising human FIX cDNA (hFIX), was cloned downstream of a liver-specific minimal transthyretin (TTRm) promoter in an adeno-associated viral vector 9 (AAV9) backbone. This vector was further improved to AAV9-SerpEnh-TTRm-hFIX, which comprised an additional hepatocyte-specific regulatory element, namely the Serpin regulatory sequence ("Serp" or "SerpEnh"), upstream of the TTRm promoter. To improve the function of this vector, a minute virus of mice (MVM) intron was cloned in between the TTRm promoter and the hFIX transgene (AAV9-SerpEnh-TTRm-MVM-hFIX). Next, the hFIX transgene was codon-optimized in order to augment the expression of the protein (AAV9-SerpEnh-TTRm-MVM-co-hFIX). A further improvement encompassed a mutation, namely the R338L, Padua mutation (Fig. 3C), of the co-hFIX fragment (AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L).

Vectors:**[0100]**

- AAV9-TTRm-hFIX
- AAV9-SerpEnh-TTRm-hFIX
- AAV9-SerpEnh-TTRm-MVM-hFIX
- AAV9-SerpEnh-TTRm-MVM-co-hFIX (Fig. 3B)
- AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L (Fig. 3A,C)

Vector production and purification

[0101] Calcium phosphate (Invitrogen Corp, Carlsbad, CA, USA) co-transfection of AAV-293 cells with the AAV plasmid of interest, a chimeric packaging construct and an adenoviral helper plasmid, were used to produce AAV vectors as described in VandenDriessche T et al. (2007, VandenDriessche T., Thorrez L, Acosta-Sanchez, Petrus I, Wang L, Ma L, De Waele L, Iwasaki Y, Giillijns V, Wilson JM, Collen D, Chuah MK; Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost, 2007. 5(1): p. 16-24), which is specifically incorporated by reference herein. Cells were harvested two days after transfection and lysed by freeze/thaw cycles and sonication, followed by bezonase (Novagen, Madison, WI, USA) and deoxycholic acid (Sigma-

Aldrich, St Louis, MO, USA) treatments and 3 consecutive rounds of cesium chloride (Invitrogen Corp, Carlsbad, CA, USA) density gradient ultracentrifugation. AAV vector containing fractions were collected and concentrated in Dulbecco's phosphate buffered saline (PBS) (Gibco, BRL) containing 1 mM MgCl₂.

[0102] Quantitative real-time PCR with SYBR® Green and primers for the bovine growth hormone polyadenylation sequence (bGHpolyA) was used to determine vector titers. The forward primer sequence was 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3). The reverse primer used was 5'-GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:5). To generate standard curves, known copy numbers (10^2 - 10^7) of the corresponding vector plasmids were used.

Animal experiments and clotting assays

[0103] Vector administration was carried out by tail vein injection on adult hemophilia B mice at doses of 1×10^9 vg/mouse, 5×10^9 vg/mouse and 2×10^{10} vg/mouse. Whole blood was collected into buffered citrate by phlebotomy of the retro-orbital plexus. Human FIX antigen concentration in citrated plasma was determined by enzyme-linked immunosorbent assay (ELISA) specific for hFIX antigen (Diagnostica Stago, France) using manufacturer's protocol. FIX activity was assessed using BIOPHEN Factor IX chromogenic assay (Hyphen BioMed, Neuville-sur-Oise, France) according to the manufacturer's protocol. For both assays, serially diluted hFIX standards were used for calibration.

[0104] D-dimer levels were determined by ELISA, according to the manufacturers instructions (Hyphen Biomed, Neuville-sur-Oise, France).

[0105] Tail-clipping assay was performed. Mice were anesthetized and tail was placed in prewarmed 37°C normal saline solution for 2 minutes and subsequently cut at 2-3 mm diameter. Tail was then immediately placed in 37°C normal saline solution and monitored for bleeding and survival.

Immunizations and detection of anti-FIX antibodies

[0106] Immunizations were carried out by subcutaneous injection of 5 µg of recombinant human (rh)FIX protein (BeneFix, Pfizer, Italy) in incomplete Freund's adjuvant (IFA) (Sigma-Aldrich, USA). Briefly, 96-well microtiter plates were coated with hFIX (1µg/ml) and serially diluted standards made of purified mouse IgG (Invitrogen, Europe). The plate was incubated overnight at 4° C. On day 2, the samples of mouse plasma were diluted in dilution buffer, loaded on the pre-coated plates and incubated overnight at 4°C. Experimental plasma samples were obtained from mice injected with AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L. Plasma from phosphate-buffered saline (PBS)-injected mice immunized with rhFIX was used as control. The plate was then incubated with horseradish peroxidase (HRP)-goat anti-mouse IgG

(Invitrogen, Europe) secondary antibody. Anti-hFIX antibody levels were measured following incubation with detection buffer constituting 12ml 0.01M sodium citrate, 12mg o-phenylenediamine and 2.5 µl hydrogen peroxide (Invitrogen, Europe). The chromogenic reaction was monitored by determining the absorbance at 450 nm.

Vector DNA and mRNA quantification

[0107] Genomic DNA was extracted from different tissues using the DNeasy Blood & Tissue Kit (Qiagen, Chatsworth, CA, USA). 100ng DNA was analyzed using qPCR ABI Prism 7900HT (Applied Biosystems, Foster City/CA, USA) with bGHPolyA specific primers 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3) (forward) and 5'-GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4) (Reverse). To generate standard curves, known copy numbers of the corresponding vector plasmid was used.

[0108] The mRNA was isolated from different organs using a NucleoSpin RNA extraction kit (Machery-Nagel, Germany). Using a cDNA synthesis kit (Invitrogen corp, Carlsbad, CA, USA), RNA from each organ was reverse transcribed to cDNA. cDNA was then analyzed by qPCR ABI Prism 7900HT (Applied Biosystems, Foster City/CA, USA) using bGHPolyA specific primers 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3) (forward) and 5'-GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4) (Reverse). To expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression, obtained by using the forward primer 5'-GAAGGTGAAGGTCGGAGTC-3' (SEQ ID NO:18) and reverse primer 5'-GAAGATGGTGATGGGATTTC-3' (SEQ ID NO:19).

Statistics

[0109] Data were analyzed using Microsoft Excel Statistics package. Values shown in the figures are the mean + SEM. Specific values were obtained by comparison using t-test.

Results

[0110] Figure 4 shows that administration of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector to hemophilia B mice provides for significantly higher FIX levels and activity compared to the AAV9-SerpEnh-TTRm-MVM-co-hFIX vector. The FIX response was dose-dependent. Therapeutic FIX levels could be attained at relatively low vector doses of 1×10^9 vgc/mouse, 5×10^9 vgc/mouse, and 2×10^{10} vgc/mouse. Furthermore, these vector doses are safe as no thrombolysis was observed (Fig. 4J). Figure 5 shows that FIX was specifically expressed in the liver (Fig. 5 C-D), despite transduction of the vector in other organs (Fig. 5 A-B).

[0111] To further assess the clinical relevance of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-

R338L vector, a tail-clipping assay was performed on hemophilia B mice treated with 1×10^9 vg/mouse of the vector (n=5). Wild-type (C57BL6) (n=4) and untreated hemophilia B (HemoB) mice (n=4) were used as controls. Survival rate for each cohort was monitored and the FIX clotting activity were analyzed. The results are summarized in Table 1 and show that administration of the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vector allows for correcting the bleeding phenotype.

Table 1: Tail-clipping assay

	Survival	FIX activity
Wild-type mice	4/4	-
untreated HemoB mice	0/4	0.0013%
treated HemoB mice	5/5	33%

[0112] To assess the immune consequences of expressing the hyper-functional FIX Padua at high levels, the anti-FIX antibody response before and after active immunization with wild-type FIX protein and adjuvant was analyzed. The results show that immune tolerance could be achieved since none of the mice treated with the AAV9-SerpEnh-TTRm-MVM-co-hFIX-R338L vectors developed anti-FIX antibodies, in contrast to the controls that were not treated with this vector (Fig.4K).

Example 3: Liver-specific expression of FVIII via AAV vector gene delivery.

Materials and methods

Vector construction

[0113] AAV-based vectors were constructed that express a codon-optimized B domain-deleted human coagulation factor VIII (hFVIIIcopt) cDNA (Ward et al., 2011) from the minimal TTR (TTRm) promoter operably linked to the nucleic acid regulatory element Serpin enhancer ("Serp" or "SerpEnh") described in WO 2009/130208, which is specifically incorporated by reference herein. The codon-optimized B domain-deleted human FVIII cDNA was PCR amplified and subcloned into a pGEM-T easy plasmid (Promega, Belgium) and after restriction with SpeI-BamHI, the FVIII cDNA was cloned into the NheI-BglII restricted pAAV-SerpEnh-TTRm vector to generate AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA (also indicated as AAVss-SerpTTRm-MVM-FVIIIcopt-sv40pA herein). This vector also contained a small intron from minute virus of mouse (MVM) to boost FVIII expression levels.

Vector production

[0114] For titration of the AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vector, primers binding the SV40 polyA region were used, including 5'-TGATGCTATTGCTTTATTTGTAACC-3' (SEQ ID NO:20) as forward primer, 5'-CCTGAACCTGAAACATAAAATGA-3' (SEQ ID NO:21) as reverse primer and 5'-FAM-AGCTGCAATAAACAAGTTAACAACAACAATTGCA-TAMRA-3' (SEQ ID NO:22) as probe. Titers were achieved in the normal range of $2\text{-}5 \times 10^{12}$ vg/ml. Briefly, reactions were performed in TaqMan® Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Known copy numbers ($10^2\text{-}10^7$) of the vector plasmid used to generate the AAV vector were used to generate the standard curves.

Animal studies

[0115] The AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vectors were injected intravenously into adult male SCID mice (CB17/lcrTac/Prkdc scid) at a dose of 5×10^9 vg/mouse or 2.5×10^{11} vg/kg.

FVIII expression analysis

[0116] Human (h) FVIII antigen levels were assayed in citrated mouse plasma using a hFVIII-specific enzyme-linked immunosorbent assay (ELISA) (Asserachrom® VIII:Ag, Diagnostica Stago, France), as per the manufacturer's instructions. Samples were diluted in sample diluent provided and analyzed in triplicate. Standard curves in percentage FVIII antigen activity were constructed by diluting normal control plasma. In brief, 200 µl diluted samples and standards were pipetted into the wells of the strips pre-coated with mouse monoclonal anti-human FVIII Fab fragments and incubated for 2 hours at room temperature for antigen immobilization. The wells were then washed with the wash buffer for 5 times before adding 200 µl mouse monoclonal anti-hFVIII antibody coupled with peroxidase for immobilization of immunoconjugate. After incubation for 2 hr at room temperature and washing, 200 µl of TMB substrate was added to the wells for color development. This mixture was incubated at room temperature for exactly 5 minutes. The reaction was then stopped by 50 µl 1M H₂SO₄ and then read at 450 nm within 1h.

Results

[0117] High-titer AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vectors expressing a codon-optimized B-domain deleted human FVIII cDNA (hFVIIIcopt) from a liver-specific promoter (TTRm) operably linked to a regulatory element ("Serp" or "SerpEnh") could be

produced with a total insert size of 4913 bp (excluding ITR) (Fig. 6). Intravenous injection of a very low vector dose (5×10^9 vg/mouse) resulted in therapeutic FVIII levels approximating 421.8 ± 4.9 ng/ml (i.e. $210.9 \pm 3.1\%$ of normal levels) (Fig. 7). To our knowledge, AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA vector is the most robust AAV-FVIII vector design to date.

Example 4: Enhanced, liver-specific expression of FVIII and FIX via transposon-based gene delivery.

Materials and methods

[0118] The codon-optimized hyperactive PB transposase (huPB) was cloned into pcDNA3 and expressed from the CAG promoter (Fig. 8A,B). The hyperactive SBmax transposase was cloned into pcDNA3 and expressed from the CAG promoter (Fig. 8K,L). A codon-optimized B-domain deleted FVIII (hFVIIIcopt), described as SQ FVIII (co) in Ward et al. (2011) was cloned by conventional cloning techniques into a PB transposon to generate the PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA-D4Z4 (Fig. 8C,D). The human codon-optimized FIX cDNA and the codon-optimized FIX cDNA with the hyperactivating Padua mutation were cloned by conventional cloning techniques into a PB transposon to generate the PB_micro_T_No_Ins_TTRminSerpMVM_hFIXco_bghpA (Fig. 8E,F) and PB_micro_T_No_Ins_TTRminSerpMVM_hFIXco_Padua_bghpA (Fig. 8G,H), respectively. The human codon-optimized FIX cDNA was cloned by conventional cloning techniques into an SB-based vector to generate pT2BH_TTRminSerpMVM_hFIXco_bghpA (Fig. 8I,J).

[0119] The transgenes were expressed from a liver-specific minimal transthyretin (TTRm) promoter along with the Serpin enhancer ("Serp" or "SerpEnh"). The constructs also contained a mouse mini-intron (MVM) and a polyadenylation site. The recombinant clones were verified by restriction analysis and sequencing.

[0120] The different FVIII-transposons and matching plasmids encoding the cognate hyperactive transposases (i.e. huPB and SBmax, respectively) were purified by ion exchange chromatography and transfected by hydrodynamic transfection at varying transposon/transposase ratios and concentrations into adult mice. Controls without transposase were employed. The FIX expression was monitored by ELISA or using chromogenic activity assays in hemophilia B mice. FVIII expression in SCID mice was assessed using a human FVIII-specific ELISA.

Results

[0121] Incorporation of the Serpin enhancer into the PB transposons resulted in robust, stable

gene transfer efficiencies in hepatocytes yielding high unprecedented activity of the codon-optimized FIX Padua (hFIXco-R338L), when the hyperactive hyPB transposase was employed (Fig. 9A). Conversely, in the absence of the hyperactive hyPB transposase, expression declined gradually to basal levels, consistent with our previous observations that transposition is required for stable gene expression in the liver. Molecular analysis, performed 1 year post-transfection, confirmed stable genomic integration of the FIX-transposons. Moreover, side-by-side comparisons revealed a nearly 100-fold increase in FIX expression with this optimized FIX transposon compared to early-generation transposon design.

[0122] Fig. 10 demonstrates that the use of the liver-specific Serpin enhancer ("Serp" or "SerpEnh") in conjunction with codon-optimized B-domain deleted FVIII (hFVIIIcopt), and the hyperactive hyPB system resulted in robust, stable gene transfer efficiencies in hepatocytes, yielding high unprecedented expression levels of FVIII. Conversely, in the absence of the hyperactive hyPB transposase, expression declined gradually to basal levels. This confirms that stable genomic integration by transposition is required for stable hepatic FVIII gene expression.

[0123] Sleeping Beauty (SB) transposon (pT2BH_TTRminSerpMVM_hFIXco_bghpa) was compared side by side with the PiggyBac (PB) transposon (PB_micro_T_No_Ins_SerpTTRminMVM_hFIXco_BGHPA) in immunodeficient NOD SCID mice using two different doses as indicated (Fig. 11). One month post-injection of the transposon and transposase plasmids, blood was collected. FIX ELISA was performed to determine the amount of FIX expression. About 1500-2000 ng/ml of FIX antigen was detected in both, SB and PB, transposons. These data show that the SB and PB vectors are equally potent and can induce high therapeutic level of FIX expression amounting to about 30-40 % of normal FIX.

[0124] No adverse events were noted in the different mouse models with any of the transposons, regardless of the transgene, that could be ascribed to the transposition or to the transient transposase expression.

[0125] To further ascertain the safety of the PB transposons we administered the transposons by hydrodynamic transfection into a tumor prone mouse model. In this model, mice were injected repeatedly with the carcinogen N,N-diethylnitrosamine (DEN) and developed hepatocellular carcinoma. The tumor burden was assessed 36 weeks post-DEN injection. We did not observe any statistically significant difference in tumor mass or number of tumor nodules in mice treated with the transposons vs. controls without transposition. These data indicate that PB transposition in itself does not significantly increase tumorigenicity, even in an HCC tumor-prone mouse model, which supports its safety.

Example 5: Enhanced expression of FVIII and FIX by cloning the MVM intron into the nucleic acid expression cassette.

Materials and methods

[0126] A piggyBac transposon plasmid was constructed that comprises human FIX cDNA cloned downstream of a liver-specific minimal transthyretin (TTRmin) promoter operably linked to the Serpin regulatory sequence ("Serp" or "SerpEnh" or "HSH8"). The bovine growth hormone poly A (bghpA) was provided as a transcription termination signal. Human FIX cDNA comprises a truncated 1.4 kb intron A between exons 1 and the following exons 2-8. A schematic representation of said transposon, denoted as pB_hFIXIA, is shown in Figure 12A.

[0127] A piggyBac transposon plasmid was constructed that contains a synthetic codon-optimized human FIX cDNA without intron A. Said codon-optimized hFIX cDNA was cloned downstream of a liver-specific minimal transthyretin (TTRmin) promoter operably linked to the Serpin regulatory sequence ("Serp" or "SerpEnh" or "HSH8"). A minute virus of mice (MVM) intron was cloned between the TTRmin promoter and the hFIXco transgene. The bovine growth hormone poly A (bghpA) was provided as a transcription termination signal. A schematic representation of said transposon, denoted as pB_hFIXco, is shown in Figure 12B. The plasmids were constructed by conventional cloning and DNA synthesis.

[0128] Hemophilia B mice were hydrodynamically injected with 10 µg transposon plasmid and 2 µg of mouse transposase plasmid mpBase (Fig. 12C) or empty control plasmid (Fig. 12D) diluted in 2 ml of PBS into the tail vein. Typically, the injection took less than 10 s for each mouse. Determination of hFIX levels and activity occurred as described in Example 2.

Transposon genome copy number quantification

[0129] Genomic DNA was extracted from frozen liver samples according to DNeasy Blood & Tissue Kit protocol (Qiagen, Chatsworth, CA, USA). RNase A (Qiagen, Chatsworth, CA, USA) treatment was carried out to eliminate carry-over RNA. Transposon copy numbers were quantified by qPCR using a primer set against a specific region common to both transposon constructs using forward primer 5'- AACAGGGGCTAAGTCCACAC -3' (SEQ ID NO: 25) and reverse primer 5'- GAGCGAGTGTTCGATACTCT -3' (SEQ ID NO: 26). Briefly, 50 ng of genomic DNA from each sample was subjected to qPCR in triplicate using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City/CA, USA) and Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City/CA, USA). Copy number was determined comparing the amplification signal with a standard curve consisting of serial dilutions over a 6 log range of the corresponding linearized plasmid spiked with 50 ng of liver genomic DNA from saline-injected mouse (slope ≈ -3,3, intercept ≈ 35, efficiency % ≈ 100). Average copies per diploid genome were calculated taking into account that one murine diploid genome = 5,92 pg.

hFIX mRNA expression analysis

[0130] Total RNA was extracted from frozen liver samples using a miRCURY™ RNA isolation kit (Exiqon, Denmark). DNase (Thermo Scientific, USA) treatment was carried out. The reverse transcription reaction was performed starting from 1 µg of total RNA from each sample using the SuperScript® III First Strand cDNA Synthesis Kit (Life Technologies, USA). Next, a cDNA amount corresponding to 10 ng of total RNA from each sample was analyzed in triplicate by quantitative (q)PCR using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City/CA, USA) and Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City/CA, USA). The following primer set was used: forward primer 5'-GCCTTCTAGTTGCCAGCCAT-3' (SEQ ID NO:3), reverse primer 5'-GGCACCTTCCAGGGTCAAG-3' (SEQ ID NO:4). The hFIX mRNA levels were normalized using a primer set against the mRNA of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (mGAPDH) which is uniformly and constantly expressed in all samples (i.e. forward primer 5'-ATCAAGAAGGTGGTGAAGCAGGCA-3' (SEQ ID NO:27) and reverse primer 5'-TGGAAGAGTGGGAGTTGCTGTTGA-3' (SEQ ID NO:28)). RNA samples were amplified with and without reverse transcriptase to exclude genomic DNA amplification. The $2^{-\Delta\Delta Ct}$ relative quantification method was used to determine the relative changes in hFIX mRNA expression level. The ΔCt was calculated by subtracting the Ct of mGAPDH mRNA from the Ct of the hFIX mRNA ($Ct_{hFIX} - Ct_{GAPDH}$). The $\Delta\Delta Ct$ was calculated by subtracting the ΔCt of the reference sample (highest Ct) from the ΔCt of each sample ($\Delta Ct_{sample} - \Delta Ct_{reference}$). Fold-change was determined by using the equation $2^{-\Delta\Delta Ct}$.

Results

[0131] As shown in Figures 12E and F, hFIX expression and activity is transient and gradually declines to basal levels in mice that were co-injected with the empty control plasmid (Fig. 12E: pB_hFIXIA + empty plasmid: 46 ± 13 ng/ml hFIX, $0,87 \pm 0,2\%$ normal clotting activity and Fig. 12F: pB_hFIXco + empty plasmid: 48 ± 22 ng/ml hFIX, $0,97 \pm 0,49\%$ normal clotting activity). These results indicate that stable transposition is necessary for sustained expression, but the non-integrated pB-hFIXIA or pB-hFIXco plasmids may have contributed to the initial surge in hFIX expression

[0132] The transposon plasmid comprising the MVM intron yielded significantly higher hFIX levels and activity as compared to the plasmid without MVM intron when co-delivered with the mouse transposase plasmid (Fig. 12E,F). Liver-directed hydrodynamic co-transfection of the pB-hFIXIA transposon without MVM intron (10 µg) along with 2 µg mPB plasmid, resulted in stable therapeutic hFIX antigen and activity levels for at least up to 12 months in hemophilic FIX-deficient mice (Fig. 12E, 1168 ± 218 ng/ml hFIX and $32 \pm 6\%$ normal clotting activity). Similarly, liver-directed co-transfection of the pB_hFIXco transposon with MVM intron and mPB plasmid resulted in a significant ≈ 12 -fold higher ($p < 0.001$) hFIX protein and activity level that stabilized in the supra-physiologic range (Fig. 12F: 13290 ± 990 ng/ml hFIX and $313 \pm 7\%$ normal clotting activity). The increase in hFIX protein levels was consistent with a more than

57-fold increase in hFIX mRNA levels when comparing the transposon with and without the MVM intron (Fig. 12 H), although the transposon copies per genome content were similar in the liver of mice that were injected with pB hFIXIA and pB hFIXco (Fig. 12G).

Example 6: Comparison of expression cassettes comprising a FVIII transgene.

Material and methods

[0133] The AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid of Example 3 was compared to:

1. (a) AAV9ss-TTRm-MVM-hFVIII-SV40pA,
2. (b) AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA, and
3. (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA.

[0134] AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA plasmid (c) was constructed by excising the Serpin enhancer from AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA plasmid.

[0135] Mice were hydrodynamically injected with 2 µg or 5 µg of the plasmid DNA diluted in 2 ml of phosphate buffered saline (PBS) and injected into the tail vein. Typically, the injection took less than 10 s for each mouse. FVIII expression analysis was carried out as described in Example 3.

Results

[0136] The AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA (c) and AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA (d) constructs were hydrodynamically injected in mice at 2 µg and 5 µg DNA, and human FVIII levels were measured 1, 2 and 6 days post-transfection.

[0137] The effect of cloning the Serpin enhancer into the expression cassette on hFVIII levels can be calculated by dividing the hFVIII levels measured in mice injected with construct (d) by the levels measured in mice injected with construct (c). 3- to 6-fold higher hFVIII levels can be obtained by cloning the Serpin enhancer into the expression cassette (Table 2).

[0138] The codon-optimized B domain-deleted human coagulation factor VIII (hFVIIIcopt) cDNA was reported to achieve 29- to 44-fold increase in expression (Ward et al. 2011). We used the average increase in expression of 36.5 to predict the hFVIII levels in mice that are transfected with AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA construct (b), namely by dividing the hFVIII levels measured in mice transfected with construct (d) by 36.5.

[0139] Based on said predicted hFVIII levels in mice that are hydrodynamically injected with AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA construct (b), we can further predict the hFVIII levels in mice that are hydrodynamically injected with AAV9ss-TTRm-MVM-hFVIII-SV40pA construct (a) by dividing said predicted hFVIII levels by the calculated effect of cloning the Serpin enhancer into the expression cassette on hFVIII levels.

[0140] The measured and predicted hFVIII levels in mice hydrodynamically injected with the different constructs a-d are summarized in Table 3 and Figures 13A and 13B.

Table 3: hFVIII levels in mice hydrodynamically injected with 2 or 5 µg of plasmids (a) AAV9ss-TTRm-MVM-hFVIII-SV40pA, (b) AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA, (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA, and (d) AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-SV40pA.

	(a) AAVss-TTRm-MVM-hFVIII	(b) AAVss-SERP-TTRm-hFVIII	(c) AAVss-TTR-MVM-hFVIIIcopt	(d) AAVss-SERP-TTR-MVM-hFVIIIcopt
	Predicted level: (a) = (b) : [(d): (c)]	Predicted level: (b) = (d) : 36,5x	Measured level	Measured level
	<i>no SERP, no codon-optimization</i>	<i>SERP</i>	<i>codon-optimization</i>	<i>SERP + codon-optimization</i>
Day 1	2 µg = 11/4 = 3 ng/ml	2 µg = 11 ng/ml	2 µg = 102 ng/ml	2 µg = 412 ng/ml
	5 µg = 20/3,3 = 6 ng/ml	5 µg = 20 ng/ml	5 µg = 227 ng/ml	5 µg = 751 ng/ml
Day 2	2 µg = 4,1/1,9 = 2 ng/ml	2 µg = 4,1 ng/ml	2 µg = 77 ng/ml	2 µg = 150 ng/ml
	5 µg = 11,7/3,3 = 3,5 ng/ml	5 µg = 11,7 ng/ml	5 µg = 129 ng/ml	5 µg = 429 ng/ml
Day 6	2 µg = 1/3,5 = 0,28 ng/ml	2 µg = 1 ng/ml	2 µg = 11 ng/ml	2 µg = 39 ng/ml
	5 µg = 6,4/5,9 = 1 ng/ml	5 µg = 6,4 ng/ml	5 µg = 39 ng/ml	5 µg = 233 ng/ml

[0141] The data shows that expression cassettes comprising the specific combination of the codon-optimized B domain-deleted human coagulation factor VIII (hFVIIIcopt) cDNA described in Ward et al. (2011) and the Serpin enhancer can induce hFVIII levels that are significantly higher as compared to the sum of the hFVIII levels that are obtained by expression cassettes comprising each of these elements alone (Table 4, Figures 13C and 13D). In other words, said specific combination of hFVIIIcopt cDNA and the Serpin enhancer provides for a synergistic effect on hFVIII levels.

Table 4: Comparison of hFVIII levels induced by AAV9ss-SerpEnh-TTRm-MVM-hFVIIIcopt-

SV40pA construct (d) as compared to the levels induced by (b) AAV9ss-SerpEnh-TTRm-MVM-hFVIII-SV40pA construct and (c) AAV9ss-TTRm-MVM-hFVIIIcopt-SV40pA construct, and as compared to the levels induced by (a) AAV9ss-TTRm-MVM-hFVIII-SV40pA construct.

	(b) + (c)	(d) / [(b)+(c)]	(d) / (a)
Day 1	2 µg = 11 + 102 = 113 ng/ml	2 µg = 412 / 113 = 3,6x >>>	2 µg = 412 / 3 = 137x >>>
	5 µg = 20 + 227 = 247 ng/ml	5 µg = 751 / 247 = 3x >>>	5 µg = 751 / 6 = 125x >>>
Day 2	2 µg = 77 + 4 = 81 ng/ml	2 µg = 150/81 = 1,8x >>>	2 µg = 150/2 = 75x >>>
	5 µg = 11 + 129 = 140 ng/ml	5 µg = 429 / 140 = 3x >>>	5 µg = 429 / 3,5 = 122x >>>
Day 6	2 µg = 11 + 1 = 12 ng/ml	2 µg = 39/12 = 3,25x >>>	2 µg = 39 / 0,28 = 139x >>>
	5 µg = 39 + 6,4 = 45,4 ng/ml	5 µg = 233 / 45,4 = 5,1x >>>	5 µg = 233 / 1 = 223x >>>

Example 7: Comparison of expression cassettes comprising a FIX transgene.

Material and methods

[0142] AAV-based plasmids comprising a FIX transgene were constructed as described in Example 2.

[0143] FIX knockout mice were hydrodynamically injected with 2 µg of each of the following FIX plasmids diluted in 2 ml of phosphate buffered saline (PBS) into the tail vein:

1. (a): AAVsc-TTRm-MVM-hFIX-pA;
2. (b): AAVsc-SerpEnh-TTRm-MVM-hFIX-pA;
3. (c): AAVsc-TTRm-MVM-hFIXco-pA
4. (d): AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA
5. (e): AAVsc-TTRm-MVM-hFIXcoPadua-pA
6. (f): AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA

[0144] Blood was collected from these mice at day 2 and day 6 post-injection. FIX activity was determined as described in Example 2.

Results

[0145] FIX activity as measured in the different mice is summarized in Table 5.

Table 5: hFIX activity at days 2 and 6 post-injection in mice hydrodynamically injected with 2 μ g of (a) AAVsc-TTRm-MVM-hFIX-pA plasmid, (b) AAVsc-SerpEnh-TTRm-MVM-hFIX-pA plasmid, (c) AAVsc-TTRm-MVM-hFIXco-pA plasmid, (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA plasmid, (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid, and (f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA plasmid.

	(a) AAVsc-TTRm-MVM-hFIX-pA	(b) AAVsc-SerpEnh-TTRm-MVM-hFIX-pA	(c) AAVsc-TTRm-MVM-hFIXco-pA	(d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA	(e) AAVsc-TTRm-MVM-hFIXcoPadua-pA	(f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA
	no SERP, no codon-optimization, no Padua	SERP	codon-optimization	SERP + codon-optimization	codon-optimization + Padua	SERP + codon-optimization + Padua
Day 2	5.92%	42.99%	6.36%	74.25%	75.09%	289.34%
Day 6	1.00%	12.90%	0.23%	34.32%	18.48%	265.71%

[0146] The data shows that the specific combination of codon-optimized human coagulation factor IX (hFIXco) cDNA and the Serpin enhancer results in hFIX activity that is higher than would have been predicted based on the sum of the hFIX activity determined in mice hydrodynamically injected with plasmids (b) and (c) comprising either a Serpin enhancer (b) or a codon-optimized hFIX transgene (c) (Table 6, Figures 14A and 14B). In other words, said specific combination of hFIXco cDNA and the Serpin enhancer provides for a synergistic effect on hFIX activity.

[0147] To evaluate the combination of the Serpin enhancer and the Padua mutation on hFIX activity, hFIX activity in mice hydrodynamically injected with (f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA plasmid was compared versus hFIX activity in mice hydrodynamically injected with (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA plasmid and (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid (Table 6, Figures 14C and 14D). The combination of the Serpin enhancer and the Padua mutation provides for a synergistic effect on hFIX activity.

[0148] Also the combination of the Serpin enhancer with codon-optimized transgene encoding hFIX containing the Padua mutation shows synergy on hFIX activity, as revealed by comparing hFIX activity in mice injected with (f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA plasmid versus hFIX activity in mice injected with (b) AAVsc-SerpEnh-TTRm-MVM-hFIX-pA plasmid, and (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid.

Table 6: Comparison of hFIX activity induced by the different FIX plasmids: (a) AAVsc-TTRm-MVM-hFIX-pA plasmid, (b) AAVsc-SerpEnh-TTRm-MVM-hFIX-pA plasmid, (c) AAVsc-TTRm-MVM-hFIXco-pA plasmid, (d) AAVsc-SerpEnh-TTRm-MVM-hFIXco-pA plasmid, (e) AAVsc-TTRm-MVM-hFIXcoPadua-pA plasmid, and (f) AAVsc-SerpEnh-TTRm-MVM-hFIXcoPadua-pA plasmid.

(b) + (c)	(d) / (b) + (c)	(d) + (e)	(f) / (d) + (e)	(b) + (e)	(f) / (b) + (e)	(d) / (a)	(f) / (a)
	SERP + codon-optimization		SERP + Padua		SERP + codon-optimization + Padua		
42,99 + 6,36 = 49,35%	74,25 / 49,35 = 1,5x ↑	74,25 + 75,09 = 149,34%	289,34 / 149,34 = 1,9x ↑	42,99 + 75,09 = 118,08%	289,34 / 118,08 = 2,5x ↑	74,25 / 5,92 = 12,5x	289,34 / 5,92 = 48,9x
12,90 + 0,23 = 13,13%	34,32 / 13,13 = 2,6x ↑	34,32 + 18,48 = 52,80%	265,71 / 52,80 = 5,0x ↑	12,90 + 18,48 = 31,38%	265,71 / 31,38 = 8,5x ↑	34,32 / 1 = 34,32x	265,71 / 1 = 265,71x

Example 8: Evaluation of the piggyBac transposon system.

Materials and methods *Transposon constructs*

[0149] pB_hFIXIA (Fig. 12A) and pB_hFIXco (Fig. 12B) plasmids were constructed as described in Example 5.

[0150] A terminal inverted repeat of pB_hFIXco (IR_{wt}) was replaced by a terminal inverted repeat containing T53C and C136T point mutation (IR_{mut16}) to generate pB_hFIXco/IR_{mut16} (Fig. 15A).

[0151] The terminal inverted repeats of pB_hFIXco were replaced by micro terminal inverted repeats as described in Meir et al. (2011) (IR_{micro}) to yield pB_hFIXco/IR_{micro} (Fig. 15B).

[0152] pB_hFIX-R338L plasmid (Fig. 15C) containing hyper-functional, codon-optimized hFIX transgene with Padua mutation was constructed by site-directed mutagenesis using pB_hFIXco/IR_{micro} as template.

Hydrodynamic injection, analysis of hFIX levels and activity and anti-hFIX antibodies

[0153] Plasmids were diluted in 2 ml of Dulbecco's PBS and hydrodynamically delivered to adult mice (6-7-week-old) by rapid tail vein injection. At different time intervals, we collected whole blood ($\approx 200\mu\text{l}$) by phlebotomy of the retro-orbital plexus in eppendorf tubes prefilled with 20% citrate buffer that were centrifuged at 14000 r.p.m. for 5 min at 4°C. The citrated plasma was stored at -80°C for future analysis.

[0154] hFIX antigen levels and activity and antibodies directed against hFIX were analyzed as described in Example 2.

Tail clipping assay

[0155] A tail-clipping assay was used on hemophilic mice to assess phenotypic correction of the bleeding phenotype. Briefly, the tails of mice were transected (1 cm from the end) and mice were monitored for clotting and survival. Tail clip was performed on immobilized mice, allowing continuous blood collection at room temperature and total blood volume, bleeding time and survival rate were monitored.

Results

[0156] To assess the immune consequences of treating hemophilia B mice with piggyBac transposons expressing hFIXIA, hFIXco or hFIXco-R338L, the anti-FIX antibody response was analyzed after active immunization with recombinant hFIX antigen and adjuvant.

[0157] None of the hemophilia B mice treated with the PB transposons expressing hFIXIA, hFIXco or hFIXco-R338L (Padua) developed an anti-hFIX specific antibody response (Fig.15E). This indicates that liver-directed gene therapy using the various PB transposons encoding either hFIXIA, hFIXco or hFIXco-R338L (Padua) induced immune tolerance to the hFIX protein.

[0158] A tail-clip assay showed that the bleeding diathesis of hemophilia B mice transfected with pB-hFIXIA or pB-hFIXco and plasmid encoding mPBase was phenotypically corrected 1 year post-transfection (Table 7). Bleeding time and volume were lower in mice transfected with plasmid comprising codon-optimized hFIX transgene and MVM intron compared to mice transfected with wild-type hFIX transgene.

Table 7: Phenotypic correction of murine hemophilia B following tail clipping 48 weeks after gene transfer. 2 μg plasmid encoding mPBase was co-delivered with the indicated transposon plasmids via hydrodynamic injection. hFIX concentration (ng/ml) at the time of tail clipping is indicated. Bleeding time and volume were assayed following clipping of a section of tail 1 cm in length. Values represent means $\pm$ SEM

Group	Transposon plasmid	hFIX (ng/ml)	Bleeding time (min)	Bleeding volume (μ l)	Survival
C57BL/6	none	0	30 $\pm$ 5	146 $\pm$ 31	3/3
FIX ^{-/-}	none	0	294 $\pm$ 50	1433 $\pm$ 57	0/3
FIX ^{-/-}	pB_hFIXIA	1168 $\pm$ 218	109 $\pm$ 10	677 $\pm$ 52	3/3
FIX ^{-/-}	pB_hFIXco	13290 $\pm$ 990	57 $\pm$ 12	500 $\pm$ 45	3/3

[0159] The efficiency of the piggyBac platform could be improved by using the hyperactive PB transposase (hyPBase) described in Yusa et al. (2011) (Fig. 15D), allowing the use of lower transposon/transposase doses. This hyPBase contained several mutated residues compared to the mouse codon-usage optimized mPBase (compare Fig. 15D with 12C). Liver-directed hydrodynamic transfection of immune deficient SCID mice with 500 ng of *pB-hFIXco* transposon along with 1000 ng hyPB resulted in stable supra-physiologic hFIX levels corresponding to 200% of normal hFIX levels (Fig. 15F). These FIX levels were significantly higher ($p < 0.001$) than what could be achieved with the original mPB transposase. Similarly, liver-directed transfection of SCID mice with 50 ng of *pB-hFIXco* transposon plasmid along with 100 ng hyPB resulted in a dose-dependent effect yielding therapeutic hFIX levels corresponding to 20% of normal levels. This represented a significant 20-fold increase ($p < 0.001$) in FIX levels compared to when the mPB transposase was used (Fig 15G).

[0160] To evaluate the effect of the terminal repeats *IR_{micro}* and *IR_{mut16}* on the *in vivo* potency of the PB transposons, mice were hydrodynamically injected with *pB-hFIXco* (Fig.12B), *pB-hFIXco/IR_{mut16}* (Fig. 15A) or *β -hFIXco/IR_{micro}* (Fig. 15B) along with hyPBase. A significant 1.5-fold increase in hFIX expression was apparent when the *IR_{micro}* was used compared to its wild-type counterpart (Fig. 15 H-I). Liver-directed transfection of the *PB-hFIXco/IR_{micro}* transposon (500 ng) along with 1000 ng hyPB transposase-encoding plasmid resulted in stable FIX levels reaching approximately 300% of normal hFIX levels (Fig. 15H). Similarly, at 10-fold lower *PB-hFIXco/IR_{micro}* and hyPB doses a dose-dependent decrease in hFIX expression was apparent, yielding 30% of normal hFIX levels (Fig. 15I). In contrast, FIX expression was not or only slightly increased when the *IR_{mut16}* was used compared to the *IR_{wt}*. (Fig. 15 J-K).

References

[0161]

ANNONI A, BROWN BD, CANTORE A, SERGI LS, NALDINI L, and RONCAROLO MG. (2009). In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. *Blood* 114, 5152-5161

ARRUDA VR, STEDMAN HH, HAURIGOT V, and BUCHLIS G. (2010). Peripheral transvenular

delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. *Blood* 115, 4678-88.

AXELROD JH, READ MS, BRINKHOUS KM, and VERMA IM. (1990). Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. *Proc Natl Acad Sci USA*; 87, 5173-7.

BROWN BD, SHI CX, POWELL S, HURLBUT D, GRAHAM FL, and LILLICRAP D. (2004). Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. *Blood* 103, 804-10.

BROWN BD, CANTORE A, ANNONI A, SERGI LS, LOMBARDO A, DELLA VALLE P, D'ANGELO A, and NALDINI L. (2007). A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. *Blood* 110, 4144-52.

Brunetti-Pierri N, Grove NC, Zuo Y, Edwards R, Palmer D, Cerullo V, Teruya J, Ng P.

Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. *Hum Gene Ther*. 2009 May;20(5):479-85.

BUCHLIS G, PODSAKOFF GM, RADU A, HAWK SM, FLAKE AW, MINGOZZI F, and HIGH KA. (2012). Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. *Blood* 119, 3038-41.

BUDKER V, ZHANG G, KNECHTLE S, WOLFF JA. Naked DNA delivered intraportally expresses efficiently in hepatocytes. (1996) *Gene Ther*. Jul;3(7):593-8.

CANTORE A, NAIR N, DELLA VALLE P, DI MATTEO M, MÀTRAI J, SANVITO F, BROMBIN C, DI SERIO C, D'ANGELO A, CHUAH M, NALDINI L, VANDENDRIESSCHE T. Hyper-functional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. *Blood*. 2012. Oct 4.

CHANG, J., JIN, J., LOLLAR, P., BODE, W., BRANDSTETTER, H., HAMAGUCHI, N., STRAIGHT, D. L. &STAFFORD, D. W. (1998). Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. *J Biol Chem* 273(20): 12089-12094.

CHOWDHURY JR, GROSSMAN M, GUPTA S, CHOWDHURY NR, BAKER JR JR, WILSON JM. (1991) Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. *Science*. Dec 20;254(5039):1802-5.

CHUAH MK, SCHIEDNER G, THORREZ L, BROWN B, JOHNSTON M, GILLIJNS V, HERTEL S, VAN ROOIJEN N, LILLICRAP D, COLLEN D, VANDENDRIESSCHE T, and KOCHANNEK S. (2003). Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. *Blood* 101, 1734-43.

Chuah MK, Nair N, VandenDriessche T. Recent progress in gene therapy for hemophilia. *Hum Gene Ther*. 2012a Jun;23(6):557-65.

Chuah MK, Nair N, VandenDriessche T. Recent progress in gene therapy for hemophilia. *Hum Gene Ther.* 2012b Jun;23(6):557-65.

Chuah MK, VandenDriessche T. Platelet-directed gene therapy overcomes inhibitory antibodies to factor VIII. *J Thromb Haemost.* 2012c Aug;10(8):1566-9

DONSANTE A, MILLER DG, LI Y, VOGLER C, BRUNT EM, RUSSELL DW, and SANDS MS. (2007). AAV vector integration sites in mouse hepatocellular carcinoma. *Science* 317, 477.

DOBRZYNSKI E, FITZGERALD JC, CAO O, MINGOZZI F, WANG L, and HERZOG RW (2006) Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. *Proc Natl Acad Sci USA* 103, 4592 - 4597.

EHRHARDT A, and KAY MA. (2002). A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. *Blood* 99, 3923-30.

FIELDS PA, ARRUDA VR, ARMSTRONG E, KIRK CHU, MINGOZZI, F. HAGSTROM, J., HERZOG R, HIGH KA. (2001). Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. *Mol. Ther.* 4, 201-210.

FOLLENZI A, BATTAGLIA M, LOMBARDO A, ANNONI A, RONCAROLO MG, and NALDINI L. (2004). Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. *Blood* 103, 3700-9.

GAO GP, ALVIRA MR, WANG L, JOHNSTON J, WILSON JM. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci USA* 99, 11854 -9.

GAO G, VANDENBERGH LH, ALVIRA MR LU Y, CALCEDO R, ZHOU X, and WILSON JM. (2004). Clades of Adeno-associated viruses are widely disseminated in human tissues. *J. Viro* 78, 6381 - 6388.

HERZOG RW, YANG EY, COUTO LB, HAGSTROM JN, ELWELL D, FIELDS PA, BURTON M, BELLINGER DA, READ MS, BRINKHOUS KM, PODSAKOFF GM, NICHOLS TC, KURTZMAN GJ, and HIGH KA. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. *Nat Med.* 5, 56-63.

HERZOG RW, MOUNT JD, ARRUDA VR, HIGH KA, and LOTHROP CD Jr. (2001). Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. *Mol Ther.* 4, 192-200.

HERZOG RW, HAGSTROM JN, KUNG SH, TAI SJ, WILSON JM, FISHER KJ, and HIGH KA. (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. *Proc Natl Acad Sci USA.* 94, 5804 - 5809.

HERZOG RW, FIELDS PA, ARRUDA VR, BRUBAKER JO, ARMSTRONG E, MCCLINTOCK D,

BELLINGER DA, COUTO LB, NICHOLS TC, HIGH KA (2002) Influence of vector dose on factor IX-specific T and B cell responses in muscle- directed gene therapy. *Hum Gene Ther* 13, 1281-1291.

HIGH KA. (2001). Gene Transfer as an approach to treating Hemophilia. *Circ Res.* 88, 137-144.

HIGH KA. (2011) Gene therapy for hemophilia: a long and winding road. *J Thromb Haemost.* 9 Suppl. 1: 2-11.

BAINBRIDGE J, SMITH AJ, BARKER S, et al. (2008) Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis. *N Engl J Med.* 358, 2231-2239.

JIANG H, LILLICRAP D, and PATARROYO-WHITE S. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. *Blood.* 108, 107-15.

KAO, C. Y., LIN, C. N., YU, I. S., TAO, M. H., WU, H. L., SHI, G. Y., YANG, Y. L., KAO, J. T. & LIN, S. W. (2010). FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. *Thromb Haemost* 104(2): 355-365.

KAY MA, BAILEY P, ROTHENBERG S, LELAND F, FLEMING L, PONDER KP, LIU T, FINEGOLD M, DARLINGTON G, POKORNY W, WOO SLC. (1992) Expression of human alpha 1 - antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. *Proc Natl Acad Sci USA.* Jan 1;89(1):89-93.

KAY MA, MANNO CS, RAGNI MV, COUTO LB, MCCLELLAND A, GLADER B, CHEW AJ, TAI SJ, HERZOG RW, ARRUDA V, JOHNSON F, SCALLAN C, SKARSGARD E, FLAKE AW, and HIGH KA. (2000). Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. *Nat Genet.* 24, 257- 61.

KISTNER A, GOSSEN M, ZIMMERMANN F, JERECIC J, ULLMER C, LYBBERT H, BUJARD H. (1996) Doxycycline- mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc Natl Acad Sci U S A.* Oct 1;93(20): 10933-8.

KREN BT, UNGER GM, SJEKLOCHA L, TROSSEN AA, KORMAN V, DIETHELEM-OKITA BM, REDING MT, and STEER CJ. (2009). Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. *J Clin Invest.* 119, 2086-99.

KURIYAMA S, YOSHIKAWA M, ISHIZAKA S, TSUJII T, LKENAKA K, KAGAWA T, MORITA N, MIKOSHIBA K. (1991) A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. *Cell Struct Funct.* Dec;16(6):503-10.

LI H, MALANI N, HAMILTON SR, SCHLACHTERMAN A, BUSSADORI G, EDMONSON SE, SHAH R, ARRUDA VR, MINGOZZI F, WRIGHT JF, BUSHMAN FD, and HIGH KA. (2011). Assessing the potential for AAV vector genotoxicity in a murine model. *Blood.* 117, 3311-9.

LIN, C. N., KAO, C. Y., MIAO, C. H., HAMAGUCHI, N., WU, H. L., SHI, G. Y., LIU, Y. L., HIGH, K. A. & LIN, S. W. (2010). Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. *J Thromb Haemost* 8(8): 1773-1783.

LIU F, SONG Y, LIU D. (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. *Gene Ther.* Jul;6(7):1258-66.

MANNO CS, PIERCE GF, and ARRUDA VR. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med.* 12, 342-7.

MATES L, CHUAH MK, BELAY E, JERCHOW B, MANOJ N, ACOSTA-SANCHEZ A, GRZELA DP, SCHMITT A, BECKER K, MATRAI J, MA L, SAMARA-KUKO E, GYSEMANS C, PRYPUTNIEWICZ D, MISKEY C, FLETCHER B, VANDENDRIESSCHE T., IVICS Z, and IZSVAK Z. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. *Nat Genet.* 41, 753-61.

MÁTRAI J, CHUAH MK, and VANDENDRIESSCHE T. (2010a). Pre clinical and clinical progress in hemophilia gene therapy. *Curr Opin Hematol.* 17, 387-92.

MÁTRAI J, CHUAH MK, and VANDENDRIESSCHE T. (2010b). Recent advances in lentiviral vector development and applications. *Mol Ther.* 18, 477-90.

MÁTRAI J, CANTORE A, BARTHOLOMAE CC, ANNONI A, WANG W, ACOSTA-SANCHEZ A, SAMARA-KUKO E, DE WAELE L, MA L, GENOVESE P, DAMO M, ARENS A, GOUDY K, NICHOLS TC, VON KALLE C, L CHUAH MK, RONCAROLO MG, SCHMIDT M, VANDENDRIESSCHE T, and NALDINI L. (2011). Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. *Hepatology* 53, 1696-707.

MATSUI H, SHIBATA M, BROWN B, LABELLE A, HEGADRON C, ANDREWS C, CHUAH M, VANDENDRIESSCHE T, MIAO CH, HOUGH C, and LILLICRAP D. (2009). A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3⁺ T regulatory cells. *Blood.* 114, 677-85.

MATSUI H, HEGADORN C, OZELO M, BURNETT E, TUTTLE A, LABELLE A, McCARY PB Jr., NALDINI L, BROWN B, HOUGH C, and LILLICRAP D. (2011). A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. *Mol Ther.* 19, 723-30.

McCARTY DM, MONAHAN PE, and SAMULSKI RJ. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther.* 8, 1248-54.

McCARTY DM, FU H, MONAHAN PE, TOULSON CE, NAIK P, and SAMULSKI RJ. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to

overcome the rate-limiting step to transduction in vivo. *Gene Ther.* 10, 2112-8.

McIntosh, J. et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. *Blood* (2013).

MIAO CH, OHASHI K, PATIJN GA, MEUSE L, YE X, THOMPSON AR, and KAY MA .(2000). Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. *Mol Ther.* 1, 522-32.

MIAO H.Z., SIRACHAINAN N., PALMER L., et al. (2004). Bioengineering of coagulation factor VIII for improved secretion. *Blood* 103(9):3412-3419.

MILANOV, ET AL., 2012 Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice *Blood* 119:602-611.

MILLER AD. (1990) Retrovirus packaging cells. *Hum Gene Ther.* Spring;1 (1):5-14.

MINGOZZI F, LIU YL, DOBRZYNSKI E, KAUFHOLD A, LIU JH, WANG Y, ARRUDA VR, HIGH KA, and HERZOG RW. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. *J Clin Invest.* 111, 1347-56.

MINGOZZI F, MAUS MV, HUI DJ, SABATINO DE, MURPHY SL, RASKO JE, RAGINI MV, MANNO CS, SOMMER J, JIANG H, PIERCE GF, ERTL HC, and HIGH KA. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. *Nat Med.* 13, 419-22.

MOUNT JD, HERZOG RW, TILLSON DM, GOODMAN SA, ROBINSON N, MCCLELAND ML, BELLINGER D, NICHOLS TC, ARRUDA VR, LOTHROP CD JR, and HIGH KA. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. *Blood* 99, 2670-6.

NALDINI L, BLOMER U, GALLAY P, ORY D, MULLIGAN R, GAGE FH, VERMA IM, TRONO D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science.* Apr 12;272(5259):263-7.

NATHWANI AC, DAVIDOFF AM, HANAWA H, YUNYU HU, HOFFER FA, NIKANOROV A, SLAUGHTER C, NG CYC, ZHOU J, LOZIER J, MANDRELL TD, VANIN EF, and NIENHUIS AW. (2002). Sustained high- level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. *Blood* 100, 1662-1669.

NATHWANI AC, GRAY JT, NG CY, ZHOU J, SPENCE Y, WADDINGTON SN, TUDDENHAM EG, KEMBALL COOK G, McINTOSH J, BOON-SPIJKER M, MERTENS K, DAVIDOFF AM. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. *Blood* 107, 2653-61.

NATHWANI AC, TUDDENHAM EG, RANGARAJAN S, ROSALES C, MCINTOSH J, LINCH DC, CHOWDARY P, RIDDELL A, PIE AJ, HARRINGTON C, O'BEIRNE J, SMITH K, PASI J,

GLADER B, RUSTAGI P, NG CY, KAY MA, ZHOU J, SPENCE Y, MORTON CL, ALLAY J, COLEMAN J, SLEEP S, CUNNINGHAM JM, SRIVASTAVA D, BASNER-TSCHAKARJAN E, MINGOZZI F, HIGH KA, GRAY JT, REISS UM, NIENHUIS AW, and DAVIDOFF AM. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med*. 365, 2357-2365.

OHLFEST JR, FRANSEN JL, FRITZ S, LOBITZ PD, PERKINSON SG, CLARK KJ, NELSESTUEN G, KEY NS, MCLVOR RS, HACKETT PB, and LARGAESPADA DA. (2004). Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. *Blood* 105, 2691-8.

Petrus, I., Chuah, M. & VandenDriessche, T. Gene therapy strategies for hemophilia: benefits versus risks. *J Gene Med* 12, 797-809 (2010). SANDBERG H, ALMSTEDT A, BRANDT J, et al. (2001). Structural and functional characteristics of the B domain-deleted recombinant factor VIII protein, r-VIII SQ. *Thromb Haemost*. 85(1): 93-100.

SCHUETTRUMPF, J., HERZOG, R. W., SCHLACHTERMAN, A., KAUFHOLD, A., STAFFORD, D. W. & ARRUDA, V. R. (2005). Factor IX variants improve gene therapy efficacy for hemophilia B. *Blood* 105(6): 2316-2323.

SIMIONI, P., TORMENE, D., TOGNIN, G., GAVASSO, S., BULATO, C., IACOBELLI, N. P., FINN, J. D., SPIEZIA, L., RADU, C. & ARRUDA, V. R. (2009). X-linked thrombophilia with a mutant factor IX (factor IX Padua). *N Engl J Med* 361(17): 1671-1675.

SNYDER RO, MIAO CH, PATIJN GA, SPRATT SK, DANOS O, NAGY D, GOWN AM, WINTHER B, MEUSE L, COHEN LK, THOMPSON AR, and KAY MA. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat Genet*. 16, 270 - 276.

SNYDER RO, MIAO C, MEUSE L, TUBB J, DONAHUE BA, HUI-FENG LIN, STAFFORD DW, PATEL S, THOMPSON AR, NICHOLS T, READ MS, BELLINGER DA, BRINKHOUS KM, and KAY MA. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. *Nat Med*. 5, 64-70.

TRAPNELL BC. (1993) Adenoviral vectors for gene transfer. *Adv. Drug Del. Rev*. 12: 185-199.

VANDENBERGHE LH, WANG L, SOMANATHAN S, ZHI Y, FIGUEREDO J, CALCEDO R, SANMIGUEL J, DESAI RA, CHEN CS, JOHNSTON J, GRANT RL, GAO G, and WILSON JM. (2006). Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. *Nat Med*. 12, 967-71.

VANDENDRIESCHE T, VANSLEMBROUCK V, GOOVAERTS I, ZWINNEN H, VANDERHAEGHEN ML, COLLEN D, and CHUAH MK. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. *Proc Natl Acad Sci USA*. 96, 10379-84.

VANDENDRIESSCHE T, THORREZ L, NALDINI L, FOLLENZI A, MOONS L, ZWI BERNEMAN, COLLEN D, and CHUAH MK. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. *Blood* 100, 813-22.

VANDENDRIESSCHE T, THORREZ L, ACOSTA-SANCHEZ A, PETRUS I, WANG L, MA L, DE WAELE L, IWASAKI Y, GILLIJNS V, WILSON JM, COLLEN D, and CHUAH MK. (2007). Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. *J Thromb Haemost.* 5, 16-24.

VANDENDRIESSCHE T, IVICS Z, IZSVÁK Z, and CHUAH MK. (2009). Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. *Blood* 114, 1461-8.

VANDENDRIESSCHE T, and CHUAH MK. (2012). Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. *Hum Gene Ther.* 23, 4-6.

WANG L, TAKABE K, BIDLINGMAIER SM, ILL CR, and VERMA IM. (1999). Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. *Proc Natl Acad Sci USA* 96, 3906-3910.

WANG L, NICHOLS TC, READ MS, BELLINGER DA, and VERMA IM. (2000). Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. *Mol Ther.* 1, 154-158.

WANG L, CAO O, SWALM B, DOBRZYNSKI E, MINGOZZI F, and HERZOG RW (2005) Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. *Gene Ther* 12, 1453-464.

WARD NJ, BUCKLEY SM, WADDINGTON SN, VANDENDRIESSCHE T, CHUAH MK, NATHWANI AC, McLINTOSH J, TUDDENHAM EG, KINNON C, THRASHER AJ, and McVEY JH (2010) Codon optimization of human factor VIII cDNAs leads to high-level expression. *Blood* 117, 798-807.

Ward, N.J. et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. *Blood* 117, 798-807 (2011).

WU Z, SUN J, ZHANG T, YIN C, YIN F, VAN DYKE T, SAMULSKI RJ, and MONAHAN PE. (2008). Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. *Mol Ther.* 16, 280-9.

XU L, GAO C, and SANDS MS. (2003). Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. *Blood* 101, 3924 - 3932.

XU L, NICHOLS TC, SARKAR R, Mc CORQUODALE S, BELLINGER DA, PONDER KP. (2005). Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia

A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 102, 6080-6085.

YAMADA T, IWASAKI Y, TADA H, IWABUKI H, CHUAH MK, VANDENDRIESSCHE T, FUKUDA H, KONDO A, UEDA M, SENO M, TANIZAWA K, KURODA S. (2003) Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. Aug;21 (8):885-90.

YANT SR, MEUSE L, CHIU W, IVICS Z, IZSVAK Z, and KAY MA. (2000). Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet. 25, 35-41.

Yusa et al. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A. 2011;108(4):1531-6.

ZHANG G, BUDKER V, WOLFF JA. (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. Jul 1 ;10(10):1735-7.

ZHONG L, LI B, MAH CS, GOVINDASAMY L, AGBANDJE-MCKENNA, COOPER M, HERZOG RW, ZOLOTUKHIN I, WARRINGTON JR. KH, WEIGEL-VAN AKEN K, HOBBS JA, ZOLOTUKHIN S, MUZYCZKA N, and SRIVASTAVA A (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105, 7827-32.

SEQUENCE LISTING

[0162]

<110> Vrije Universiteit Brussel

<120> Vectors for liver-directed gene therapy of hemophilia and methods and use thereof

<130> VUB-057-PCT2

<150> PCT/EP2012/071297

<151> 2012-10-26

<150> PCT/EP2013/064054

<151> 2013-07-03

<160> 30

<170> PatentIn version 3.3

<210> 1

<211> 6044

<212> DNA

<213> Artificial

<220>

<223> Adenoviral expression vector pdsAAVsc SerpEnh TTRmin MVM FIXcoptMT-bghpA

<400> 1

```

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag      60
cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggtat ttccatgagc     120
gtttttcctg ttgcaatggc tggcggtaat attgttcttg atattaccag caaggccgat     180
agtttgagtt cttctactca ggcaagtgat gttattacta atcaaagaag tattgcgaca     240
acggttaatt tgcgtgatgg acagactctt ttactcggtg gcctcactga ttataaaaac     300
acttctcagg attctggcgt accgttctctg tctaaaatcc ctttaatcgg cctcctgttt     360
agctcccgct ctgattctaa cgaggaaagc acgttatacg tgctcgtcaa agcaaccata     420
gtacgcgccc tgtagcggcg cattaagcgc ggcggtgtg gtggttacgc gcagcgtgac     480
cgctacactt gccagcgccc tagcgcccg cctttctgct ttcttccctt cctttctcgc     540
cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttccgatt     600
tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatggtt cacgtagtgg     660
gccatcgccc tgatagacgg tttttcgccc ttgacggtg gagtccacgt tctttaatag     720
tggactcttg ttccaaactg gaacaacact caacctatc tcggtctatt cttttgattt     780
ataagggttt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt     840
taacgcgaat ttttaaaaaa tattaacggt tacaatttaa atatttgctt atacaatctt     900
cctgtttttg gggcttttct gattatcaac cggggtacat atgattgaca tgctagtttt     960
acgattaccg ttcategcct gcactgcgcg ctcgctcgt cactgaggcc gcccgggcaa    1020

agcccgggcg tcgggcgacc tttggtcgcc cggcctcagt gagcgagcga gcgcgcagag    1080
agggagtgga attcacgcgt ggtacgatct gaattcggt caattcacgc gtggtacggc    1140
cgcggtaccg gcgcgccggg ggaggctgct ggtgaatatt aaccaaggtc accccagtta    1200
tcggaggagc aaacaggggc taagtcaca cgcgtgttac cgtctgtctg cacatttcgt    1260
agagcgagtg ttccgatact ctaatctccc taggcaaggt tcatatttgt gtaggttact    1320
tattctcctt ttgttgacta agtcaataat cagaatcagc aggtttggag tcagcttggc    1380
agggatcagc agcctggggt ggaaggagg ggtataaaag ccccttcacc aggagaagcc    1440
gtcacacaga tcacaagct cctgaagagg taagggttta agggatggtt ggttggtggg    1500
gtattaatgt ttaattacct ggagcacctg cctgaaatca ctttttttca ggttggttag    1560
catgcagcgc gtgaacatga tcatggccga gagccccggc ctgatcacca tctgcctgct    1620
gggtacctg ctgagcgccg agtgaccctg gttcctggac caggagaacg ccaacaagat    1680
cctgaaccgc cccaagcgtt acaacagcgg caagctggag gagttcgtgc agggcaacct    1740
ggagcgcgag tgcattggag agaagtgcag cttcgaggag gcccgcgagg tgttcgagaa    1800
caccgagcgc accaccgagt tctggaagca gtacgtggac ggcgaccagt gcgagagcaa    1860
cccctgcctg aacggcggca gctgcaagga cgacatcaac agctacgagt gctggtgccc    1920

```

cttcggettc gagggcaaga actgcgagct ggacgtgacc tgcaacatca agaacggccg 1980
 ctgcgagcag ttctgcaaga acagcgccga caacaagggtg gtgtgcagct gcaccgaggg 2040
 ctaccgcctg gccgagaacc agaagagctg cgagcccgcc gtgcccttcc cctgcggccg 2100
 cgtgagcgtg agccagacca gcaagctgac ccgcgcgag gccgtgttcc ccgacgtgga 2160
 ctacgtgaac agcaccgagg ccgagaccat cctggacaac atcaccacaga gcaccagag 2220
 cttcaacgac ttcaccgcg tggtgggcgg cgaggacgcc aagcccgcc agttccctg 2280
 gcaggtggtg ctgaacggca aggtggacgc ttctgcggc ggagcatcg tgaacgagaa 2340
 gtggatcgtg accgcgcgcc actgcgtgga gaccggcgtg aagatcaccc tggtggccgg 2400
 cgagcacaac atcgaggaga ccgagcacac cgagcagaag cgcaacgtga tccgcatcat 2460
 cccccaccac aactacaacg ccgccatcaa caagtacaac cagcatatcg ccctgctgga 2520
 gctggacgag cccctggtgc tgaacagcta cgtgaccccc atctgcatcg ccgacaagga 2580
 gtacaccaac atcttcctga agttcggcag cggtacgtg agcggttggg gccgcgtgtt 2640
 ccacaagggc cgcagcgccc tggtgctgca gtacctgcgc gtgcccctgg tggaccgcgc 2700
 cacctgcctg cgcagacca agttaccat ctacaacaac atgttctgcg ccggttcca 2760
 cgaggcgccg cgcgacagct gccaggcgga cagcgccggc cccacgtga ccgaggtgga 2820
 gggcaccagc ttctgaccg gcatcatcag ctggggcgag gagtgcgcca tgaagggcaa 2880
 gtacggcatc tacaccaagg tgagccgcta cgtgaactgg atcaaggaga agaccaagct 2940

 gacctggaga tctgatcagc ctcgactgtg ccttctagtt gccagccatc tgttgtttgc 3000
 cctcccccog tgccttcctt gacctggaa ggtgccactc ccactgtcct ttctaataa 3060
 aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg ggggtgggtg 3120
 gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcattgctg ggatctgata 3180
 gcaggcatgc tggggagaga tcgatctagg aacccctagt gatggagttg gccactccct 3240
 ctctgcgcgc tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct 3300
 ttggtcgccc ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aacccccccc 3360
 ccccccccc tgcattcagg cgattctctt gtttgcctca gactctcagg caatgacctg 3420
 atagcctttg tagagacctc tcaaaaatag ctacctctc cggcatgaat ttatcagcta 3480
 gaacggttga atatcatatt gatggtgatt tgaactgtct cggcctttct caccgtttg 3540
 aatctttacc tacacattac tcaggcattg catttaaaat atatgagggt tctaaaaatt 3600
 tttatccttg cgttgaaata aaggcttctc ccgcaaaagt attacagggt cataatgttt 3660
 ttggtacaac cgatttagct ttatgctctg aggctttatt gcttaatttt gctaattctt 3720
 tgccttgccct gtatgattta ttggatgttg gaattcctga tgcggtatatt tctccttacg 3780
 catctgtgcg gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc 3840
 gcatagttaa gccagccccg acaccgcca acaccgctg acgcgccctg acgggcttgt 3900
 ctgctcccg ccatcgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 3960
 aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg gcctcgtgat acgcctattt 4020
 ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttttcgggga 4080
 aatgtgcgcg gaaccctat ttgtttattt ttctaataac attcaaatat gtatccgctc 4140
 atgagacaat aacctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 4200

```

caacatttcc gtgtggccct tattcccttt tttgcgccat tttgccttcc tgtttttgct 4260
caccagaaaa cgtgggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt 4320
tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt 4380
tttccaatga tgagcacttt taaagtcttg ctatgtggcg cggattatc ccgtattgac 4440
gccgggcaag agcaactcgg tcgccgcata cactattctc agaattgactt gggtgagtac 4500
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 4560
gccataacca tgagtataa cactgcggcc aacttacttc tgacaacgat cggaggaccg 4620
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 4680
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 4740
atggcaacaa cgttgcgcaa actattaact ggcgaaactac ttactctagc ttcccgcaa 4800

caattaatag actggatgga ggccgataaa gttgcaggac cacttctgcg ctccggccctt 4860
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 4920
attgcagcac tggggccaga tggtaagccc tcccgatcgt tagttatcta caccagggg 4980
agtcaggcaa ctatggatga acgaaataga cagatcgtg agataggtgc ctactgatt 5040
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt 5100
catttttaat ttaaaaggat ctagggtgaag atcctttttg ataactctcat gacccaaatc 5160
ccttaacgtg agttttcggt ccactgagcg tcagaccccg tagaaaagat caaaggatct 5220
tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta 5280
ccagcgttgg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa ggtaactggc 5340
ttcagcagag cgcagatacc aaatactgtc cttctagtgt agccgtagt aggccaccac 5400
ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct 5460
gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat 5520
aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agcccagctt ggagcgaacg 5580
acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac gcttcccgaa 5640
gggagaaaag cggacaggta tccggttaagc ggcagggtcg gaacaggaga gcgcacgagg 5700
gagcttccag ggggaaacgc ctggtatctt tatagtctctg tcgggtttcg ccacctctga 5760
cttgagcgtc gattttttgt atgctcgtca gggggcgga gcctatggaa aaacgccagc 5820
aacgcggcct ttttaagggt cctggccttt tgctggcctt ttgtcacat gttctttcct 5880
gcggttatccc ctgattctgt ggataaccgt attaccgcct ttgagtgagc tgataccgct 5940
cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg aggaagcgga agagcgccca 6000
atacgcaaac cgctctctcc cgcgcggttg ccgattcatt aatg 6044

```

<210> 2

<211> 6044

<212> DNA

<213> Artificial

<220>

<223> Adenoviral expression vector pdsAAVsc SerpEnh TTRmin MVM FIXcopt-PADUA-bghpA

<400> 2

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc cttcccaac agttgcgcag	60
cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggtat ttccatgagc	120
gtttttcctg ttgcaatggc tggcggtaat attgtttctg atattaccag caaggccgat	180
agtttgagtt cttctactca ggcaagtgat gttattacta atcaaagaag tattgcgaca	240
acggttaatt tgcgtgatgg acagactctt ttactcgttg gcctcactga ttataaaaac	300
acttctcagg attctggcgt accgttcctg tctaaaatcc ctttaatcgg cctcctgttt	360
agctcccgct ctgattctaa cgaggaaagc acgttatatg tgctcgtcaa agcaaccata	420
gtacgcgcgc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac	480
cgctacaact gccagcgcgc tagcgcccg ccttttcgct ttcttccctt cctttctcgc	540
cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttcgatt	600
tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatggtt cacgtagtgg	660
gccatcgccc tgatagacgg tttttcgcgc ttgacgttg gagtccacgt tctttaatag	720
tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgattt	780
ataagggtatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt	840
taacgcgaat tttaacaaaa tattaacgtt tacaatttaa atatttgctt atacaatctt	900
cctgtttttg gggtttttct gattatcaac cgggggtacat atgattgaca tgctagtttt	960
acgattaccg ttcacgcct gcactgcgcg ctgcctcgt cactgaggcc gcccgggcaa	1020
agccccggcg tcgggcgacc tttggtcgcc cggcctcagt gagcgagcga gcgcgcagag	1080
agggagtggg attcacgcgt ggtacgatct gaattcggta caattcacgc gtggtacggc	1140
cgcggtaccg gcgcgcgggg ggaggtcgt ggtgaatatt aaccaaggtc accccagtta	1200
tcggaggagc aaacaggggc taagtcaca cgcgtggtac cgtctgtctg cacatttcgt	1260
agagcgagtg ttccgatact ctaatctccc taggcaaggt tcatatttgt gtaggttact	1320
tattctcctt ttgttgacta agtcaataat cagaatcagc aggtttggag tcagcttggc	1380
agggatcagc agcctgggtt ggaaggagg ggtataaaag ccccttcacc aggagaagcc	1440
gtcacacaga tcacaagct cctgaagagg taagggttta agggatggtt ggttgggtgg	1500
gtattaatgt ttaattacct ggagcacctg cctgaaatca ctttttttca ggttggctag	1560
catgcagcgc gtgaacatga tcatggcga gagccccgc ctgatcacca tctgcctgct	1620
gggctacctg ctgagcgcgc agtgcacctg gttcctggac cagcagaacg ccaacaagat	1680
cctgaacgcg cccaagcgt acaacagcgc caagctggag gagttcgtgc agggcaacct	1740
ggagcgcgag tgcattggagg agaagtgcag cttcgaggag gcccgcgagg tgttcgagaa	1800
caccgagcgc accaccgagt tctggaagca gtacgtggac ggcgaccagt gcgagagcaa	1860
cccctgcctg aacggcggca gctgcaagga cgacatcaac agctacgagt gctggtgcc	1920
cttcggcttc gagggcaaga actgcgagct ggaagtgaac tgcaacatca agaacggccg	1980
ctgcgagcag ttctgcaaga acagcgcga caacaagggt gtgtgcagct gcaccgaggg	2040
ctaccgcctg gccgagaacc agaagagctg cgagcccgcc gtgcccttcc cctgcggccg	2100
cgtgagcgtg agccagacca gcaagctgac ccgcgcgag gccgtgttcc ccgacgtgga	2160

ctacgtgaac agcaccgagg ccgagaccat cctggacaac atcaccagag gcaccagag 2220
 cttcaacgac ttcacccgcg tgggtggcgg cgaggacgcc aagcccgccc agttcccctg 2280
 gcaggtggtg ctgaacggca aggtggacgc cttctgcggc ggcagcatcg tgaacgagaa 2340
 gtggatcgtg accgccgccc actgcgtgga gaccggcgtg aagatcaccg tggtgcccg 2400
 cgagcacaac atcgaggaga ccgagcacac cgagcagaag cgcaacgtga tccgcatcat 2460
 cccccaccac aactacaacg ccgccatcaa caagtacaac cagcatatcg ccctgctgga 2520
 gctggacgag ccctggtgc tgaacagcta cgtgaccccc atctgcatcg ccgacaagga 2580
 gtacaccaac atcttctctga agttcggcag cggtacgtg agcggctggg gccgcgtgtt 2640
 ccacaagggc cgcagcgcgc tgggtgctgca gtacctgcgc gtgcccctgg tggaccgcgc 2700
 cacctgcctg ctgagcacca agttcaccat ctacaacaac atgttctgcg ccggcttcca 2760
 cgagggcggc cgcgacagct gccaggcgga cagcggcggc cccacgtga ccgagggtga 2820
 gggcaccagc ttcctgaccg gcatcatcag ctggggcgag gagtgcgcca tgaagggcaa 2880
 gtacggcatc tacaccaagg tgagccgcta cgtgaactgg atcaaggaga agaccaagct 2940
 gacctggaga tctgatcagc ctcgactgtg ctttctagt tgcagccatc tgttgtttgc 3000
 ccctcccccg tgccttcctt gacctggaa ggtgccactc ccactgtcct ttctaataa 3060
 aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg ggggtgggtg 3120
 gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg ggatctgata 3180
 gcaggcatgc tggggagaga tcgatctagg aaccctagt gatggagttg gccactccct 3240
 ctctgcgcgc tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct 3300
 ttggtcgccc ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aacccccccc 3360
 ccccccccc tgcattgcag cgattctctt gtttgcctca gactctcagg caatgacctg 3420
 atagcctttg tagagacctc tcaaaaatag ctacctctc cggcatgaat ttatcagcta 3480
 gaacggttga atatcatatt gatggtgatt tgactgtctc cggcctttct caccgtttg 3540
 aatctttacc tacacattac tcaggcattg catttaaaat atatgaggtg tctaaaaatt 3600
 tttatccttg cgttgaaata aaggcttctc ccgcaaaagt attacaggtg cataatgttt 3660
 ttggtacaac cgatttagct ttatgctctg aggctttatt gcttaatttt gctaattctt 3720
 tgccttgccct gtatgattta ttggatgttg gaattcctga tgcggtatct tctccttacg 3780
 catctgtgag gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc 3840
 gcatagttaa gccagccccg acaccgcca acaccgctg acgcgccctg acgggcttgt 3900
 ctgctcccg catccgctta cagacaagct gtgaccgtct cgggagctg catgtgtcag 3960
 aggttttcac cgtcatcacc gaaacgcgag agacgaaagg gcctcgtgat acgcctatct 4020
 ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttttcgggga 4080
 aatgtgcgag gaaccctat ttgtttatct ttctaaatac attcaaata gtatccgctc 4140
 atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 4200
 caacatttcc gtgtcgccct tattcccttt ttgcgccat ttgcccctc tgtttttgct 4260
 caccagaaa cgctggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt 4320
 tacatcgaac tggatctcaa cagcggtgag atccttgaga gttttcgccc cgaagaacgt 4380

tttccaatga tgagcacttt taaagttctg ctatgtggcg cggattattc ccgtattgac	4440
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatactt ggttgagtac	4500
tcaccagtca cagaaaagca tottacggat ggcatgacag taagagaatt atgcagtgt	4560
gccataacca tgagtataa cactgcggcc aacttacttc tgacaacgat cggaggaccg	4620
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgctt tgatcgttgg	4680
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca	4740
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccgga	4800
caattaatag actggatgga ggcggataaa gttgcaggac cacttctcgc ctccggcctt	4860
ccggtcggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc	4920
attgcagcac tggggccaga tggtaagccc tcccgatcgc tagttatcta cacgacgggg	4980
agtcaggcaa ctatggatga acgaaataga cagatcgtg agataggtgc ctactgatt	5040
aagcattggc aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt	5100
catttttaat ttaaaaggat ctaggatgaag atcctttttg ataattctcat gaccaaaatc	5160
ccttaacgtg agttttcgtt ccactgagcg tcagaccctg tagaaaagat caaaggatct	5220
tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta	5280
ccagcggtagg tttgttttgc ggatcaagag ctaccaactc tttttccgaa ggtaactggc	5340
ttcagcagag cgcagatacc aaatactgtc cttctagtgt agcgtagtgt aggccaccac	5400
ttcaagaact ctgtagcacc gcctacatac ctgcctctgc taatcctgtt accagtggct	5460
gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat	5520
aaggcgcagc ggtcgggctg aacggggggg tcgtgcacac agcccagctt ggagcgaacg	5580
acctacaccg aactgagata cctacagcgt gagctatgag aaagcggcac gcttcccga	5640
gggagaaaag cggacaggta tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg	5700
gagcttccag ggggaaaagc ctggtatctt tatagtctcg tcgggtttcg ccacctctga	5760
cttgagcgtc gatttttctg atgctcgtca ggggggcgga gcctatggaa aaacgccagc	5820
aacgcggcct ttttacgggt cctggccttt tgctggcctt ttgctcacat gttctttcct	5880
gcgttatccc ctgattctgt ggataaccgt attaccgctt ttgagtgagc tgataccgct	5940
cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg aggaagcgga agagcgccca	6000
atacgcaaac cgctctctcc cgcgcgttgg ccgattcatt aatg	6044

<210> 3

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 3

gccttctagt tgccagccat 20

<210> 4

<211> 20

<212> DNA

<213> Artificial

<220>

<223> probe

<400> 4

tgtttgcccc tcccccgctc 20

<210> 5

<211> 19

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 5

ggcaccttc agggtaag 19

<210> 6

<211> 7849

<212> DNA

<213> Artificial

<220>

<223> Adenoviral expression vector AAVss-SerpEnh-TTRm-MVM-hFVIIIcopt-sv40pA

<220>

<221> misc_feature

<222> (508)..(508)

<223> n is a, c, g, or t

<400> 6

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgctc	60
gggcgacctt tggtcgcccc gcctcagtga gcgagcgagc gcgcagagag ggagtggcca	120
actccatcac taggggttcc tgcggccgcg gtaccggcgc gccgggggag gctgctggtg	180
aatattaacc aaggtcacc cagttatcgg aggagcaaac aggggctaag tccacacgag	240
tggtaccgtc tgtctgcaca tttcgtagag cgagtgttcc gatactctaa tctccctagg	300
caagggtcat atttgtgtag gttacttatt ctccctttgt tgactaagtc aataatcaga	360
atcagcaggt ttggagtcag cttggcaggg atcagcagcc tgggttgga ggagggggta	420
taaaagcccc ttcaccagga gaagccgtca cacagatcca caagctcctg aagaggtaag	480
ggtttaagg atggttggtt ggtgggnat taatgttta ttacctggag cacctgcctg	540
aaatcacttt ttttcaggtt ggctagtatg cagatcgagc tgtccacctg cttttttctg	600

tgcctgctgc ggttctgctt cagcgccacc cggcgggtact acctgggccc cgtggagctg	660
tcctgggaact acatgcagag cgacctgggc gagctgcccg tggacgcccg gttccccccc	720
agagtgccca agagcttccc cttcaacacc agcgtggtgt acaagaaaac cctgttcgtg	780
gagttcaccc accacctgtt caatatcgcc aagcccaggc cccctggat gggcctgctg	840
ggccccacca tccaggccga ggtgtacgac accgtggtga tcacctgaa gaacatggcc	900
agccaccccg tgagcctgca cgccgtgggc gtgagctact ggaaggccag cgagggcgcc	960
gagtacgacg accagaccag ccagcgggag aaagaagatg acaagggtgt cctggcggc	1020
agccacacct acgtgtggca ggtgctgaaa gaaaacggcc ccatggcctc cgacccccctg	1080
tgcctgacct acagctacct gagccacgtg gacctggtga aggacctgaa cagcggcctg	1140
atcggcgctc tgctcgtctg ccgggagggc agcctggcca aagagaaaac ccagacctg	1200
cacaagttca tcctgctgtt cgccgtgttc gacgagggca agagctggca cagcgagaca	1260
aagaacagcc tgatgcagga ccgggacgcc gcctctgcca gagcctggcc caagatgcac	1320
accgtgaacg gctacgtgaa cagaagcctg cccggcctga ttggctgcca ccggaagagc	1380
gtgtactggc acgtgatcgg catgggcacc acacccgagg tgcacagcat ctttctggaa	1440
gggcacacct ttctgggtccg gaaccaccgg caggccagcc tggaaatcag ccctatcacc	1500
ttcctgaccg ccagacact gctgatggac ctgggccagt tcctgctgtt ttgccacatc	1560
agctctcacc agcacgacgg catggaagcc tacgtgaagg tggactcttg ccccgaggaa	1620
cccagctgc ggtgaagaa caacgaggaa gccgaggact acgacgacga cctgaccgac	1680
agcgagatgg acgtggtgcg gttcgacgac gacaacagcc ccagcttcat ccagatcaga	1740
agcgtggcca agaagcacc caagacctgg gtgcactata tcgccgccga ggaagaggac	1800
tgggactacg ccccccgtgt gctggcccc gacgacagaa gctacaagag ccagtacctg	1860
aacaatggcc ccagcggat cggccggaag tacaagaaag tgcggttcat ggctacacc	1920
gacgagacat tcaagaccgg ggaggccatc cagcacgaga gcggcatcct gggccccctg	1980
ctgtacggcg aagtgggcga cactgtctg atcatcttca agaaccaggc tagccggccc	2040
tacaacatct accccacgg catcacggac gtgcggcccc tgtacagcag gcggctgccc	2100
aagggcgctga agcacctgaa ggacttcccc atcctgcccg gcgagatctt caagtacaag	2160
tggaccgtga ccgtggagga cggccccacc aagagcgacc ccagatgcct gacccggtac	2220
tacagcagct tcgtgaacat ggaacgggac ctggcctccg ggtgatcgg acctctgctg	2280
atctgtatca aagaaagcgt ggaccagcgg ggcaaccaga tcatgagcga caagcggaac	2340
gtgatcctgt tcagcgtgtt cgatgagaac cgttcctggt atctgaccga gaacatccag	2400
cggtttctgc ccaacctgc cggcgtgcag ctggaagatc ccgagttcca ggccagcaac	2460
atcatgcact ccatcaatgg ctacgtgttc gactctctgc agctctccgt gtgtctgcac	2520
gaggtggcct actggtacat cctgagcatc ggcgccaga ccgacttctt gacgtgttc	2580
ttcagcggct acacctcaa gcacaagatg gtgtacgagg acacctgac cctgttccct	2640
ttcagcggcg agacagtgtt catgagcatg gaaaaccccg gcctgtggat tctgggctgc	2700
cacaacagcg acttccggaa ccggggcatg accgccctgc tgaagggtgc cagctgcgac	2760
aagaacaccg gcgactacta cgaggacagc tacgaggata tcagcgcta cctgtgtcc	2820
aagaacaacg ccatacgaac ccggagcttc agccagaacc ccccgctgt gacgcgtcac	2880

cagcgggaga	tcaccocggac	aaccctgcag	tccgaccagg	aagagatcga	ttacgacgac	2940
accatcagcg	tggagatgaa	gaaagaggat	ttcgatatct	acgacgagga	cgagaaccag	3000
agccccagaa	gcttcagaa	gaaaaccocgg	cactacttca	ttgcgcgcgt	ggagaggctg	3060
tgggactacg	gcatgagttc	tagccccac	gtgctgcgga	accgggccca	gagcggcagc	3120
gtccccagt	tcaagaaagt	ggtgtttccag	gaattcacag	acggcagctt	caccagcct	3180
ctgtatagag	gcgagctgaa	cgagcacctg	ggctgtctgg	ggcctacat	cagggccgaa	3240
gtggaggaca	acatcatggt	gaccttcocgg	aatcaggcca	gcagacccta	ctccttctac	3300
agcagcctga	tcagctacga	agaggaccag	cggcagggcg	ccgaaccccg	gaagaacttc	3360
gtgaagccca	acgaaaccaa	gacctacttc	tggaaagtgc	agcaccacat	ggccccacc	3420
aaggacgagt	tcgactgcaa	ggcctggggc	tacttcagcg	acgtggatct	ggaaaaggac	3480
gtgcactctg	gactgattgg	ccactcctg	gtctgccaca	ctaacaccct	caaccccgcc	3540
cacggccgcc	aggtgaccgt	gcaggaattc	gccctgttct	tcaccatctt	cgacgagaca	3600
aagtccctggt	acttcaccga	gaatatggaa	cggaaactgca	gagccccctg	caacatccag	3660
atggaagatc	ctaccttcaa	agagaactac	cggttccacg	ccatcaacgg	ctacatcatg	3720
gacaccctgc	ctggcctggt	gatggcccag	gaccagagaa	tccggtggta	tctgctgtcc	3780
atgggcagca	acgagaatat	ccacagcatc	cacttcagcg	gccacgtggt	caccgtgcgg	3840
aagaaagaag	agtacaagat	ggccctgtac	aacctgtacc	ccggcgtggt	cgagacagtg	3900
gagatgctgc	ccagcaaggc	cggcatctgg	cgggtggagt	gtctgatcgg	cgagcacctg	3960
cacgctggca	tgagcaccct	gtttctggtg	tacagcaaca	agtgccagac	ccactgggc	4020
atggcctctg	gccacatccg	ggacttccag	atcaccgcct	ccggccagta	cggccagtgg	4080
gccccaaagc	tggccagact	gcactacagc	ggcagcatca	acgcctggtc	caccaaagag	4140
cccttcagct	ggatcaaggt	ggacctgctg	gcccctatga	tcatccacgg	cattaagacc	4200
cagggcgcca	ggcagaagtt	cagcagcctg	tacatcagcc	agttcatcat	catgtacagc	4260
ctggacggca	agaagtggca	gacctaccgg	ggcaacagca	ccggcaccct	gatggtgttc	4320
ttcggcaatg	tggacagcag	cggcatcaag	cacaacatct	tcaaccccc	catcattgcc	4380
cggtacatcc	ggctgcaccc	caccacttac	agcattagat	ccacactgag	aatggaactg	4440
atgggctgcg	acctgaactc	ctgcagcatg	cctctgggca	tggaaagcaa	ggccatcagc	4500
gacgcccaga	tcacagccag	cagctacttc	accaacatgt	tgcacacctg	gtccccctcc	4560
aaggccaggc	tgcacctgca	gggcccgtcc	aacgcctggc	ggcctcaggt	caacaacccc	4620
aaagaatggc	tgcaggtgga	ctttcagaaa	accatgaagg	tgaccggcgt	gaccaccocag	4680
ggcgtgaaaa	gcctgctgac	cagcatgtac	gtgaaagagt	ttctgatcag	cagctctcag	4740
gatggccacc	agtggaccct	gttcttttcag	aacggcaagg	tgaaagtgtt	ccagggcaac	4800
caggactcct	tcacccccgt	ggtgaactcc	ctggaccccc	ccctgctgac	ccgtacctg	4860
agaatccacc	cccagtcctg	ggtgcaccag	atcgccctca	ggatggaagt	cctgggatgt	4920
gaggcccagg	atctgtactg	atgaggatct	aggctcgaca	tgctttattt	gtgaaatttg	4980
tgatgctatt	gctttatttg	taaccattat	aagctgcaat	aaacaagtta	acaacaacaa	5040
ttgcattcat	tttatgtttc	aggttcaggg	ggagggtgtg	gaggtttttt	aaactcgaga	5100
tggggggggg	gggggggggg	tggggggggg	gtgggggggg	gggtgggggg	gggggggggg	5160

cccacggccg caggaacccc cagtcacgga gtcggccact ccccccctgc gggcccgccc 5180
 gctcactgag gccggggcag caaaggctgc ccgacgcccg ggctttgccc gggcggcctc 5220
 agtgagcgag cgagcgcgca gctgcctgca gggcgccctg atgcgggtatt ttctccttac 5280
 gcattctgtgc ggtattttcac accgcatacg tcaaagcaac catagtagcg gccctgtagc 5340
 ggcgcattaa gcgcggcggg tgtgggtggtt acgcgcagcg tgaccgctac acttgccagc 5400
 gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt cgcgggcttt 5460
 ccccgtaag ctctaaatcg ggggctccct ttagggttcc gatttagtgc ttacggcac 5520
 ctcgacccca aaaaacttga tttgggtgat ggttcacgta gtgggccatc gccctgatag 5580
 acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact cttgttccaa 5640
 actggaacaa cactcaaccc tatctcgggc tattcttttg atttataagg gattttgccg 5700
 atttcggcct attgggttaa aaatgagctg atttaacaaa aatttaacgc gaattttaac 5760
 aaaatattaa cgtttacaat tttatggtgc actctcagta caatctgctc tgatgccgca 5820
 tagttaagcc agccccgaca cccgccaaac ccgctgacg cgccttgacg ggcttgtctg 5880

 ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat gtgtcagagg 5940
 ttttcaccgt catcacgaa acgcgcgaga cgaaagggcc tcgtgatacg cctattttta 6000
 taggttaatg tcattgataat aatggtttct tagacgtcag gtggcacttt tcggggaaat 6060
 gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg 6120
 agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa 6180
 catttcogtg tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac 6240
 ccagaaacgc tgggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac 6300
 atcgaaactgg atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt 6360
 ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc 6420
 gggcaagagc aactcggctc ccgcatacac tattctcaga atgacttggg tgagtactca 6480
 ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgtgccc 6540
 ataaccatga gtgataaac tcgggccaac ttacttctga caacgatcgg aggaccgaag 6600
 gagctaaccg cttttttgca caacatgggg gatcatgtaa ctgccttga tcgttgggaa 6660
 ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg 6720
 gcaacaacgt tgcgcaaaact attaaactgg gaactactta ctctagcttc ccggcaacaa 6780
 ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg 6840
 gctggctggt ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt 6900
 gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt 6960
 caggcaacta tggatgaacg aaatagacag atcgtgaga taggtgctc actgattaag 7020
 cattgtaac tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat 7080
 ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct 7140
 taacgtgagt tttcgttcca ctgagcgta gaccccgtag aaaagatcaa aggatcttct 7200
 tgagatcctt tttttctgcg cgtaatctgc tgcctgcaaa caaaaaaacc accgtacca 7260
 gcggtgggtt gtttgccgga tcaagagcta ccaactcttt ttcgaagggt aactggcttc 7320
 agcagagcgc agataccaaa tactgtcctt ctagtgtagc cgtagttagg ccaccacttc 7380


```

aagaactctg tagcaccgcc tacatacctc gctctgctaa tctgtttacc agtggctgct 7440
gccagtggcg ataagtctgt tcttaccggg ttggactcaa gacgatagtt accggataag 7500
gcgacagcgt cgggctgaac ggggggttgg tgcacacagc ccagcttggg gcgaacgacc 7560
tacaccgaac tgagatacct acagcgtgag ctatgagaaa gcgccacgct tccgaaggg 7620
agaaaggcgg acaggtatcc ggtaagcggc agggctcgaa caggagagcg cacgagggag 7680
cttcagggg gaaacgcctg gtatctttat agtctgtcg ggtttcgcca cctctgactt 7740
gagcgtcgat ttttgtgatg ctgctcaggg gggcggagcc tatggaaaaa cgccagcaac 7800

gcggcctttt tacggttcct ggccttttgc tggcctttg ctcacatgt 7849

```

<210> 7

<211> 4377

<212> DNA

<213> Artificial

<220>

<223> Codon-optimized B domain deleted human coagulation factor VIII (hFVIIIcopt)

<400> 7

```

atgcagatcg agctgtccac ctgctttttt ctgtgcctgc tgcggttctg cttcagcgcc 60
acccggcggg actacctggg gcgcgtggag ctgtcctggg actacatgca gagcgacctg 120
ggcgagctgc ccgtggacgc ccggttcccc ccagagtgcc ccaagagctt ccccttcaac 180
accagcgtgg tgtacaagaa aacctgttc gtggagtcca ccgaccacct gttcaatatc 240
gccaagccca ggcacctctg gatgggcctg ctgggcccc ccatccaggc cgagggtgac 300
gacaccgtgg tgatcacctt gaagaacatg gccagccacc ccgtgagcct gcacgccgtg 360
ggcgtgagct actggaaggc cagcgagggc gccgagtacg acgaccagac cagccagcgg 420
gagaaagaag atgacaaggt gttccctggc ggcagccaca cctacgtgtg gcagggtgctg 480
aaagaaaacg gcccctatgg ctccgacccc ctgtgcctga cctacagcta cctgagccac 540
gtggacctgg tgaaggacct gaacagcggc ctgatcggcg ctctgctcgt ctgccgggag 600
ggcagcctgg ccaaagagaa aaccagacc ctgcacaagt tcatcctgct gttcgccgtg 660
ttcgacgagg gcaagagctg gcacagcgag acaaagaaca gcctgatgca ggaccgggac 720
gccgcctctg ccagagcctg gcccagatg cacaccgtga acggctacgt gaacagaagc 780
ctgcccggcc tgattggctg ccaccggaag agcgtgtact ggcacgtgat cggcatgggc 840
accacaccog aggtgcacag catctttctg gaagggcaca ctttctggt ccggaaccac 900
cggcaggcca gcctggaaat cagccctatc accttctga ccgccagac actgctgatg 960
gacctgggcc agttcctgct gttttgccac atcagctctc accagcacga cggcatggaa 1020
gcctacgtga aggtggactc ttgccccgag gaacccagc tgcggatgaa gaacaacgag 1080
gaagccgagg actacgacga cgacctgacc gacagcgaga tggacgtggt gcggttcgac 1140
gacgacaaca gcccagctt catccagatc agaagcgtgg ccaagaagca cccaagacc 1200
tgggtgcact atatcgccgc cgaggaagag gactgggact acgccccctt ggtgctggcc 1260
cccgacgaca gaagctacaa gagccagtac ctgaacaatg gcccccagcg gatcggccgg 1320

```

aagtacaaga aagtgcggtt catggcctac accgacgaga cattcaagac ccgggagggcc	1380
atccagcacg agagcggcat cctgggcccc ctgctgtacg gcgaagtggg cgacacactg	1440
ctgatcatct tcaagaacca ggctagccgg ccctacaaca tctacccccca cggcatcacc	1500
gacgtgcggc ccctgtacag caggcggctg cccaagggcg tgaagcacct gaaggacttc	1560
cccatcctgc ccggcgagat cttcaagtac aagtggaccg tgaccgtgga ggacggcccc	1620
accaagagcg accccagatg cctgacccgg tactacagca gcttcgtgaa catggaacgg	1680
gacctggcct ccgggctgat cggacctctg ctgatctgct acaaagaaag cgtggaccag	1740
cggggcaacc agatcatgag cgacaagcgg aacgtgatcc tgttcagcgt gttcgatgag	1800
aaccggtcct ggtatctgac cgagaacatc cagcggtttc tgcccaacct tgccggcgtg	1860
cagctggaag atcccagatt ccaggccagc aacatcatgc actccatcaa tggctacgtg	1920
ttcgactctc tgcagctctc cgtgtgtctg cagcaggtgg cctactggta catcctgagc	1980
atcggcgccc agaccgactt cctgagcgtg ttcttcagcg gctacacctt caagcacaag	2040
atggtgtacg aggacacctt gacctgttc cctttcagcg gcgagacagt gtccatgagc	2100
atggaaaacc ccggcctgtg gattctgggc tgccacaaca gcgacttcg gaaccggggc	2160
atgaccgccc tgetgaaggt gtccagctgc gacaagaaca ccggcgacta ctacgaggac	2220
agctacgagg atatcagcgc ctacctgtg tccaagaaca acgccatcga accccggagc	2280
ttcagccaga accccccgt gctgacgct caccagcggg agatcacccg gacaaccctg	2340
cagtccgacc aggaagagat cgattacgac gacaccatca gcgtggagat gaagaaagag	2400
gatttcgata tctacgacga ggacgagaac cagagcccca gaagcttcca gaagaaaacc	2460
cggcactact tcattgccgc cgtggagagg ctgtgggact acggcatgag ttctagcccc	2520
cacgtgtctg ggaaccgggc ccagagcggc agcgtgcccc agttcaagaa agtgggtgtc	2580
caggaattca cagacggcag cttcacccag cctctgtata gaggcgagct gaacgagcac	2640
ctggggctgc tggggcccta catcagggcc gaagtggagg acaacatcat ggtgaccttc	2700
cggaatcagg ccagcagacc ctactccttc tacagcagcc tgatcagcta cgaagaggac	2760
cagcggcagg gcgcgaacc ccggaagaac ttcgtgaagc ccaacgaaac caagacctac	2820
ttctggaaag tgcagcacca catggcccc accaaggacg agttcgactg caaggcctgg	2880
gcctacttca gcgacgtgga tctggaaaag gacgtgcact ctggactgat tggccactc	2940
ctggtctgcc acactaacac cctcaacccc gccacggcc gccaggtagc cgtgcaggaa	3000
ttcgccctgt tcttcacat cttcgacgag acaaagtcct ggtacttcac cgagaatatg	3060
gaacggaact gcagagcccc ctgcaacatc cagatggaag atcctacctt caaagagaac	3120
taccggttc acgccatcaa cggctacatc atggacacct tgcctggcct ggtgatggcc	3180
caggaccaga gaatccggtg gtatctgctg tccatgggca gcaacgagaa tatccacagc	3240
atccacttca gcggccacgt gttcacctg cggaagaaag aagagtacaa gatggccctg	3300
tacaacctgt accccggcgt gttcgagaca gtggagatgc tgcccagcaa ggccggcatc	3360
tggcgggtgg agtgtctgat cggcgagcac ctgcacgctg gcatgagcac cctgtttctg	3420
gtgtacagca acaagtgcc aacccccctg ggcatggcct ctggccacat ccgggacttc	3480
caqatcaccc cctccqcca gtacqccaq tqqqcccca aqctqccaq actqcactac	3540

```

agcggcagca tcaacgcctg gtccaccaa gagcccttca gctggatcaa ggtggacctg 3600
ctggccccta tgatcatcca cggcattaag acccagggcg ccaggcagaa gttcagcagc 3660
ctgtacatca gccagttcat catcatgtac agcctggacg gcaagaagtg gcagacctac 3720
cggggcaaca gcaccggcac cctgatgggtg ttcttcggca atgtggacag cagcggcatc 3780
aagcacaaca tcttcaaccc ccccatcatt gcccggtaca tccggctgca ccccaccac 3840
tacagcatta gatccacact gagaatggaa ctgatgggct gcgacctgaa ctctgcagc 3900
atgcctctgg gcatggaaag caaggccatc agcgacgcc agatcacagc cagcagctac 3960
ttcaccaaca tggtcgccac ctgggtcccc tccaaggcca ggctgcacct gcagggccgg 4020
tccaacgcct ggcggcctca ggtcaacaac cccaaagaat ggctgcaggt ggactttcag 4080
aaaaccatga aggtgaccgg cgtgaccacc cagggcgtga aaagcctgct gaccagcatg 4140
tacgtgaaag agttttgat cagcagctct caggatggcc accagtggac cctgttcttt 4200
cagaacggca aggtgaaagt gttccagggc aaccaggact ccttcacccc cgtggtgaac 4260
tccttggaac cccccctgct gacccgctac ctgagaatcc acccccagtc ttgggtgcac 4320
cagatcgccc tcaggatgga agtcctggga tgtgaggccc aggatctgta ctgatga 4377

```

<210> 8

<211> 72

<212> DNA

<213> Artificial

<220>

<223> Serpin enhancer (SerpEnh)

<400> 8

```

gggggaggct gctggtgaat attaaccaag gtcaccccag ttatcggagg agcaaacagg 60

```

```

ggctaagtcc ac 72

```

<210> 9

<211> 202

<212> DNA

<213> Artificial

<220>

<223> Minimal transthyretin promoter (TTRm)

<400> 9

```

gtctgtctgc acatttcgta gagcgagtgt tccgatactc taatctccct aggcaaggtt 60

```

```

catatttggtg taggttactt attctccttt tgttgactaa gtcaataatc agaatcagca 120

```

```

ggtttggagt cagcttgga gggatcagca gcctgggttg gaaggagggg gtataaaagc 180

```

```

cccttcacca ggagaagccg tc 202

```

<210> 10

<211> 92

<212> DNA

<213> Artificial

$\langle 220 \rangle$

<223> Minute virus mouse (MVM) intron

$\langle 220 \rangle$

<221> misc_feature

 $\langle 222 \rangle$ (38)..(38)

<223> n is a, c, g, or t

<400> 10

aagaggtaa ggtttaaggg atggttgggt ggtggggnat taatgtttaa ttacctggag 60

cacctgcctg aaatcacttt ttttcagggtt gg 92

$\langle 210 \rangle$ 11

<211> 134

<212> DNA

<213> Artificial

$\langle 220 \rangle$

<223> Simian virus 40 (SV40) polyadenylation signal (pA)

<400> 11

atgctttatt tgtgaaattt gtgatgctat tgctttattt gtaaccatta taagctgcaa 60

taaacaagtt aacaacaaca attgcattca ttttatgttt caggttcagg gggaggtgtg 120

ggaggttttt taaa 134

<210> 12

<211> 7653

<212> DNA

<213> Artificial

$\langle 220 \rangle$

<223> pcDNA3_mouseCO_hyPiggyBac_Transposase_MT plasmid

<400> 12

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg cgtggagcta gttattaata gtaatcaatt 240

acgggggtcat tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaatt 300

ggcccgctg gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatggt 360

cccatagtaa cgtcaatagg gactttccat tgacgtcaat ggggtggagta tttaacggtaa 420

actgccact tggcagtaca tcaagtgtat catatgccaa gtacgcccc tattgacgtc 480

— — —

aatgacggta aatggccgcg ctggcattat gccagttaca tgacottatg ggactttcct	540
acttggcagt acatctacgt attagtcatc gctattacca tggatgatgcg gttttggcag	600
tacatcaatg ggcggtggata gcggtttgac tcacggggat ttccaagtct ccacccatt	660
gacgtcaatg ggagtttggt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac	720
aactccggcc cattgacgca aatgggcggg aggcgtgtac ggtgggaggt ctatataagc	780
agagctcgtt tagtgaaccg tcagatcgcc tggagacgcc atccacgctg ttttgacctc	840
catagaagac accgggaccg atccagcctc cgcggattcg aatcccggcc gggaacgggtg	900
cattggaacg cggattcccc gtgccaagag tgacgttaagt accgcctata gagtctatag	960
gcccacaaaa aatgctttct tcttttaata tacttttttg tttatcttat ttctaatact	1020
ttccctaate tctttcttct agggcaataa tgatacaatg tatcatgcct ctttgaccca	1080
ttctaagaa taacagtgat aatttctggg ttaaggcaat agcaatattt ctgcatataa	1140
atatttctgc atataaattg taactgatgt aagaggttct atattgctaa tagcagctac	1200
aatccagcta ccattctgct tttattttat ggttgggata aggtcggatt attctgagtc	1260
caagctaggg ccttttgcta atcatgttca taactcttat ctccctcca cagctcctgg	1320
gcaacgtgct ggtctgtgtg ctggcccatc actttggcaa agaattggga ttccaacatc	1380
gatgcgcgca ccatgggcag cagcctggac gacgagcaca tctgagcgc cctgctgcag	1440
agcgacgacg agctggtcgg cgaggacagc gacagcgagg tgagcgacca cgtgagcgag	1500
gacgacgtgc agtccgacac cgaggaggcc ttcacgcagc aggtgcacga ggtgcagcct	1560
accagcagcg gctccgagat cctggacgag cagaacgtga tcgagcagcc cggcagctcc	1620
ctggccagca acaggatcct gaccctgcc cagaggacca tcaggggcaa gaacaagcac	1680
tgctggtcca cctccaagcc caccaggcgg agcagggtgt ccgccctgaa catcgtgaga	1740
agccagaggg gccccaccag gatgtgcagg aacatctacg acccctgct gtgcttcaag	1800
ctgttcttca ccgacgagat catcagcgag atcgtgaagt ggaccaacgc cgagatcagc	1860
ctgaagaggg gggagagcat gaccagcgc accttcaggg acaccaacga ggacgagatc	1920
tacgccttct tcggcatcct ggtgatgacc gccgtgagga aggacaacca catgagcacc	1980
gacgacctgt tcgacagatc cctgagcatg gtgtactga gcgtgatgag cagggacaga	2040
ttcgacttcc tgatcagatg cctgaggatg gacgacaaga gcatcaggcc caccctgcgg	2100
gagaacgacg tgttcacccc cgtgagaaag atctgggacc tgttcatcca ccagtgcac	2160
cagaactaca cccctggcgc ccacctgacc atcgacgagc agctgctggg cttcaggggc	2220
aggtgcccc tcagggtgta tatcccaac aagcccagca agtacggcat caagatcctg	2280
atgatgtgcg acagcggcac caagtacatg atcaacggca tgcctacct gggcaggggc	2340
accagacca acggcgtgcc cctgggcgag tactacgtga aggagctgtc caagcccgtc	2400
cacggcagct gcagaaacat cacctgcgac aactggttca ccagcatccc cctggccaag	2460
aacctgctgc aggagcccta caagctgacc atcgtgggca ccgtgagaag caacaagaga	2520
gagatcccc aggtectgaa gaacagcagg tccaggcccg tgggcaccag catgttctgc	2580
ttcgacggcc cctgaccct ggtgtcctac aagcccaagc ccgccaagat ggtgtacctg	2640
ctgtccagct gcgacgagga cggcagcatc aacgagagca ccggcaagcc ccagatggtg	2700
atgtactaca accagaccaa gggcggcgtg gacaccctgg accagatgtg cagcgtgatg	2760
acgtacacac acacacacac acgtacacac acacacacac acgtacacac acacacacac	2820

acctgcagca gaaagaccaa caggtggccc atggccctgc tgcacggcat gatcaacatc	2820
gcctgcacaa acagcttcat catctacagc cacaacgtga gcagcaaggg cgagaaggtg	2880
cagagccgga aaaagtccat gcggaacctg tacatggggc tgacctccag cttcatgagg	2940
aagaggctgg agggcccccac cctgaagaga tacctgaggg acaacatcag caacatcctg	3000
cccaaggagg tgcccgccac cagcgacgac agcaccgagg agcccgatgat gaagaagagg	3060
acctactgca cctactgtcc cagcaagatc agaagaaagg ccagcgccag ctgcaagaag	3120
tgtaagaagg tcattctgcc ggagcacaac atcgacatgt gccagagctg tttctgactc	3180
gagcatgcat ctagagggcc ctattctata gtgtcaccta aatgctagag ctgctgac	3240
agcctcgact gtgccttcta gttgccagcc atctgttgtt tgccctccc ccgtgccttc	3300
cttgaccctg gaaggtgcc accccactgt cctttcctaa taaaatgagg aaattgcac	3360
gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg acagcaaggg	3420
ggaggattgg gaagacaata gcaggcatgc tggggatgag gtgggctcta tggcttctga	3480
ggcggaaaga accagctggg gctctagggg gtatccccac gcgccctgta gcggcgcat	3540
aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc	3600
gccgcctcct ttgcgtttct tcccttcctt tctgcgcacg ttgcgcggct ttccccgtca	3660
agctctaaat cggggcatcc ctttaggggt ccgatttagt gctttacggc acctcgaccc	3720
caaaaaactt gattaggggt atggttcacg tagtgggcca tgcacctgat agacggtttt	3780
tgcacctttg acgttgaggt ccacgttctt taatagtggg ctcttggtcc aaactggaac	3840
aacactcaac cctatctcgg tctattcttt tgatttataa gggattttgg ggatttcggc	3900
ctattgggta aaaaatgagc tgatttaaca aaaatttaac gcgaattaat tctgtggaat	3960
gtgtgtcagt taggggtgtg aaagtcccca ggctccccag gcaggcagaa gtatgcaaag	4020
catgcatctc aattagttag caaccagggt tggaaagtcc ccaggctccc cagcaggcag	4080
aagtatgcaa agcatgcatc tcaattagtc agcaaccata gtccccccc taactccgcc	4140
catccccccc ctaactccgc ccagttccgc ccattctccg ccccatgggt gactaatttt	4200
ttttatttat gcagaggccg aggcgcctc tgccctctgag ctattccaga agtagtgagg	4260
aggctttttt ggaggcctag gcttttgcaa aaagctcccg ggagcttgta tatccatttt	4320
cggatctgat caagagacag gatgaggatc gtttcgcatg attgaacaag atggattgca	4380
cgcaggttct ccggccgctt ggggtggagag gctattcggc tatgactggg cacaacagac	4440
aatcggctgc tctgatgcc ccgtgttccg gctgtcagcg caggggcgcc cggttctttt	4500
tgtcaagacc gacctgtccg gtgccctgaa tgaactgcag gacgaggcag cgcggctatc	4560
gtggctggcc acgacgggag ttccctgcgc agctgtgctc gacgttgtca ctgaagcggg	4620
aagggactgg ctgctattgg gcgaagtgcc ggggcaggat ctctgtcat ctcacctgac	4680
tcctgcagag aaagtatcca tcatggctga tgcaatgcgg cggctgcata cgcttgatcc	4740
ggctacctgc ccattcgacc accaagcgaa acatcgcatc gagcgagcac gtactcggat	4800
ggaagccggg ctgtgtgac aggatgatct ggacgaagag catcaggggc tcgcgccagc	4860
cgaactgttc gccaggctca aggcgcgcac gcccgacggc gaggatctcg tctgaccca	4920
tggcgatgcc tgcttgccga atatcatggt ggaatatggc cgcttttctg gattcatcga	4980
ctgtggccgg ctgggtgtgg cggaccgcta tcaggacata gcgttggtca cccgtgatat	5040

tgctgaagag	cttggcggcg	aatgggctga	ccgcttcctc	gtgctttacg	gtatcgccgc	5100
tcccgattcg	cagcgcacgc	ccttctatcg	ccttcttgac	gagttcttct	gagcgggact	5160
ctgggggttcg	aaatgaccga	ccaagcgacg	cccaacctgc	catcacgaga	tttcgattcc	5220
accgcgcgct	totatgaaag	gttgggcttc	ggaatcgttt	tccgggacgc	cggctggatg	5280
atcctccagc	gcggggatct	catgctggag	ttcttcgccc	accccaactt	gtttattgca	5340
gcttataatg	gttacaaata	aagcaatagc	atcacaaatt	tcacaaataa	agcatttttt	5400
tcactgcatt	ctagttgtgg	tttgtccaaa	ctcatcaatg	tatcttatca	tgtctgtata	5460
cgcgcgacct	ctagctagag	cttggcgtaa	tcatggtcac	agctgtttcc	tgtgtgaaat	5520
tgttatccgc	tcacaattcc	acacaacata	cagaccggaa	gcataaagtg	taaagcctgg	5580
ggtgcctaata	gagtgcgcta	actcacatta	attgcgttgc	gctcactgcc	cgccttccag	5640
tccggaaaacc	tgctcgtgcc	gctgcattaa	tgaatcggcc	aacgcgcggg	gagaggcggc	5700
ttgcgtattg	ggcgcctctc	cgccttcctc	ctcactgact	cgcgcgcctc	ggcgttcggc	5760
ctgcgcgcag	cggtatcagc	tcactcaaa	gcggtaatac	ggttatccac	agaatcaggg	5820
gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	ccgtaaaaag	5880
gccgcgttgc	tggcgttttt	ccataggctc	cgcgcgcctg	acgagcatca	caaaaatcga	5940
cgcctcaagtc	agagggtggc	aaacccgaca	ggactataaa	gataaccaggc	gtttccccct	6000
ggaagctccc	tcgtgcgcctc	tcctgttcgc	accctgccgc	ttaccggata	cctgtccgcc	6060
tttctccctt	cgggaagcgt	ggcgccttct	caatgctcac	gctgtaggta	tctcagttcg	6120
gtgtaggtcg	ttcgcctcaa	gctgggctgt	gtgcacgaac	cccccgttca	gcccgcacgc	6180
tgcgccttat	ccggtacta	tcgtcttgag	tccaaccgcg	taagacacga	cttatcgcca	6240
ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	tgctacagag	6300
ttcttgaagt	ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	tatctgcgct	6360
ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	caaacaaacc	6420
accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	aaaaaaagga	6480
tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	cgaaaaactca	6540
cgttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	cctttttaat	6600
taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	tgacagttac	6660
caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcgttc	atccatagtt	6720
gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	tggccccagt	6780
gctgcaatga	taccgcgaga	cccacgctca	ccggtccag	atttatcagc	aataaaccag	6840
ccagccggaa	gggcccagcg	cagaagtggc	cctgcaactt	tatccgcctc	catccagtct	6900
attaattggt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	gcgcaacggt	6960
gttgccattg	ctacaggcat	cgtgggtgtca	cgcctcgtct	ttgggtatggc	ttcattcagc	7020
tccggttccc	aacgatcaag	gcgagttaca	tgatccccc	tggtgtgcaa	aaaagcgggt	7080
agtccttcgc	gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtgtt	atcactcatg	7140
gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	cttttctgtg	7200
actggtgagt	actcaaccaa	gtcattctga	gaatagtgtg	tgccggcgacc	gagttgctct	7260

```

tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa agtgctcatc 7320
attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt gagatccagt 7380
tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcggt 7440
tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg 7500
aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta tcagggttat 7560
tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg 7620
cgcacatttc cccgaaaagt gccacctgac gtc 7653

```

<210> 13

<211> 8514

<212> DNA

<213> Artificial

<220>

<223> PB_Minimal_T_(T53C-C136T)_D4Z4_TTRminSerpMVM_hFVIIIcopt_SV40pA_D4 Z4
transposon

<220>

<221> misc_feature

<222> (1335)..(1335)

<223> n is a, c, g, or t

<400> 13

```

ctaaattgta agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc 60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga 120
gatagggttg agtggtgttc cagtttgtaa caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatcaagt tttttggggt cgaggtgccg taaagcacta aatcggaacc ctaaaggag 300
ccccgatatt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa 360
agcgaaggga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420
cacaccgcc gcgcttaatg cgccgctaca gggcgcgctc cattcgccat tcaggctgcg 480
caactgttg gaaggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg 540
gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttccagt cacgacgttg 600
taaaacgaag gccagtgagc gcgcttaacc ctagaagat aatcatattg tgacgtacgt 660
taaagataat catgcgtaaa attgacgcat gtgttttatc ggtctgtata tcgaggttta 720
tttattaatt tgaatagata ttaagtttta ttatatctac acttacatac taataataaa 780
ttcaacaaac aatttattta tggtttatcta tttattaaaa aaaaacaaaa actcaaaatt 840
tcttctataa agtaacaaaa cttttatcga taacttcgta taatgtatgc tatacgaagt 900
tatagagggg cggaagggac gtaggaggg aggcaggag gcaggaggc agggaggaac 960
ggaggaggc ggccgcggta ccggcgcgcc gggggaggct gctggtgaat attaaccaag 1020
gtcaccgccag ttatcgagg agcaaacagg ggctaagtcc acacgcgtgg taccgtctgt 1080
atgacatttc atgacgggga atgttgggt atgttgggt atgttgggt atgttgggt 1140

```

ctgcacattt cgtagagcga ggttccgat acctaatct ccttaggcaa ggttcaattt 1140
 tgtgtagggt acttattctc cttttgttga ctaagtcaat aatcagaatc agcaggtttg 1200
 gagtcagctt ggcagggatc agcagcctgg gttggaagga gggggtataa aagccccttc 1260
 accaggagaa gccgtcacac agatccacaa gctcctgaag aggtaagggt ttaagggatg 1320
 gttggttggg ggggnattaa tgtttaatta cctggagcac ctgcctgaaa tcactttttt 1380
 tcaggttggc tagtatgcag atcgagctgt ccacctgctt tttctgtgc ctgctgcggt 1440
 tctgcttcag cgcaccccg cgtactacc tgggcgcggt ggagctgtcc tgggactaca 1500
 tgcagagcga cctgggcgag ctgcccgtgg acgcccgtt cccccccaga gtgccaaga 1560
 gcttcccctt caacaccagc gtggtgtaca agaaaacct gtctgtggag ttcaccgacc 1620
 acctgttcaa tatcgccaag cccaggcccc cctggatggg cctgctgggc ccaccatcc 1680

aggcagaggt gtacgacacc gtggtgatca cctgaagaa catggccagc caccocgtga 1740
 gcctgcacgc cgtgggcgtg agctactgga aggccagcga gggcgccgag tacgacgacc 1800
 agaccagcca gcgggagaaa gaagatgaca aggtgttccc tggcggcagc cacacctacg 1860
 tgtggcaggt gctgaaagaa aacggcccca tggcctccga cccctgtgc ctgacctaca 1920
 gctacctgag ccacctggac ctggtgaagg acctgaacag cggcctgac gccgctctgc 1980
 tcgtctgccg ggagggcagc ctggccaaag agaaaacca gacctgcac aagttcatcc 2040
 tgctgttcgc cgtgttcgac gagggcaaga gctggcacag cgagacaaag aacagcctga 2100
 tgcaggaccg ggacgcgcgc tctgccagag cctggcccaa gatgcacacc gtgaacggct 2160
 acgtgaacag aagcctgccc ggccgtattg gctgccaccg gaagagcgtg tactggcacg 2220
 tgatcggcat gggcaccaca cccgaggtgc acagcatctt tctggaaggg cacacctttc 2280
 tggctcggaa ccaccggcag gccagcctgg aaatcagccc tatcaccttc ctgaccgccc 2340
 agacactgct gatggacctg ggccagttec tgcgtttttg ccacatcagc tctcaccagc 2400
 acgacggcat ggaagcctac gtgaagggtg actcttgcgc cgaggaacct cagctgcgga 2460
 tgaagaacaa cgaggaagcc gaggactacg acgacgacct gaccgacagc gagatggacg 2520
 tgggtcgggt cgacgacgac aacagcccca gttcatcca gatcagaagc gtggccaaga 2580
 agcaccocaa gacctgggtg cactatatcg ccgccgagga agaggactgg gaactcgcgc 2640
 ccctggtgct ggcccccgac gacagaagct acaagagcca gtacctgaac aatggcccc 2700
 agcggatcgg ccggaagtac aagaaagtgc ggttcatggc ctacaccgac gagacattca 2760
 agaccggga ggccatccag cagagagcg gcatacctgg cccctgctg tacggcgaag 2820
 tgggcgacac actgctgac atcttcaaga accaggctag ccggccctac aacatctacc 2880
 cccacggcat caccgacgtg cggccccgtt acagcaggcg gctgcccagg gccgtgaagc 2940
 acctgaagga cttccccatc ctgcccggcg agatcttcaa gtacaagtgg accgtgaccg 3000
 tggaggaccg cccacccaag agcgacccca gatgcctgac ccggtactac agcagcttcg 3060
 tgaacatgga acgggacctg gcctccgggc tgatcggacc tctgctgac tgetacaaag 3120
 aaagcgtgga ccagcggggc aaccagatca tgagcgacaa gcggaacgtg atcctgttca 3180
 gcgtgttcga tgagaaccgg tcctggtatc tgaccgagaa catccagcgg tttctgcca 3240
 acctgcccg cgtgcagctg gaagatccc agttccaggc cagcaacatc atgcactcca 3300
 tcaatggcta cgtgttcgac tctctgcagc tctccgtgtg tctgcacgag gtggcctact 3360

ggtacatcct gagcatcggc gccagaccg acttcctgag cgtgttcttc agcggctaca 3420
 ccttcaagca caagatggtg tacgaggaca ccctgaccct gtcccttttc agcggcgaga 3480
 cagtgttcat gagcatggaa aaccccggcc tgtggattct gggctgccac aacagcgact 3540
 tccggaaccg gggcatgacc gccctgctga aggtgtccag ctgcgacaag aacaccggcg 3600

 actactacga ggacagctac gaggatatca gcgcctacct gctgtccaag aacaacgcca 3660
 tcgaaccccg gagcttcagc cagaaccccc ccgtgctgac gcgtcaccag cgggagatca 3720
 cccggacaac cctgcagtcc gaccaggaag agatcgatta cgacgacacc atcagcgtgg 3780
 agatgaagaa agaggatttc gatattctacg acgaggacga gaaccagagc cccagaagct 3840
 tcgagaagaa aacccggcac tacttcattg ccgcctgga gaggtgtgg gactacggca 3900
 tgagttctag cccccacgtg ctgcggaacc gggcccagag cggcagcgtg cccagttca 3960
 agaaagtggg gttccaggaa ttcacagacg gcagcttcac ccagcctctg tatagaggcg 4020
 agctgaacga gcacctgggg ctgctggggc cctacatcag ggccgaagtg gaggacaaca 4080
 tcatggtgac cttccggaat caggccagca gaccctactc cttctacagc agcctgatca 4140
 gctacgaaga ggaccagcgg cagggcgccg aaccccgga gaacttcgtg aagcccaacg 4200
 aaaccaagac ctacttcttg aaagtgcagc accacatggc cccaccaag gacgagttcg 4260
 actgcaaggc ctgggcctac ttcagcgacg tggatctgga aaaggacgtg cactctggac 4320
 tgattggccc actcctggtc tgccacacta acacctcaa cccgcccac ggccgccagg 4380
 tgaccgtgca ggaattcgcc ctgttcttca ccatcttcga cgagacaaag tcctggtact 4440
 tcaccgagaa tatggaacgg aactgcagag cccctgcaa catccagatg gaagatccta 4500
 ccttcaaaga gaactaccgg ttccacgcca tcaacggcta catcatggac accctgcctg 4560
 gcctggtgat ggcccaggac cagagaatcc ggtggtatct gctgtccatg ggcagcaacg 4620
 agaatatcca cagcatccac ttcagcggcc acgtgttcac cgtgcggaag aaagaagagt 4680
 acaagatggc cctgtacaac ctgtaccccg gcgtgttcga gacagtggag atgctgccca 4740
 gcaaggccgg catctggcgg gtggagtgtc tgatcggcga gcacctgcac gctggcatga 4800
 gcacctgtt tctggtgtac agcaacaagt gccagacccc actgggcatg gcctctggcc 4860
 acatccggga cttccagatc accgcctccg gccagtacgg ccagtgggccc cccaagctgg 4920
 ccagactgca ctacagcggc agcatcaacg cctggtccac caaagagccc ttcagctgga 4980
 tcaagtgga cctgctggcc cctatgatca tccacggcat taagaccag ggcgccaggc 5040
 agaagttcag cagcctgtac atcagccagt tcatcatcat gtacagcctg gacggcaaga 5100
 agtggcagac ctacccggggc aacagcaccg gcacctgat ggtgttcttc ggcaatgtgg 5160
 acagcagcgg catcaagcac aacatcttca acccccccat cattgcccgg tacatccggc 5220
 tgcaccccac ccactacagc attagatcca cactgagaat ggaactgatg ggctgcgacc 5280
 tgaactcctg cagcatgcct ctgggcatgg aaagcaaggc catcagcgac gccagatca 5340
 cagccagcag ctacttcacc aacatgttcg ccacctggtc cccctccaag gccaggctgc 5400
 acctgcaggg ccggtccaac gcctggcggc ctcaggtcaa caacccaaa gaatggctgc 5460

 aggtggactt tcagaaaacc atgaagtgga ccggcgtgac caccagggc gtgaaaagcc 5520
 tgctgaccag catgtacgtg aaagagtttc tgatcagcag ctctcaggat ggccaccagt 5580

ggaccctggt ctttcagaac ggcaaggatga aagtgttcca gggcaaccag gactccttca	5640
cccccggtgt gaactccctg gacccccccc tgtgacccg ctacctgaga atccaccccc	5700
agtcttgggt gcaccagatc gccctcagga tggaaagcct gggatgtgag gcccaggatc	5760
tgtactgatg aggatctagg ctogacatgc tttatttgtg aaatttgtga tgetattgct	5820
ttatttgtaa ccattataag ctgcaataaa caagttaaca acaacaattg cattcatttt	5880
atgtttcagg ttcaggggga ggtgtgggag gttttttaaa ctcgagaccg gtagaggggc	5940
ggaagggacg ttaggaggga ggcagggagg cagggaggca gggaggaacg gagggagata	6000
acttcgtata atgtatgcta tacgaagtta tgatatctat aacaagaaaa tatatatata	6060
ataagttatc acgtaagtag aacacgaaat aacaatataa ttatcgtatg agttaaatct	6120
taaaagtcac gtaaaagata atcatgcgtc attttgactc acgcggttgt tatagttcaa	6180
aatcagtgc acctaccgca ttgacaagca cgcctcacgg gagctccaag cggcgactga	6240
gatgtcctaa atgcacagcg acggattcgc gctattttaga aagagagagc aatatttcaa	6300
gaatgcacgc gtcaatttta cgcagactat ctttctaggg ttaagcgcgc ttggcgtaat	6360
catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac	6420
gagccggaag cataaagtgt aaagcctggg gtgcctaagt agtgagctaa ctcacattaa	6480
ttgcgttgcg ctcaactgcc gctttccagt cgggaaacct gtcgtgccag ctgcattaat	6540
gaatcgccca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc gcttctcgc	6600
tcaetgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct caetcaaagg	6660
cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag	6720
gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc	6780
gccccctga cgagcatcac aaaaatcgac gctcaagtca gagtgggcga aaccgcacag	6840
gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga	6900
ccctgcgct taccggatac ctgtccgcct ttctccctc gggaagcgtg gcgctttctc	6960
atagctcacg ctgtaggatc ctcaattcgg tgtaggtcgt tcgctccaag ctgggctgtg	7020
tgcacgaacc ccccgctcag ccgcacgct gcgccttacc cggttaactat cgtcttgagt	7080
ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca	7140
gagcgaggta tgtaggcggg gctacagagt tcttgaagtg gtggcctaac tacggctaca	7200
ctagaaggac agtatttggg atctgcgctc tgcgtgaagc agttaccttc ggaaaaagag	7260
ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtaggttt tttgtttgca	7320
agcagcagat tacgcgcaga aaaaaggat ctcaagaaga tcctttgatc tttctacgg	7380
ggctcgacgc tcagtggaac gaaaactcac gttaagggat tttggctatg agattatcaa	7440
aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatac atctaaagta	7500
tatatgagta aacttggctc gacagttacc aatgcttaat cagtgaggca cctatctcag	7560
cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga	7620
tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac	7680
cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc	7740
ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta	7800
gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac	7860

```

gctcgtcgtt tggatatggct tcattcagct ccggttccca acgatcaagg cgagttacat 7920
gatcccccat gttgtgcaaa aaagcgggta gtccttcggg tcctccgata gttgtcagaa 7980
gtaagtgtggc cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg 8040
tcatgccatc cgtaagatgc ttttctgtga ctgggtgagta ctcaaccaag tcattctgag 8100
aatagtgtat gggcgacccg agttgctctt gcccgggcgc aatacgggat aataccgcgc 8160
cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct 8220
caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat 8280
cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg 8340
ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc 8400
aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta 8460
tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccac 8514

```

<210> 14

<211> 5097

<212> DNA

<213> Artificial

<220>

<223> PB_micro_T_No_ins_TTRminSerpMVM_FIXco_bgHPA transposon

<400> 14

```

ctaaattgta agcgttaata ttttgtaa attcgcgtta aatttttgtt aaatcagctc 60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga 120
gatagggttg agtggtgttc cagtttgga caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatcaagt tttttggggg cgaggtgccg taaagcacta aatcggaacc ctaaaggag 300
ccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa 360
agcgaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420

cacacccgcc gcgcttaatg cgcgctaca gggcgctcc cattcgccat tcaggtgctg 480
caactgttgg gaaggcgat cggcgccggc ctcttcgcta ttacgccagc tggcgaaagg 540
gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt cagcagcttg 600
taaaacgacg gccagtgagc gcgcttaacc ctagaaagat aatcatattg tgacgtacgt 660
taaagataat catgcgtaaa attgacgcat gataacttcg tataatgtat gctatacgaa 720
gttatgcggc cgcggtaccg gcgcgccggg ggaggctgct ggtgaatatt aaccaaggtc 780
accccagtta tcggaggagc aaacaggggc taagtccaca cgcgtggtac cgtctgtctg 840
cacatttcgt agagcgagtg ttccgatact ctaatctccc taggcaaggt tcatatttgt 900
gtaggttact tattctcctt ttgttgacta agtcaataat cagaatcagc aggtttggag 960
tcagcttggc agggatcagc agcctgggtt ggaaggaggg ggtataaaaag ccccttcacc 1020
aggagaagcc gtcacacaga tccacaagct cctgaagagg taagggttta agggatggtt 1080
ggttggtggg gtattaatgt ttaattaact ggagcacctg cctgaaatca ctttttttca 1140

```

ggttgggcta gcccaccatg cagcgcgatga acatgatcat ggccgagagc cccggcctga	1200
tcaccatctg cctgctgggc tacctgctga gcgccgagtg caccgtgttc ctggaccacg	1260
agaacgcaa caagatcctg aaccgcccc aagcgctacaa cagcggcaag ctggaggagt	1320
tcgtgcaggg caacctggag cgcgagtga tggaggagaa gtgcagcttc gaggaggccc	1380
gcgaggtgtt cgagaacacc gagcgaccca ccgagttctg gaagcagtac gtggacggcg	1440
accagtgcga gagcaacccc tgccatgaacg gcggcagctg caaggacgac atcaacagct	1500
acgagtgtctg gtgccccttc ggcttcgagg gcaagaactg cgagctggac gtgacctgca	1560
acatcaagaa cggccgctgc gagcagttct gcaagaacag cgcgcgacaac aagtggtgt	1620
gcagctgcac cgagggctac cgcccgccg agaaccagaa gagctgcgag cccgcccgtgc	1680
ccttccccctg cggccgcgtg agcgtgagcc agaccagcaa gctgacccgc gccgaggccg	1740
tgttccccga cgtggactac gtgaacagca ccgaggccga gaccatcctg gacaacatca	1800
cccagagcac ccagagcttc aacgacttca cccgcgtggt gggcggcgag gacgccaagc	1860
ccggccagtt cccctggcag gtggtgctga acggcaaggt ggacgccttc tgcggcgga	1920
gcatcgtgaa cgagaagtgg atcgtgaccg ccgccactg cgtggagacc ggcgtgaaga	1980
tcaccgtggt ggcggcgag cacaacatcg aggagaccga gcacaccgag cagaagcgca	2040
acgtgatccg catcatcccc caccacaaat acaacgccgc catcaacaag tacaaccacg	2100
acatgcacct gctggagctg gacgagcccc tgggtgctga cagctacgtg acccccatct	2160
gcatcgcga caaggagtac accaaccatct tcctgaagtt cggcagcggc tacgtgagcg	2220
gctggggccg cgtgttccac aagggccgca gcgcctggt gctgcagtac ctgcgcgtgc	2280
ccctggtgga ccgcgccacc tgccatgcga gcaccaagtt caccatctac aacaacatgt	2340
tctgcgccgg cttccacgag ggcggccggc acagctgcca gggcgacagc ggcggccccc	2400
acgtgaccga ggtggagggc accagcttcc tgaccggcat catcagctgg ggcgaggagt	2460
gcgccatgaa gggcaagtac ggcattctaca ccaaggtgag ccgctacgtg aactggatca	2520
aggagaagac caagctgacc taatgaaaga tggatttcca aggttaattc attggaattg	2580
aaaattaaca gccccccccc cccccccct gcagatctag agctcgtga tcagcctcga	2640
ctgtgccttc tagttgccag ccattctgtt tttgcccctc ccccgctgct tccttgaccc	2700
tggaaagtgc cactccact gtcccttcc aataaaatga ggaaattgca tcgcattgtc	2760
tgagtaggtg tcattctatt ctggggggtg ggggtgggca ggacagcaag ggggaggatt	2820
gggaagacaa tagcaggcat gctggggacc ggtataactt cgtataatgt atgctatacg	2880
aagttatgca tgcgtcaatt ttacgcagac tatctttcta gggtaagcg cgcttggcgt	2940
aatcatggtc atagctgttt cctgtgtgaa attgttatcc gctcacaatt ccacacaaca	3000
tacgagccgg aagcataaag tgtaaagcct ggggtgccta atgagtgagc taactcacat	3060
taattgcgtt gcgctcactg cccgctttcc agtcgggaaa cctgtcgtgc cagctgcatt	3120
aatgaatcgg ccaacgcgcg gggagaggcg gtttgctat tgggcgctct tccgcttcct	3180
cgctcactga ctgcgtgcgc tcggctgttc ggctgcggcg agcggatatca gctcactcaa	3240
aggcggtaat acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa	3300
aaggccagca aaaggccagg aaccgtaaaa aggcgcgtt gctggcggtt ttccataggc	3360
tccgcccccc tgacgagcat caaaaaatc gacgctcaag tcagaggtgg cgaaaccgca	3420

```

caggactata aagataaccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc 3480
cgacctgcgc gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 3540
ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt cgttcgctcc aagctgggct 3600
gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 3660
agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggg aacaggatta 3720
gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct 3780
acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 3840
gagttggtag ctcttgatcc ggcaaaaaa ccaccgctgg tagcgggtgt tttttgttt 3900
gcaagcagca gattacgcgc agaaaaaag gatctcaaga agatcctttg atcttttcta 3960
cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat 4020
caaaaaggat ctccacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa 4080
gtatatatga gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct 4140
cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgctgtg tagataacta 4200

cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct 4260
caccggctcc agatttatca gcaataaacc agccagccgg aaggggcgag cgcagaagtg 4320
gtcctgcaac tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa 4380
gtagtccgcc agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt 4440
cacgctcgtc gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta 4500
catgatcccc catgttgctc aaaaaagcgg ttagctcctt cggctcctcc atcgttgta 4560
gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta 4620
ctgtcatgcc atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct 4680
gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg 4740
cgccacatag cagaacttta aaagtgtc tcatggaaa acgttcttcg gggcgaaaac 4800
tctcaaggat cttaccgctg ttgagatcca gtctgatgta acccactcgt gcacccaact 4860
gatcttcagc atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa 4920
atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt 4980
ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 5040
gtatttagaa aaataaacia atagggttc cgcgcacatt tccccgaaa gtgccac 5097

```

<210> 15

<211> 5097

<212> DNA

<213> Artificial

<220>

<223> PB_micro_T_No_ins_TTRminSerpMVM_FIXco_Padua_bghpA transposon

<400> 15

```

ctaaattgta agcgttaata ttttgtaaa attcgcgtta aatttttgtt aaatcagctc 60
attttttaac caataacccc aaatccgcaa aatcccttat aaatcaaaa aataacccaa 120

```

```

-----
gatagggttg agtgttgttc cagtttgga caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatacaagt tttttggggt cgagggtgccg taaagcacta aatcggaacc ctaaagggag 300
ccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa 360
agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420
cacaccgcc gcgcttaatg gcgcgctaca gggcgcgctc cattcgccat tcaggctggc 480
caactgttgg gaaggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg 540
gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt cagcagcttg 600
taaaacgacg gccagtgagc gcgcttaacc ctagaagat aatcatattg tgacgtacgt 660
taaagataat catgcgtaaa attgacgcat gataacttcg tataatgtat gctatacgaa 720

gttatgcggc cgcggtaccg gcgcgcggg ggaggctgct ggtgaatatt aaccaagtc 780
acccagtta tcggaggagc aaacaggggc taagtccaca cgcgtggtac cgtctgtctg 840
cacatttcgt agagcgagtg ttccgatact ctaatctccc taggcaaggc tcatatttgt 900
gtaggttact tattctcctt ttgttgacta agtcaataat cagaatcagc aggtttggag 960
tcagcttggc agggatcagc agcctgggtt ggaaggaggg ggtataaaag ccccttcacc 1020
aggagaagcc gtcacacaga tccacaagct cctgaagagg taagggttta agggatggtt 1080
ggttggtggg gtattaatgt ttaattacct ggagcacctg cctgaaatca ctttttttca 1140
ggttgggcta gccaccatg cagcgcgtga acatgatcat ggcgagagc cccggcctga 1200
tcaccatctg cctgctgggc tacctgctga gcgccagtg caccgtgttc ctggaccacg 1260
agaacgcaa caagatcctg aaccgcccc aagcgtacaa cagcggcaag ctggaggagt 1320
tcgtgcaggg caacctggag cgcgagtga tggaggagaa gtgcagcttc gaggaggccc 1380
gcgaggtgtt cgagaacacc gagcgacca ccgagttctg gaagcagtac gtggacggcg 1440
accagtgcga gagcaacccc tgctgaacg gcggcagctg caaggacgac atcaacagct 1500
acgagtgtg gtgccccttc ggcttcgagg gcaagaactg cgagctggac gtgacctgca 1560
acatcaagaa cggcgcgtgc gagcagttct gcaagaacag cgcgacaac aaggtggtgt 1620
gcagctgcac cgagggtac cgctggccg agaaccagaa gagctgcgag cccgccgtgc 1680
ccttcccctg cggcgcgtg agcgtgagc agaccagcaa gctgaccgc gccgaggccg 1740
tgttccccga cgtggactac gtgaacagca ccgaggccga gaccatcctg gacaacatca 1800
cccagagcac ccagagcttc aacgacttca cccgcgtggt gggcggcgag gacgccaagc 1860
ccggccagtt ccctggcag gtggtgctga acggcaagggt ggacgccttc tgcggcgga 1920
gcatcgtgaa cgagaagtgg atcgtgaccg ccgccactg cgtggagacc ggcgtgaaga 1980
tcaccgtggt ggcggcgag cacaacatcg aggagaccga gcacaccgag cagaagcgca 2040
acgtgatccg catcatcccc caccacaact acaacgccgc catcaacaag tacaaccacg 2100
acatcgccct gctggagctg gacgagcccc tgggtgctgaa cagctacgtg accccatct 2160
gcatcgccga caaggagtac accaacadct tcctgaagtt cggcagcggc tacgtgagcg 2220
gctggggccg cgtgttccac aagggccgca gcgcctggt gctgcagtac ctgcgcgtgc 2280
-----

```

ccctggtgga ccgcgccacc tgcctgctga gcaccaagtt caccatctac aacaacatgt 2340
 tctgcgccgg cttccacgag ggcggccggg acagctgcc a ggcgcacagc ggcggccccc 2400
 acgtgaccga ggtggagggc accagcttcc tgaccggcat catcagctgg ggcgaggagt 2460
 gcgccatgaa gggcaagtac ggcattctaca ccaaggtgag ccgctaogtg aactggatca 2520
 aggagaagac caagctgacc taatgaaaga tggatttcca aggttaattc attggaattg 2580

 aaaattaaca gccccccccc cccccccct gcagatctag agctcgctga tcagcctcga 2640
 ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgctcct tccttgacct 2700
 tggaagggtc cactcccact gtcccttccct aataaaatga ggaaattgca tcgcattgtc 2760
 tgagtaggtg tcattctatt ctgggggggtg ggggggggca ggacagcaag ggggaggatt 2820
 gggaagacaa tagcaggcat gctggggacc ggtataactt cgtataatgt atgctatacg 2880
 aagttatgca tgcgtcaatt ttacgcagac tatctttcta gggttaagcg cgtttggcgt 2940
 aatcatggtc atagctgttt cctgtgtgaa attgttatcc gctcacaatt ccacacaaca 3000
 tacgagccgg aagcataaag tgtaaagcct ggggtgccta atgagtgagc taactcacat 3060
 taattgcgtt gcgctcactg cccgcttcc agtcgggaaa cctgtcgtgc cagctgcatt 3120
 aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat tgggcgctct tccgcttccct 3180
 cgctcactga ctcgctgcgc tcggctgttc ggtgcggcg agcgggtatca gctcactcaa 3240
 aggcggtaat acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa 3300
 aaggccagca aaaggccagg aaccgtaaaa aggcgcgctt gctggcgctt tcccataggc 3360
 tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagagggtg cgaaacccga 3420
 caggactata aagataccag gcgtttccccc ctggaagctc cctcgctgcgc tctcctgttc 3480
 cgaccctgcc gcttacggga taactgtccg cctttctccc ttcgggaagc gtggcgcttt 3540
 ctcatagctc acgctgtagg tatctcagtt cggtgtaggc cgttcgctcc aagctgggct 3600
 gtgtgcacga acccccctt cagcccgaac gctgcgcctt atccggtaac tatcgtcttg 3660
 agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta 3720
 gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct 3780
 aactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 3840
 gagttggtag ctcttgatcc ggcaacaaa ccaccgctgg tagcgggtgt ttttttgttt 3900
 gcaagcagca gattacgcgc agaaaaaag gatctcaaga agatccttg atcttttcta 3960
 cggggtctga cgctcagtg aacgaaaact cacgttaagg gattttggtc atgagattat 4020
 caaaaaggat cttcacctag atccttttaa attaaaaatg aagtttttaa tcaatctaaa 4080
 gtatatatga gtaaaacttg tctgacagtt accaatgctt aatcagtgag gcacctatct 4140
 cagcgatctg tetatttctg tcatccatag ttgcctgact ccccgctctg tagataacta 4200
 cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgca gaccacgct 4260
 caccggctcc agatttatca gcaataaacc agccagccgg aaggggcgag cgcagaagtg 4320
 gtccgcaac tttatccgcc tccatccagt ctattaattg ttgcccggaa gctagagtaa 4380
 gtagttcgcc agttaaatgt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt 4440
 cacgctcgtc gtttggtatg gcttcattca gctccggtc ccaacgatca aggcgagtta 4500

 catgatcccc catgttgtgc aaaaaagcgg ttagctcctt cggctcctcc atcgttgtca 4560

```

gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta 4620
ctgtcatgcc atccgtaaga tgcttttctg tgactgggtga gtactcaacc aagtcattct 4680
gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg 4740
cgccacatag cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac 4800
totcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact 4860
gatcttcagc atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa 4920
atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt 4980
ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 5040
gtatttagaa aaataaacia ataggggttc cgcgcacatt tccccgaaaa gtgccac 5097

```

<210> 16

<211> 14

<212> PRT

<213> Artificial

<220>

<223> linker

<400> 16

```

Ser Phe Ser Gln Asn Pro Pro Val Leu Thr Arg His Gln Arg
1           5           10

```

<210> 17

<211> 6891

<212> DNA

<213> Artificial

<220>

<223> pCDNA3 _CMVBGI _SBMAX_bghpA plasmid

<400> 17

```

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggtag gcgttttgcg ctgcttcgcg cgtggagcta gttattaata gtaatcaatt 240
acggggtcac tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat 300
ggcccgctg gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatggt 360
cccatagtaa cgtcaatagg gactttccat tgacgtcaat gggtggagta ttacggttaa 420
actgcccact tggcagtaca tcaagtgtat catatgcaa gtacgcccc tattgacgtc 480
aatgacggta aatggccgcg ctggcattat gccagtaga tgaccttatg ggactttcct 540

acttggcagt acatctacgt attagtcac gctattacca tggatgatgc gttttggcag 600
tacatcaatg ggcgtggata gcggtttgac tcacggggat ttccaagtct ccacccatt 660
gacgtcaatg ggagtttggt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac 720

```

aactccgccc cattgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc	780
agagctcggt tagtgaaccg tcagatcgcc tggagacgcc atccacgctg ttttgacctc	840
catagaagac accgggaccg atccagcctc cgcggattcg aatcccggcc gggaaacggtg	900
cattggaacg cggattcccc gtgccaagag tgacgtaagt accgcctata gagtctatag	960
gcccacaaaa aatgctttct tcttttaata tacttttttg tttatcttat ttctaatact	1020
ttccctaata tctttctttc agggcaataa tgatacaatg tatcatgcct ctttgcacca	1080
ttctaagaa taacagtgat aatttctggg ttaaggcaat agcaatattt ctgcatataa	1140
atatttctgc atataaattg taactgatgt aagaggtttc atattgctaa tagcagctac	1200
aatccagcta ccattctgct tttattttat ggttgggata aggctggatt attctgagtc	1260
caagctaggc ccttttgcta atcatgttca tacctcttat ctctctcca cagctcctgg	1320
gcaacgtgct ggtctgtgtg ctggcccatc actttggcaa agaattggga ttcgaacatc	1380
gatgcgcgca ccattggaaa atcaaaaaga atcagccaag acctcagaaa aagaattgta	1440
gacctccaca agtctggttc atccttggga gcaatttccc gacgcctggc ggtaccacgt	1500
tcattctgtac aaacaatagt acgcaagtat aaacaccatg ggaccacgca gccgtcatac	1560
cgctcaggaa ggagacgcgt tctgtctcct agagatgaac gtacttttgt gcgaaaagtg	1620
caaatcaatc ccagaacaac agcaaaggac ctgtgtgaaga tgctggagga aacagggtaca	1680
aaagtatcta tatccacagt aaaacgagtc ctatatcgac ataacctgaa aggccactca	1740
gcaaggaaga agccactgct ccaaaaccga cataagaaag ccagactacg gtttgcaact	1800
gcacatgggg acaaagatct aacttttttg agaaatgtcc tctgggtctga tgaacaaaa	1860
atagaactgt ttggccataa tgaccatcgt tatgtttgga ggaagaaggg ggaggcttgc	1920
aagccgaaga acaccatccc aaccgtgaag cacgggggtg gcagcatcat gttgtggggg	1980
tgctttgctg caggagggac tggtaaaactt gtccgaatag aaggcatcat ggacgcgggtg	2040
cagtatgtgg atatattgaa gcaacatctc aagacatcag tcaggaagtt aaagcttggt	2100
cgcaaatggg tcttccaaca cgacaatgac cccaagcata ctccaaagt tgtggcaaaa	2160
tggcttaagg acaacaaagt caaggtattg gactggccat cacaaagccc tgacctcaat	2220
cctatagaaa atttgtgggc agaactgaaa aagcgtgtgc gagcaaggag gcctacaaac	2280
ctgactcagt tacaccagct ctgtcaggag gaatgggcca aaattcaccc aaattattgt	2340
gggaagcttg tggaaggcta cccgaaacgt ttgacccaag ttaacaatt taaaggcaat	2400
gctaccaaata actagctoga gcatgcctc agagggccct attctatagt gtcacctaaa	2460
tgctagagct cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg	2520
ccctccccc gtgccttctc tgaccctgga aggtgccact ccactgtcc tttcctaata	2580
aatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt	2640
ggggcaggac agcaaggggg aggattggga agacaatagc aggcattgctg gggatgcggt	2700
gggctctatg gcttctgagg cggaaagaac cagctggggc tctaggggggt atcccacgc	2760
gccctgtagc ggcgcattaa gcgcggcggg tgtggtggtt acgcgcagcg tgaccgctac	2820
acttgccagc gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccaggtt	2880
cgccggcttt ccccgtaag ctctaaatcg gggcatccct ttagggttcc gatttagtgc	2940
tttacggcac ctcgacccca aaaaacttga ttaggggtgat ggttcacgta gtgggccatc	3000

gccctgatag acggtttttc gccctttgac gttggagtcc acgttcttta atagtggact 3060
 cttgttccaa actggaacaa cactcaaccc tatctcggtc tattcttttg atttataagg 3120
 gattttgggg atttcggcct attggttaaa aaatgagctg atttaacaaa aatttaacgc 3180
 gaattaattc tgtggaatgt gtgtcagtta ggggtgtgaa agtccccagg ctccccaggc 3240
 aggcagaagt atgcaaagca tgcattctca ttagtcagca accaggtgtg gaaagtcccc 3300
 aggtccccc gacggcagaa gtatgcaaag catgcatctc aattagtcag caaccatagt 3360
 cccgccccta actccgccc tcccgcccct aactccgccc agttccgccc attctccgcc 3420
 ccatggctga ctaatTTTTT ttatttatgc agaggccgag gccgcctctg cctctgagct 3480
 attccagaag tagtgaggag gcttttttgg aggcctaggc ttttgcaaaa agctccggg 3540
 agcttgata tccattttcg gatctgatca agagacagga tgaggatcgt ttgcgatgat 3600
 tgaacaagat ggattgcacg caggttctcc ggccgcttgg gtggagaggc tattcggcta 3660
 tgactgggca caacagacaa tcggctgctc tgatgcgcc gtgttcgggc tgtcagcgca 3720
 ggggcgccc gttctttttg tcaagaccga cctgtccggt gccctgaatg aactgcagga 3780
 cgaggcagcg cggtatcgt ggctggccac gacgggcgtt ccttgccag ctgtgctcga 3840
 cgttgctact gaagcgggaa gggactggct gctattgggc gaagtgcgg ggcaggatct 3900
 cctgtcatct caccttgctc ctgccagaa agtatccatc atggctgatg caatgcggcg 3960
 gctgcatacg cttgatccgg ctacctgcc attcgaccac caagcgaaac atcgcatcga 4020
 gcgagcacgt actcggatgg aagccggtct tgtcgatcag gatgatctgg acgaagagca 4080
 tcaggggctc gcgccagccg aactgttcgc caggctcaag gcgcgcatgc ccgacggcga 4140
 ggatctcgtc gtgaacctg gcgatgcctg cttgccgaat atcatgggtg aaaatggccg 4200
 cttttctgga ttcatcgact gtggccggtt ggggtgtggc gaccgctatc aggacatagc 4260
 gttggctacc cgtgatattg ctgaagagct tggcggcgaa tgggctgacc gcttcctcgt 4320

 gctttacggt atcgccgctc ccgattcgca gcgcacgcc ttctatcgcc ttcttgacga 4380
 gttctcttga gcgggactct ggggttcgaa atgaccgacc aagcgacgcc caacctgcca 4440
 tcacgagatt tcgattccac cgcgccttc tatgaaagg tgggcttcgg aatcgttttc 4500
 cgggacgcc gctggatgat cctccagcgc ggggatctca tgetggagt ctctgccac 4560
 cccaacttgt ttattgcagc ttataatggt taaaaataa gcaatagcat caaaaatttc 4620
 acaataaag catttttttc actgcattct agttgtggtt tgtccaaact catcaatgta 4680
 tcttatcatg tctgtatacc gtgcacctc agctagagct tggcgtaatc atggtcatag 4740
 ctgtttcctg tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc 4800
 ataaagtgta aagcctgggg tgccaatga gtgagctaac tcacattaat tgcgttcgc 4860
 tcaactgccc ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa 4920
 cgcgcgggga gaggcggtt gcgtattggc cgtcttccg ctctcctcgt cactgactcg 4980
 ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 5040
 ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 5100
 gccaggaaac gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 5160
 gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 5220
 taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttcgac cctgcgctt 5280

accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca atgctcacgc 5340
 tgtaggatcc tcagttcggg gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 5400
 cccgttcagc ccgaccgctg cgccttacc ggtaactatc gtcttgagtc caaccggta 5460
 agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggat 5520
 gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5580
 gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5640
 tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgca gcagcagatt 5700
 acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 5760
 cagtggaaacg aaaactcacg ttaagggatt ttgggtcatga gattatcaaa aaggatcttc 5820
 acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 5880
 acttgggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5940
 tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc 6000
 ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cagctcacc ggctccagat 6060
 ttatcagcaa taaaccagcc agccggaagg gccgagcga gaagtggctc tgcaacttta 6120
 tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt 6180
 aatagtttgc gcaacgttgt tgccattgct acaggcatcg tgggtgtcacg ctcgctggtt 6240

 ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg 6300
 ttgtgcaaaa aagcgggttag ctccctcggg cctccgatcg ttgtcagaag taagttggcc 6360
 gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 6420
 gtaagatgct tttctgtgac tggtgagtac tcaaccaagt cattctgaga atagtgtatg 6480
 cggcgaccga gttgtctttg cccggcgtca atacgggata ataccgcgcc acatagcaga 6540
 actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6600
 ccgctgttga gatccagttc gatgtaacct actcgtgcac ccaactgatc ttcagcatct 6660
 tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6720
 ggaataaggc cgacacggaa atgttgaata ctcatactct tcctttttca atattattga 6780
 agcatttata agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6840
 aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt c 6891

<210> 18

<211> 19

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 18

gaaggatgaag gtcggagtc 19

<210> 19

<211> 20
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 19
gaagatgggtg atgggatttc 20

<210> 20
<211> 25
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 20
tgatgctatt gctttatttg taacc 25

<210> 21
<211> 23
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 21
cctgaacctg aaacataaaa tga 23

<210> 22
<211> 34
<212> DNA
<213> Artificial

<220>
<223> probe

<400> 22
agctgcaata aacaagttaa caacaacaat tgca 34

<210> 23
<211> 19
<212> DNA
<213> Artificial

<220>

<223> Fragment codon-optimized human coagulation factor IX with Padua mutation

<400> 23

cctgcctgct gagcaccaa 19

<210> 24

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Fragment codon-optimized human coagulation factor IX

<400> 24

cctgcctgcg cagcaccaa 19

<210> 25

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 25

aacaggggct aagtccacac 20

<210> 26

<211> 21

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 26

gagcgagtgt tccgatactc t 21

<210> 27

<211> 24

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 27

atcaagaagg tgggaagca ggca 24

<210> 28

<211> 24

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 28

tggaagagtg ggagttgctg ttga 24

<210> 29

<211> 67

<212> DNA

<213> Artificial

<220>

<223> IR micro

<400> 29

ttaaccctag aaagataatc atattgtgac gtacgttaaa gataatcatg cgtaaaattg 60

acgcatg 67

<210> 30

<211> 40

<212> DNA

<213> Artificial

<220>

<223> IR micro

<400> 30

gcatgcgtca atttacgca gactatcttt ctagggttaa 40

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2009130208A](#) [\[0010\]](#) [\[0010\]](#) [\[0016\]](#) [\[0031\]](#) [\[0092\]](#) [\[0113\]](#)
- [WO2011005968A](#) [\[0013\]](#) [\[0028\]](#)
- [WO20110059A](#) [\[0029\]](#)
- [EP2012071297W](#) [\[0162\]](#)
- [EP2013064054W](#) [\[0162\]](#)

Non-patent literature cited in the description

- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual Cold Spring Harbor Press 1989 0000 [\[0023\]](#)
- **AUSUBEL et al.** Current Protocols in Molecular Biology John Wiley & Sons 1999 0000 [\[0023\]](#)
- **MEIR et al.** BMC Biotechnology, 2011, vol. 11, 28- [\[0065\]](#)
- **VANDENDRIESSCHE T. THORREZ LACOSTA-SANCHEZ PETRUS IWANG LMA LDE WAELE LIWASAKI YGIILLIJNS VWILSON JME** Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy J Thromb Haemost, 2007, vol. 5, 116-24 [\[0101\]](#)
- **ANNONI ABROWN BDCANTORE ASERGI LSNALDINI LRONCAROLO MG** In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance Blood, 2009, vol. 114, 5152-5161 [\[0161\]](#)
- **ARRUDA VRSTEDMAN HHHAURIGOT VBUCHLIS G.** Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B Blood, 2010, vol. 115, 4678-88 [\[0161\]](#)
- **AXELROD JHREAD MSBRINKHOUS KMVERMA IM.** Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs Proc Natl Acad Sci USA, 1990, vol. 87, 5173-7 [\[0161\]](#)
- **BROWN BDSHI CXPOWELL S HURLBUT DGRAHAM FLILLICRAP D.** Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A Blood, 2004, vol. 103, 804-10 [\[0161\]](#)
- **BROWN BDCANTORE AANNONI ASERGI LSLOMBARDO ADELLA VALLE PD'ANGELO ANALDINI L.** A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice Blood, 2007, vol. 110, 4144-52 [\[0161\]](#)
- **BRUNETTI-PIERRI N, GROVE NC, ZUO Y, EDWARDS R, PALMER D, CERULLO V, TERUYA J, NG P** Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B Hum Gene Ther., 2009, vol. 20, 5479-85 [\[0161\]](#)

- **BUCHLIS GPODSAKOFF GMRADU AHAWK SMFLAKE AWMINGOZZI FHIGH KA.**Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transferBlood, 2012, vol. 119, 3038-41 [\[0161\]](#)
- **BUDKER VZHANG GKNECHTLE SWOLFF JA.**Naked DNA delivered intraportally expresses efficiently in hepatocytesGene Ther. Jul, 1996, vol. 3, 7593-8 [\[0161\]](#)
- **CANTORE ANAIR NDELLA VALLE PDI MATTEO MMÀTRAI JSANVITO FBROMBIN CDI SERIO CD'ANGELO ACHUAH M**Hyper-functional coagulation factor IX improves the efficacy of gene therapy in hemophilic miceBlood, 2012, [\[0161\]](#)
- **CHANG, J.JIN, J.LOLLAR, P.BODE, W.BRANDSTETTER, H.HAMAGUCHI, N.STRAIGHT, D. L.STAFFORD, D. W.**Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activityJ Biol Chem, 1998, vol. 273, 2012089-12094 [\[0161\]](#)
- **CHOWDHURY JRGROSSMAN MGUPTA SCHOWDHURY NRBAKER JR JRWILSON JM.**Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbitsScience, 1991, vol. 254, 50391802-5 [\[0161\]](#)
- **CHUAH MKSCHIEDNER GTHORREZ LBROWN BJOHNSTON MGILLIJNS VHERTEL SVAN ROOIJEN NLILLICRAP DCOLLEN D**Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectorsBlood, 2003, vol. 101, 1734-43 [\[0161\]](#)
- **CHUAH MKNAIR NVANDENDRIESSCHE T**Recent progress in gene therapy for hemophiliaHum Gene Ther, 2012, vol. 23, 6557-65 [\[0161\]](#) [\[0161\]](#)
- **CHUAH MKVANDENDRIESSCHE T**Platelet-directed gene therapy overcomes inhibitory antibodies to factor VIIIJ Thromb Haemost., 2012, vol. 10, 81566-9 [\[0161\]](#)
- **DONSANTE AMILLER DGLI YVOGLER CBRUNT EMRUSSELL DWSANDS MS.**AAV vector integration sites in mouse hepatocellular carcinomaScience, 2007, vol. 317, 477- [\[0161\]](#)
- **DOBRZYNSKI EFITZGERALD JCCAO OMINGOZZI FWANG LHERZOG RWP**Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cellsProc Natl Acad Sci USA, 2006, vol. 103, 4592-4597 [\[0161\]](#)
- **EHRHARDT AKAY MA.**A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivoBlood, 2002, vol. 99, 3923-30 [\[0161\]](#)
- **FIELDS PAARRUDA VRARMSTRONG EKIRK CHUMINGOZZI, FHAGSTROM, J.HERZOG RHIGH KA.**Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9Mol. Ther., 2001, vol. 4, 201-210 [\[0161\]](#)
- **FOLLENZI ABATTAGLIA MLOMBARDO AANNONI ARONCAROLO MGNALDINI L.**Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in miceBlood, 2004, vol. 103, 3700-9 [\[0161\]](#)
- **GAO GPALVIRA MRWANG LJOHNSTON JWILSON JM.**Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyProc Natl Acad Sci USA, 2002, vol. 99, 11854-9 [\[0161\]](#)

- **GAO GVANDENBERGH LHALVIRA MR LU YCALCEDO RZHOU XWILSON JM.** Clades of Adeno- associated viruses are widely disseminated in human tissues *J. Viro*, 2004, vol. 178, 6381-6388 [\[0161\]](#)
- **HERZOG RWYANG EYCOUTO LBHAGSTROM JNELWELL DFIELDS PABURTON MBELLINGER DAREAD MSBRINKHOUS KML** Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector *Nat Med.*, 1999, vol. 5, 56-63 [\[0161\]](#)
- **HERZOG RWMOUNT JDARRUDA VRHIGH KALOTHROP CD JR.** Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation *Mol Ther.*, 2001, vol. 4, 192-200 [\[0161\]](#)
- **HERZOG RWHAGSTROM JNKUNG SHTAI SJWILSON JMFISHER KJHIGH KA.** Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus *Proc Natl Acad Sci USA.*, 1997, vol. 94, 5804-5809 [\[0161\]](#)
- **HERZOG RWFIELDS PAARRUDA VRBRUBAKER JOARMSTRONG EMCCLINTOCK DBELLINGER DACOUTO LBNICHOLS TCHIGH KA** Influence of vector dose on factor IX-specific T and B cell responses in muscle- directed gene therapy *Hum Gene Ther.*, 2002, vol. 13, 1281-1291 [\[0161\]](#)
- **HIGH KA.** Gene Transfer as an approach to treating Hemophilia *Circ Res.*, 2001, vol. 88, 137-144 [\[0161\]](#)
- **HIGH KA.** Gene therapy for hemophilia: a long and winding road *J Thromb Haemost.*, 2011, vol. 9, 12-11 [\[0161\]](#)
- **BAINBRIDGE JSMITH AJBARKER S et al.** Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis *N Engl J Med.*, 2008, vol. 358, 2231-2239 [\[0161\]](#)
- **JIANG HLILLICRAP DPATARROYO-WHITE S.** Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dog *Blood*, 2006, vol. 108, 107-15 [\[0161\]](#)
- **KAO, C. Y. LIN, C. N. YU, I. S. TAO, M. H. WU, H. L. SHI, G. Y. YANG, Y. L. KAO, J. T. LIN, S. W. FIX-** Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis *Thromb Haemost.*, 2010, vol. 104, 2355-365 [\[0161\]](#)
- **KAY MABALEY PROTHENBERG SLELAND FFLEMING LPONDER KPLIU TFINEGOLD MDARLINGTON GPOKORNY W** Expression of human alpha 1 -antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes *Proc Natl Acad Sci USA*, 1992, vol. 89, 189-93 [\[0161\]](#)
- **KAY MAMANNO CSRAGNI MVCOUTO LBMCCLELLAND AGLADER BCHEW AJTAI SJHERZOG RWARRUDA V** Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector *Nat Genet.*, 2000, vol. 24, 257-61 [\[0161\]](#)
- **KISTNER AGOSSEN MZIMMERMANN FJERECIC JULLMER CLYBBERT HBUJARD H.** Doxycycline- mediated quantitative and tissue-specific control of gene expression in transgenic mice *Proc Natl Acad Sci U S A.*, 1996, vol. 93, 2010933-8 [\[0161\]](#)
- **KREN BTUNGER GMSJEKLOCHA LTROSSEN AAKORMAN VDIETHELEM-OKITA BMREDING MTSTEER CJ.** Nanocapsule-delivered Sleeping Beauty mediates

therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice *J Clin Invest.*, 2009, vol. 19, 2086-99 [0161]

- **KURIYAMA SYOSHIKAWA MISHIZAKA STSUJII TLKENAKA KKAGAWA TMORITA NMIKOSHIBA K.** A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector *Cell Struct Funct.*, 1991, vol. 16, 6503-10 [0161]
- **LI HMALANI NHAMILTON SRSCHLACHTERMAN ABUSSADORI GEDMONSON SESHAN RARRUDA VRMINGOZZI FWRIGHT JF** Assessing the potential for AAV vector genotoxicity in a murine model *Blood*, 2011, vol. 117, 3311-9 [0161]
- **LIN, C. N. KAO, C. Y. MIAO, C. H. HAMAGUCHI, N. WU, H. L. SHI, G. Y. LIU, Y. L. HIGH, K. A. LIN, S. W.** Generation of a novel factor IX with augmented clotting activities in vitro and in vivo *J Thromb Haemost*, 2010, vol. 8, 81773-1783 [0161]
- **LIU FSONG YLIU D.** Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA *Gene Ther.*, 1999, vol. 6, 71258-66 [0161]
- **MANNO CSPIERCE GFARRUDA VR.** Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response *Nat Med.*, 2006, vol. 12, 342-7 [0161]
- **MATES LCHUAH MKBELAY EJERCHOW BMANOJ NACOSTA-SANCHEZ AGRZELA DPSCHMITT ABECKER KMATRAI J** Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates *Nat Genet.*, 2009, vol. 41, 753-61 [0161]
- **MÁTRAI JCHUAH MKVANDENDRIESSCHE T.** Pre clinical and clinical progress in hemophilia gene therapy *Curr Opin Hematol.*, 2010, vol. 17, 387-92 [0161]
- **MÁTRAI JCHUAH MKVANDENDRIESSCHE T.** Recent advances in lentiviral vector development and applications *Mol Ther.*, 2010, vol. 18, 477-90 [0161]
- **MÁTRAI JCANTORE ABARTHOLOMAE CCANNONI AWANG WACOSTA-SANCHEZ ASAMARA-KUKO EDE WAELE LMA LGENOVESE P** Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk *Hepatology*, 2011, vol. 53, 1696-707 [0161]
- **MATSUI HSHIBATA MBROWN BLABELLE AHEGADRON CANDREWS CCHUAH MVANDENDRIESSCHE TMIAO CHHOUGH CA** A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3⁺ T regulatory cells *Blood*, 2009, vol. 114, 677-85 [0161]
- **MATSUI HHEGADORN COZELO MBURNETT ETUTTLE ALABELLE AMCCARY PB JR. NALDINI LBROWN BHOUGH CA** microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A *Mol Ther.*, 2011, vol. 19, 723-30 [0161]
- **MCCARTY DMMONAHAN PESAMULSKI RJ.** Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis *Gene Ther.*, 2001, vol. 8, 1248-54 [0161]
- **MCCARTY DMFU HMONAHAN PETOULSON CENAIK PSAMULSKI RJ** Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo *Gene Ther.*, 2003, vol. 10, 2112-8 [0161]

- **MCINTOSH, J. et al.**Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variantBlood, 2013, [0161]
- **MIAO CHOHASHI KPATIYN GAMEUSE LYE XTHOMPSON ARKAY MA**Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitroMol Ther., 2000, vol. 1, 522-32 [0161]
- **MIAO H.Z.SIRACHAINAN N.PALMER L. et al.**Bioengineering of coagulation factor VIII for improved secretionBlood, 2004, vol. 103, 93412-3419 [0161]
- **MILANOV et al.**Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in miceBlood, 2012, vol. 119, 602-611 [0161]
- **MILLER AD.**Retrovirus packaging cellsHum Gene Ther. Spring, 1990, vol. 1, 15-14 [0161]
- **MINGOZZI FLIU YLDOBRZYNSKI EKAUFHOLD ALIU JHWANG YARRUDA VRHIGH KAHERZOG RW.**Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transferJ Clin Invest., 2003, vol. 111, 1347-56 [0161]
- **MINGOZZI FMAUS MVHUI DJSABATINO DEMURPHY SLRASKO JERAGINI MYMANNO CSSOMMER JJIANG HCD8(+)** T-cell responses to adeno-associated virus capsid in humansNat Med., 2007, vol. 13, 419-22 [0161]
- **MOUNT JDHERZOG RWTILLSON DMGOODMAN SAROBINSON NMCLELAND MLBELLINGER DNICHOLS TCARRUDA VRLOTHROP CD JR**Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapyBlood, 2002, vol. 99, 2670-6 [0161]
- **NALDINI LBLOMER UGALLAY PORY DMULLIGAN RGAGE FHVERMA IMTRONO D.**In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vectorScience, 1996, vol. 272, 5259263-7 [0161]
- **NATHWANI ACDAVIDOFF AMHANAWA HYUNYU HUHOFFER FANIKANOROV ASLAUGHTER CNG CYCZHOU JLOZIER JS**Sustained high- level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaquesBlood, 2002, vol. 100, 1662-1669 [0161]
- **NATHWANI ACGRAY JTNG CYZHOU JSPENCE YWADDINGTON SNTUDDENHAM EGKEMBALL COOK GMCINTOSH JBOON-SPIJKER M**Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liverBlood, 2006, vol. 107, 2653-61 [0161]
- **NATHWANI ACTUDDENHAM EGRANGARAJAN SROSALES CMCINTOSH JLINCH DCCHOWDARY PRIDDELL APIE AJHARRINGTON CA**Adenovirus-associated virus vector-mediated gene transfer in hemophilia BN Engl J Med., 2011, vol. 365, 2357-2365 [0161]
- **OHLFEST JRFRANDSEN JLFRITZ SLOBITZ PDPERKINSON SGCLARK KJNELSESTUEN GKEY NSMCLVOR RSHACKETT PB**Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon systemBlood, 2004, vol. 105, 2691-8 [0161]

- **PETRUS, I.CHUAH, M.VANDENDRIESSCHE, T.**Gene therapy strategies for hemophilia: benefits versus risks*J Gene Med*, 2010, vol. 12, 797-809 [\[0161\]](#)
- **SANDBERG HALMSTEDT ABRANDT J et al.**Structural and functional characteristics of the B domain-deleted recombinant factor VIII proteint, r-VIII SQ*Thromb Haemost.*, 2001, vol. 85, 193-100 [\[0161\]](#)
- **SCHUETTRUMPF, J.HERZOG, R. W.SCHLACHTERMAN, A.KAUFHOLD, A.STAFFORD, D. W.ARRUDA, V. R.**Factor IX variants improve gene therapy efficacy for hemophilia B*Blood*, 2005, vol. 105, 62316-2323 [\[0161\]](#)
- **SIMIONI, P.TORMENE, D.TOGNIN, G.GAVASSO, S.BULATO, C.IACOBELLI, N. P.FINN, J. D.SPIEZIA, L.RADU, C.ARRUDA, V. R.**X-linked thrombophilia with a mutant factor IX (factor IX Padua)*N Engl J Med*, 2009, vol. 361, 171671-1675 [\[0161\]](#)
- **SNYDER ROMIAO CHPATIJN GASPRATT SKDANOS ONAGY DGOWN AMWINTHER BMEUSE LCOHEN LK**Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors*Nat Genet.*, 1997, vol. 16, 270-276 [\[0161\]](#)
- **SNYDER ROMIAO CMEUSE LTUBB JDONAHUE BAHUI-FENG LINSTAFFORD DWPATEL STHOMPSON ARNICHOLS T**Correction of hemophilia B in canine and murine models using recombinant adeno- associated viral vectors*Nat Med.*, 1999, vol. 5, 64-70 [\[0161\]](#)
- **TRAPNELL BC.**Adenoviral vectors for gene transfer*Adv. Drug Del. Rev.*, 1993, vol. 12, 185-199 [\[0161\]](#)
- **VANDENBERGHE LHWANG LSOMANATHAN SZHI YFIGUEREDO JCALCEDO RSANMIGUEL JDESAI RACHEN CSJOHNSTON J**Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid*Nat Med.*, 2006, vol. 12, 967-71 [\[0161\]](#)
- **VANDENDRIESSCHE TVANSLEMBROUCK VGOOVAERTS IZWINNEN HVANDERHAEGHEN MLCOLLEN DCHUAH MK**Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice*Proc Natl Acad Sci USA.*, 1999, vol. 96, 10379-84 [\[0161\]](#)
- **VANDENDRIESSCHE TTHORREZ LNALDINI LFOLLENZI AMOONS LZWI BERNEMANCOLLEN DCHUAH MK**Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo*Blood*, 2002, vol. 100, 813-22 [\[0161\]](#)
- **VANDENDRIESSCHE TTHORREZ LACOSTA-SANCHEZ APETRUS IWANG LMA LDE WAELE LIWASAKI YGILLIJNS VWILSON JME**Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy*J Thromb Haemost.*, 2007, vol. 5, 16-24 [\[0161\]](#)
- **VANDENDRIESSCHE TIVICS ZIZSVÁK ZCHUAH MK**Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells*Blood*, 2009, vol. 114, 1461-8 [\[0161\]](#)
- **VANDENDRIESSCHE TCHUAH MK**Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B*Hum Gene Ther.*, 2012, vol. 23, 4-6 [\[0161\]](#)

- **WANG LTAKABE KBIDLINGMAIER SMILL CRVERMA IM**Sustained correction of bleeding disorder in hemophilia B mice by gene therapyProc Natl Acad Sci USA, 1999, vol. 96, 3906-3910 [0161]
- **WANG LNICHOLS TCREAD MSBELLINGER DAVERMA IM**Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liverMol Ther., 2000, vol. 1, 154-158 [0161]
- **WANG LCAO OSWALM BDOBRZYNSKI EMINGOZZI FHERZOG RWM**Major role of local immune responses in antibody formation to factor IX in AAV gene transferGene Ther, 2005, vol. 12, 1453-464 [0161]
- **WARD NJBUCKLEY SMWADDINGTON SNVANDENDRIESSCHE TCHUAH MKNATHWANI ACMCLNTOSH JTUDDENHAM EGKINNON CTHRASHER AJ**Codon optimization of human factor VIII cDNAs leads to high-level expressionBlood, 2010, vol. 117, 798-807 [0161]
- **WARD, N.J. et al.**Codon optimization of human factor VIII cDNAs leads to high-level expressionBlood, 2011, vol. 117, 798-807 [0161]
- **WU ZSUN JZHANG TYIN CYIN FVAN DYKE TSAMULSKI RJMONAHAN PE**Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector doseMol Ther., 2008, vol. 16, 280-9 [0161]
- **XU LGAO CSANDS MS**Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia BBlood, 2003, vol. 101, 3924-3932 [0161]
- **XU LNICHOLS TCSARKAR RMC CORQUODALE SBELLINGER DAPONDER KP**Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapyProc Natl Acad Sci USA, 2005, vol. 102, 6080-6085 [0161]
- **YAMADA TIWASAKI YTADA HIWABUKI HCHUAH MKVANDENDRIESSCHE TFUKUDA HKONDO AUEDA MSENOMN**Nanoparticles for the delivery of genes and drugs to human hepatocytesNat Biotechnol., 2003, vol. 21, 8885-90 [0161]
- **YANT SRMEUSE LCHIU WIVICS ZIZSVAK ZKAY MA**Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon systemNat Genet., 2000, vol. 25, 35-41 [0161]
- **YUSA et al.**A hyperactive piggyBac transposase for mammalian applicationsProc Natl Acad Sci U S A., 2011, vol. 108, 41531-6 [0161]
- **ZHANG GBUDKER VWOLFF JA**High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNAAHum Gene Ther, 1999, vol. 10, 101735-7 [0161]
- **ZHONG LLI BMAH CSGOVINDASAMY LAGBANDJE-MCKENNACOOOPER MHERZOG RWZOLOTUKHIN IWARRINGTON JR. KHWEIGEL-VAN AKEN K**Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower dosesProc Natl Acad Sci USA, 2008, vol. 105, 7827-32 [0161]

PATENTKRAV

1. Vektor omfattende en nukleinsyreekspresionskassette omfattende en Serpin-enhancer, som er defineret ved SEQ ID nr. 8 eller en sekvens, der har 95% identitet med denne sekvens, en promotor, en "minute virus of mice" (MVM)-intron, kodon-optimeret koagulationsfaktor IX, der indeholder en hyperaktiverende mutation, og et transkriptionstermineringssignal,
hvor vektoren er en viral vektor afledt af et adenoassocieret virus (AAV), og hvor den hyperaktiverende mutation er en R338L-aminosyresubstitution.
2. Vektor ifølge krav 1, hvor promotoren er afledt af transthyretin-(TTR)-promotoren, fortrinsvis den minimale TTR-promotor.
3. Vektor ifølge et hvilket som helst af kravene 1 eller 2, hvor transkriptionstermineringssignalet er afledt af simianvirus 40-polyadenyleringssignalet eller bovint væksthormon-polyadenyleringssignalet.
4. Vektor ifølge krav 3 med SEQ ID NO: 2.
5. Vektor ifølge et hvilket som helst af kravene 1 til 3, hvor vektoren er et enkeltstrengt AAV eller et selvkomplementært AAV.
6. Vektor ifølge et hvilket som helst af kravene 1 til 5 til anvendelse til behandling af hæmofili B.
7. Farmaceutisk præparat omfattende en vektor ifølge et hvilket som helst af kravene 1 til 5 og en farmaceutisk acceptabel bærer, der eventuelt yderligere omfatter en aktiv ingrediens til behandling af hæmofili B.
8. Farmaceutisk præparat ifølge krav 7 til anvendelse til behandling af hæmofili B.
9. Farmaceutisk præparat til anvendelse ifølge krav 8 eller vektor til anvendelse ifølge krav 6, hvor behandlingen resulterer i niveauer af faktor IX i plasma hos det behandlede individ, der er lig med eller højere end den terapeutiske tærskelkoncentration på 10 mU/ml plasma i et individ, fortrinsvis lig med eller højere end den terapeutiske koncen-

tration på 50 mU/ml plasma i et individ, mere foretrukket lig med eller højere end den terapeutiske koncentration på 100 mU/ml plasma i et individ, endnu mere foretrukket lig med eller højere end den terapeutiske koncentration på 150 mU/ml plasma i et individ og endnu mere foretrukket lig med eller højere end den terapeutiske koncentration på 200 mU/ml plasma i et individ.

10. Farmaceutisk præparat til anvendelse ifølge krav 8 eller 9 eller vektor til anvendelse ifølge krav 6, hvor behandlingen omfatter transduktion af vektoren til individet i en dosis, som er lavere end eller lig med 2×10^{12} vg/kg, fortrinsvis i en dosis, som er lavere end eller lig med 6×10^{11} vg/kg, mere foretrukket i en dosis, som er lavere end eller lig med 2×10^{11} vg/kg.

DRAWINGS




Figure 1A

Figure 1B: SEQ ID 1

```

      10      20      30      40      50
CAGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAAC
GTCGTCGACCGCATTATCGCTTCTCCGGGCGTGGCTAGCGGGAAGGGTTG

      60      70      80      90     100
AGTTGCGCAGCCTGAATGGCGAATGGAATTCCAGACGATTGAGCGTCAAA
TCAACGCGTCGGACTTACCGCTTACCTTAAGGTCTGCTAACTCGCAGTTT

     110     120     130     140     150
ATGTAGGTATTTCCATGAGCGTTTTTCTGTGCAATGGCTGGCGGTAAT
TACATCCATAAAGGTACTCGCAAAAAGGACAACGTTACCGACCGCCATTA

     160     170     180     190     200
ATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCA
TAACAAGACCTATAATGGTCGTCCCGGCTATCAAACCAAGAAGATGAGT

     210     220     230     240     250
GGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATT
CCGTTCACTACAATAATGATTAGTTTCTTCATAACGCTGTTGCCAATTAA

     260     270     280     290     300
TGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAAC
ACGCACTACCTGTCTGAGAAAATGAGCCACCGGAGTGACTAATATTTTGT

     310     320     330     340     350
ACTTCTCAGGATTCTGGCGTACCGTTTCTGTCTAAAAATCCCTTTAATCGG
TGAAGAGTCCTAAGACCGCATGGCAAGGACAGATTTTAGGGAAATTAGCC

     360     370     380     390     400
CCTCCTGTTTAGCTCCCGCTCTGATTCTAACGAGGAAAGCACGTTATACG
GGAGGACAAATCGAGGGCGAGACTAAGATTGCTCCTTTCTGTGCAATATGC

     410     420     430     440     450
TGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGC
ACGAGCAGTTTCGTTGGTATCATGCGCGGGACATCGCCGCGTAATTCGCG
>

     460     470     480     490     500
GGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCC
CCGCCACACCAACCAATGCGCGTCGCACCTGGCGATGTGAACGGTCGCGGG
F1 ORIGIN
>

     510     520     530     540     550
TAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCC
ATCGCGGGCGAGGAAAGCGAAAGAAGGGAAGGAAAGAGCGGTGCAAGCGG
F1 ORIGIN
>

     560     570     580     590     600
GGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT
CCGAAAGGGGCAGTTCGAGATTTAGCCCCGAGGGAAATCCCAAGGCTAA
F1 ORIGIN
>

     610     620     630     640     650

```

```

TAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGATGGTT
ATCACGAAATGCCGTGGAGCTGGGGTTTTTTGAACTAATCCCACTACCAA
_____F1 ORIGIN_____>

      660      670      680      690      700
CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTG
GTGCATCACCCGCTAGCGGGACTATCTGCCAAAAGCGGAACTGCAAC
_____F1 ORIGIN_____>

      710      720      730      740      750
GAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACAACACT
CTCAGGTGCAAGAAATTATCACCTGAGAACAAGGTTTGACCTTGTTGTGA
_____F1 ORIGIN_____>

      760      770      780      790      800
CAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTGCCGATTT
GTTGGGATAGAGCCAGATAAGAAAATAAATATTCCTTAAACGGCTAAA

      810      820      830      840      850
CGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
GCCGGATAACCAATTTTTTACTCGACTAAATGTTTTTAAATTGCGCTTA

      860      870      880      890      900
TTTAACAAAATATTAACGTTTACAATTTAAATATTTGCTTATACAATCTT
AAATTGTTTTATAATTGCAAATGTTAAATTTATAAACGAATATGTTAGAA

      910      920      930      940      950
CCTGTTTTTGGGGCTTTCTGATTATCAACCGGGGTACATATGATTGACA
GGACAAAAACCCCGAAAGACTAATAGTTGGCCCCATGTATACTAACTGT

      960      970      980      990     1000
TGCTAGTTTTACGATTACCGTTCATCGCCTGCACTGCGCGCTCGCTCGCT
ACGATCAAAATGCTAATGGCAAGTAGCGGACGTGACGCGCGAGCGAGCGA
_____MUTATEDITR_____>

     1010     1020     1030     1040     1050
CACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCC
GTGACTCCGGCGGGCCCGTTTCGGGCCCCGAGCCCGCTGGAACACGCGG
_____MUTATEDITR_____>

     1060     1070     1080     1090     1100
CGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGAAATTCACGCGT
GCCGGAGTCACTCGCTCGCTCGCGCGTCTCTCCCTCACCTTAAGTGCGCA
_____MUTATEDITR_____>

     1110     1120     1130     1140     1150
GGTACGATCTGAATTCGGTACAATTCACGCGTGGTACGGCCGCGGTACCG
CCATGCTAGACTTAAGCCATGTTAAGTGCGCACCATGCCGGCGCCATGGC

     1160     1170     1180     1190     1200
GCGCGCCGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCAGTTA
CGCGCGGCCCCCTCCGACGACCACTTATAATTGGTTCCAGTGGGGTCAAT

                                     >Serp_enh   >mTTR/promoter
                                     |             |

```

1210 1220 1230 |1240 | 1250
 TCGGAGGAGCAAACAGGGGCTAAGTCCACACGCGTGGTACCGTCTGTCTG
 AGCCTCCTCGTTTGTCCCCGATTGAGGTGTGCGCACCATTGGCAGACAGAC

1260 1270 1280 1290 1300
 CACATTTCTGTAGAGCGAGTGTTCGATACTCTAATCTCCCTAGGCAAGGT
 GTGTAAAGCATCTCGCTCACAAGGTATGAGATTAGAGGGATCCGTTCCA

1310 1320 1330 1340 1350
 TCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATAAT
 AGTATAAACACATCCAATGAATAAGAGGAAAACAACGATTTCAGTTATTA

1360 1370 1380 1390 1400
 CAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTT
 GTCTTAGTCGTCCAAACCTCAGTCGAACCGTCCCTAGTCGTGCGACCCAA

>mTTR/5'/ut

1410 1420 1430 1440 | 1450
 GGAAGGAGGGGGTATAAAAGCCCTTCACCAGGAGAAGCCGTCACACAGA
 CCTTCCTCCCCCATATTTTCGGGAAGTGGTCCTCTTCGGCAGTGTGTCT

>MVMint

1460 | 1470 1480 1490 1500
 TCCACAAGCTCCTGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGG
 AGGTGTTTCGAGGACTTCTCCATTCCCAAATTCCTTACCAACCAACCACCC

1510 1520 1530 1540 1550
 GTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTTTCA
 CATAATTACAAATTAATGGACCTCGTGGACGGACTTTAGTGAAAAAAGT

1560 1570 1580 1590 1600
 GGTGGCTAGCATGCAGCGCGTGAACATGATCATGGCCGAGAGCCCCGGC
 CCAACCGATCGTACGTCGCGCACTTGTACTAGTACCGGCTCTCGGGGGCG
 _____HUFIXCOPTMT_____>

1610 1620 1630 1640 1650
 CTGATCACCATCTGCCTGCTGGGCTACCTGCTGAGCGCCGAGTGCACCGT
 GACTAGTGGTAGACGGACGACCCGATGGACGACTCGCGGCTCACGTGGCA
 _____HUFIXCOPTMT_____>

1660 1670 1680 1690 1700
 GTTCCTGGACCACGAGAACGCCAACAAGATCCTGAACCGCCCCAAGCGCT
 CAAGGACCTGGTGCTCTTGCGGTTGTCTAGGACTTGGCGGGGTTCGCGGA
 _____HUFIXCOPTMT_____>

1710 1720 1730 1740 1750
 ACAACAGCGGCAAGCTGGAGGAGTTCGTGCAGGGCAACCTGGAGCGCGAG
 TGTTGTGCGCGTTTCGACCTCCTCAAGCACGTCCCGTTGGACCTCGCGCTC
 _____HUFIXCOPTMT_____>

1760 1770 1780 1790 1800
 TGCATGGAGGAGAAGTGCAGCTTCGAGGAGGCCCCGAGGTGTTTCAGAA
 ACGTACCTCCTCTTCAGTCAAGCTCCTCCGGGCGCTCCACAAGCTCTT

```

____HUFIXCOPTMT____>
      1810      1820      1830      1840      1850
CACCGAGCGCACCAACGAGTTCTGGAAGCAGTACGTGGACGGCGACCAGT
GTGGCTCGCGTGGTGGCTCAAGACCTTCGTCAATGCACCTGCCGCTGGTCA
____HUFIXCOPTMT____>
      1860      1870      1880      1890      1900
GCGAGAGCAACCCCTGCCTGAACGGCGGCAGCTGCAAGGACGACATCAAC
CGCTCTCGTTGGGGACGGACTTGCCGCCGTCGACGTTCCCTGCTGTAGTTG
____HUFIXCOPTMT____>
      1910      1920      1930      1940      1950
AGCTACGAGTGCTGGTGCCCTTCGGCTTCGAGGGCAAGAACTGCGAGCT
TCGATGCTCACGACCACGGGGAAGCCGAAGCTCCCGTTCTTGACGCTCGA
____HUFIXCOPTMT____>
      1960      1970      1980      1990      2000
GGACGTGACCTGCAACATCAAGAACGGCCGCTGCGAGCAGTTCTGCAAGA
CCTGCACTGGACGTTGTAGTTCTTGCCGGCGACGCTCGTCAAGACGTTCT
____HUFIXCOPTMT____>
      2010      2020      2030      2040      2050
ACAGCGCCGACAACAAGGTGGTGTGCAGCTGCACCGAGGGCTACCGCCTG
TGTCGCGGCTGTTGTTCCACCACACGTGACGTGGCTCCCGATGGCGGAC
____HUFIXCOPTMT____>
      2060      2070      2080      2090      2100
GCCGAGAACCAGAAGAGCTGCGAGCCCGCCGTGCCCTTCCCTGCGGCCG
CGGCTCTTGGTCTTCTCGACGCTCGGGCGGCACGGGAAGGGGACGCCGGC
____HUFIXCOPTMT____>
      2110      2120      2130      2140      2150
CGTGAGCGTGAGCCAGACCAGCAAGCTGACCCGCGCCGAGGCCGTGTTCC
GCACTCGCACTCGGTCTGGTCTGTTTCGACTGGGCGCGGCTCCGGCACAAAG
____HUFIXCOPTMT____>
      2160      2170      2180      2190      2200
CCGACGTGGACTACGTGAACAGCACCGAGGCCGAGACCATCCTGGACAAC
GGCTGCACCTGATGCACTTGTCTGTGGCTCCGGCTCTGGTAGGACCTGTTG
____HUFIXCOPTMT____>
      2210      2220      2230      2240      2250
ATCACCCAGAGCACCCAGAGCTTCAACGACTTCACCCGCGTGGTGGGCGG
TAGTGGGTCTCGTGGGTCTCGAAGTTGCTGAAGTGGGCGCACCAACCGCC
____HUFIXCOPTMT____>
      2260      2270      2280      2290      2300
CGAGGACGCCAAGCCCGCCAGTTCCCTGGCAGGTGGTGTGAACGGCA
GCTCCTGCGGTTGCGGCCGGTCAAGGGGACCGTCCACCACGACTTGCCGT
____HUFIXCOPTMT____>
      2310      2320      2330      2340      2350
AGGTGGACGCCCTTCTGCGGCCGAGCATCGTGAACGAGAAGTGATCGTG
TCCACCTGCGGAAGACGCCGCCGTCGTAGCACTTGCTCTTACCTAGCAC

```

```

HUFIXCOPTMT >
2360      2370      2380      2390      2400
ACCGCCGCCCACTGCGTGGAGACCGGCGTGAAGATCACCGTGGTGGCCGG
TGGCGGCGGGTGACGCACCTCTGGCCGCACTTCTAGTGGCACCCACGGCC
HUFIXCOPTMT >
2410      2420      2430      2440      2450
CGAGCACAAACATCGAGGAGACCGAGCACACCGAGCAGAAGCGCAACGTGA
GCTCGTGTTGTAGCTCCTCTGGCTCGTGTGGCTCGTCTTCGCGTTGCACT
HUFIXCOPTMT >
2460      2470      2480      2490      2500
TCCGCATCATCCCCACCACAACTACAACGCCGCCATCAACAAGTACAAC
AGGCGTAGTAGGGGGTGGTGTGTGATGTTGCGGCGGTAGTTGTTTCATGTTG
HUFIXCOPTMT >
2510      2520      2530      2540      2550
CACGACATCGCCCTGCTGGAGCTGGACGAGCCCTGGTGTGAACAGCTA
GTGCTGTAGCGGGACGACCTCGACCTGCTCGGGGACCACGACTTGTCGAT
HUFIXCOPTMT >
2560      2570      2580      2590      2600
CGTGACCCCATCTGCATCGCCGACAAGGAGTACACCAACATCTTCCTGA
GCACTGGGGGTAGACGTAGCGGCTGTTCTCATGTGGTTGTAGAAGGACT
HUFIXCOPTMT >
2610      2620      2630      2640      2650
AGTTCGGCAGCGGCTACGTGAGCGGCTGGGGCCGCGTGTTCACAAGGGC
TCAAGCCGTCGCCGATGCACTCGCCGACCCCGGCGCACAAAGGTGTTCCCG
HUFIXCOPTMT >
2660      2670      2680      2690      2700
CGCAGCGCCCTGGTGTGCAGTACCTGCGCGTGCCCTGGTGGACCGCGC
GCGTCGCGGGACACGACGTCATGGACGCGCACGGGGACCACCTGGCGCG
HUFIXCOPTMT >
2710      2720      2730      2740      2750
CACCTGCCTGCGCAGCACCAAGTTCACCATCTACAACAACATGTTCTGCG
GTGGACGGACGCGTCGTGGTTCAAGTGGTAGATGTTGTTGTACAAGACGC
HUFIXCOPTMT >
2760      2770      2780      2790      2800
CCGGCTTCCACGAGGGCGGCCGCGACAGCTGCCAGGGCGACAGCGCGGC
GGCCGAAGGTGCTCCCGCCGGCGCTGTCGACGGTCCCGCTGTCGCCGCGC
HUFIXCOPTMT >
2810      2820      2830      2840      2850
CCCCACGTGACCGAGGTGGAGGGCACCAGCTTCCTGACCGGCATCATCAG
GGGGTGCACTGGCTCCACCTCCCGTGGTTCGAAGGACTGGCCGTAGTAGTC
HUFIXCOPTMT >
2860      2870      2880      2890      2900
CTGGGGCGAGGAGTGCGCCATGAAGGGCAAGTACGGCATCTACACCAAGG
GACCCCGCTCCTCACGCGGTACTTCCCGTTCATGCCGTAGATGTGGTTCC

```

```

____HUFIXCOPTMT____>
      2910      2920      2930      2940      2950
TGAGCCGCTACGTGAACTGGATCAAGGAGAAGACCAAGCTGACCTGGAGA
ACTCGGCGATGCACTTGACCTAGTTCCCTCTTCTGGTTTCGACTGGACCTCT
____HUFIXCOPTMT____>
      2960      2970      2980      2990      3000
TCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC
AGACTAGTCGGAGCTGACACGGAAGATCAACGGTCGGTAGACAACAAACG
      _____BGHPA_____>
      3010      3020      3030      3040      3050
CCCTCCCCCGTGCCTTCCCTTGACCCTGGAAGGTGCCACTCCCCTGTCCT
GGGAGGGGGCACGGAAGGAACCTGGGACCTTCCACGGTGAGGGTGACAGGA
      _____BGHPA_____>
      3060      3070      3080      3090      3100
TTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATT
AAGGATTATTTTACTCCTTTAACGTAGCGTAACAGACTCATCCACAGTAA
      _____BGHPA_____>
      3110      3120      3130      3140      3150
CTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAA
GATAAGACCCCCACCCACCCCGTCCCTGTCTGTCGTTCCCCCTCCTAACCCCT
      _____BGHPA_____>
      3160      3170      3180      3190      3200
GACAATAGCAGGCATGCTGGGGATCTGATAGCAGGCATGCTGGGGAGAGA
CTGTTATCGTCCGTACGACCCCTAGACTATCGTCCGTACGACCCCTCTCT
      _____BGHPA_____>
      3210      3220      3230      3240      3250
TCGATCTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGC
AGCTAGATCCTTGGGGATCACTACCTCAACCGGTGAGGGAGAGACGCGCG
      _____ITR_____>
      3260      3270      3280      3290      3300
TCGCTCGCTCACTGAGGCCGCGCCCGGCAAAAGCCCGGGCGTCGGGCGACCT
AGCGAGCGAGTGACTCCGGCGGGCCCGTTTCGGGCCCCGAGCCCGCTGGA
      _____ITR_____>
      3310      3320      3330      3340      3350
TTGGTCGCCCCGGCCCTCAGTGAGCGAGCGAGCGCGAGAGAGGGAGTGGCC
AACCAGCGGGCCGGAGTCACTCGCTCGCTCGCGCGTCTCTCCCTCACC GG
      _____ITR_____>
      3360      3370      3380      3390      3400
AACCCCCCCCCCCCCCCCCCTGCATGCAGGCGATTCTCTTGTTTGCTCCA
TTGGGGGGGGGGGGGGGGGGACGTACGTCCGCTAAGAGAACAAACGAGGT
____>
      3410      3420      3430      3440      3450
GACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAG
CTGAGAGTCCGTTACTGGACTATCGGAAACATCTCTGGAGAGTTTTTATC

```

3460 3470 3480 3490 3500
 CTACCCCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATT
 GATGGGAGAGGCCGTACTTAAATAGTCGATCTTGCCAACCTATAGTATAA

3510 3520 3530 3540 3550
 GATGGTGATTTGACTGTCTCCGGCCTTTCTCACCCGTTTGAATCTTTACC
 CTACCACTAAACTGACAGAGGCCGGAAGAGTGGGCAAACCTAGAAATGG

3560 3570 3580 3590 3600
 TACACATTACTCAGGCATTGCATTTAAAAATATGAGGGTCTAAAAATT
 ATGTGTAATGAGTCCGTAACGTAAATTTTATATACTCCCAAGATTTTTAA

3610 3620 3630 3640 3650
 TTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGT
 AAATAGGAACGCAACTTTATTTCCGAAGAGGGCGTTTTCATAATGTCCCA

3660 3670 3680 3690 3700
 CATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATT
 GTATTACAAAAACCATGTTGGCTAAATCGAAATACGAGACTCCGAAATAA

3710 3720 3730 3740 3750
 GCTTAATTTTGCTAATTCTTTGCCTTGCTGTATGATTTATTGGATGTTG
 CGAATTAACGATTAAGAAACGGAACGGACATACTAAATAACCTACAAC

3760 3770 3780 3790 3800
 GAATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACA
 CTTAAGGACTACGCCATAAAAGAGGAATGCGTAGACACGCCATAAAGTGT

3810 3820 3830 3840 3850
 CCGCATATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA
 GGCGTATACCACGTGAGAGTCATGTTAGACGAGACTACGGCGTATCAATT

3860 3870 3880 3890 3900
 GCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGT
 CGGTGCGGGCTGTGGGCGGTGTGGGCGACTGCGCGGACTGCCCAACA

3910 3920 3930 3940 3950
 CTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTG
 GACGAGGGCCGTAGGCGAATGTCTGTTGACACTGGCAGAGGCCCTCGAC

3960 3970 3980 3990 4000
 CATGTGTCAGAGGTTTTCACCGTCATCACGAAACGCGCGAGACGAAAGG
 GTACACAGTCTCCAAAAGTGGCAGTAGTGGCTTTGCGCGCTCTGCTTTCC

4010 4020 4030 4040 4050
 GCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTT
 CGGAGCACTATGCGGATAAAAAATATCCAATTACAGTACTATTATTACCAA

4060 4070 4080 4090 4100
 TCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTAT
 AGAATCTGCAGTCCACCGTGAAAAGCCCCTTTACACGCGCTTGGGGATA

4110 4120 4130 4140 4150
 TTGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAAT

AACAAATAAAAAGATTTATGTAAGTTTATACATAGGCGAGTACTCTGTTA

4160 4170 4180 4190 4200
 AACCCGTGATAAATGCTTCAATAATATTGAAAAAGGAAGATATGAGTATT
 TTGGGACTATTTACGAAGTTATTATAACTTTTTCCTTCTCATACTCATAA

>

4210 4220 4230 4240 4250
 CAACATTTCCGTGTCGCCCTTATTCCTTTTTTGCGGCATTTTCCTTCC
 GTTGTAAGGACACAGCGGGAATAAGGGAAAAACGCCGTAAAACGGAAGG

AMPR

>

4260 4270 4280 4290 4300
 TGTTTTTTGCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATC
 ACAAAAACGAGTGGGTCTTTGCGACCACTTTCATTTTCTACGACTTCTAG

AMPR

>

4310 4320 4330 4340 4350
 AGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAG
 TCAACCCACGTGCTCACCCAATGTAGCTTGACCTAGAGTTGTCGCCATTC

AMPR

>

4360 4370 4380 4390 4400
 ATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTT
 TAGGAACCTCAAAAGCGGGCTTCTTGCAAAAGGTTACTACTCGTGAAA

AMPR

>

4410 4420 4430 4440 4450
 TAAAGTTCTGCTATGTGGCGGGTATTATCCCGTATTGACGCCGGGCAAG
 ATTTCAAGACGATACACCGCGCCATAATAGGGCATAACTGCGGGCCGTTT

AMPR

>

4460 4470 4480 4490 4500
 AGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAGTAC
 TCGTTGAGCCAGCGGCGTATGTGATAAGAGTCTTACTGAACCAACTCATG

AMPR

>

4510 4520 4530 4540 4550
 TCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
 AGTGGTCAGTGTCTTTTCGTAGAATGCCTACCGTACTGTCAATCTCTTAA

AMPR

>

4560 4570 4580 4590 4600
 ATGCAGTGTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTC
 TACGTCACGACGGTATTGGTACTCACTATTGTGACGCCGGTTGAATGAAG

AMPR

>

4610 4620 4630 4640 4650
 TGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
 ACTGTTGCTAGCCTCCTGGCTTCCTCGATTGGCGAAAAACGTGTTGTAC

AMPR

>

4660 4670 4680 4690 4700
 GGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGC
 CCCCTAGTACATTGAGCGGAAGTAGCAACCCCTTGGCCTCGACTTACTTCG

```

_____  

                        AMPR  

_____  

      4710      4720      4730      4740      4750  

CATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAA  

GTATGGTTTGCTGCTCGCACTGTGGTGCTACGGACATCGTTACCGTTGTT  

_____  

                        AMPR  

_____  

      4760      4770      4780      4790      4800  

CGTTGCGCAAACTATTAAGTGGCGAACTACTTACTCTAGCTTCCCGGCAA  

GCAACGCGTTTGATAATTGACCGCTTGATGAATGAGATCGAAGGGCCGTT  

_____  

                        AMPR  

_____  

      4810      4820      4830      4840      4850  

CAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCGCG  

GTTAATTATCTGACCTACCTCCGCCATTTCACGTCCTGGTGAAGACGC  

_____  

                        AMPR  

_____  

      4860      4870      4880      4890      4900  

CTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTG  

GAGCCGGGAAGGCCGACCGACCAATAACGACTATTTAGACCTCGGCCAC  

_____  

                        AMPR  

_____  

      4910      4920      4930      4940      4950  

AGCGTGGGTCTCGCGGTATCATTTGCAGCACTGGGGCCAGATGGTAAGCCC  

TCGCACCCAGAGCGCCATAGTAACGTCGTGACCCCGGTCTACCATTGCGG  

_____  

                        AMPR  

_____  

      4960      4970      4980      4990      5000  

TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA  

AGGGCATAGCATCAATAGATGTGCTGCCCCCTCAGTCCGTTGATACCTACT  

_____  

                        AMPR  

_____  

      5010      5020      5030      5040      5050  

ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAAGCATTGGT  

TGCTTTATCTGTCTAGCGACTCTATCCACGGAGTGACTAATTCGTAACCA  

_____  

                        AMPR  

_____  

      5060      5070      5080      5090      5100  

AACTGTGACACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTT  

TTGACAGTCTGGTTCAAATGAGTATATATGAAATCTAACTAAATTTTGAA  

_____  

>  

_____  

      5110      5120      5130      5140      5150  

CATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCAT  

GTAAAAATTAAATTTTCCTAGATCCACTTCTAGGAAAAACTATTAGAGTA  

_____  

      5160      5170      5180      5190      5200  

GACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCG  

CTGGTTTTAGGGAATTGCACTCAAAAGCAAGGTGACTCGCAGTCTGGGGC  

_____  

      5210      5220      5230      5240      5250  

TAGAAAAGATCAAAGSATCTTCTTGAGATCCTTTTTTCTGCGCGTAATC  

ATCTTTTCTAGTTTCCTAGAAGAACTCTAGGAAAAAAGACGCGCATTAG  

_____  

                        PBR322 ORIGIN  

_____>

```

```

      5260      5270      5280      5290      5300
TGCTGCTTGCAAACAAAAAACCCGCTACCAGCGGTGGTTGTTTGCC
ACGACGAACGTTTGTGTTTTTGGTGGCGATGGTCGCCACCAACAAACGG
_____PBR322 ORIGIN_____>

      5310      5320      5330      5340      5350
GGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAG
CCTAGTTCTCGATGGTTGAGAAAAAGGCTTCCATTGACCGAAGTCGTCTC
_____PBR322 ORIGIN_____>

      5360      5370      5380      5390      5400
CGCAGATACCAAATACGTCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
GCGTCTATGGTTTATGACAGGAAGATCACATCGGCATCAATCCGGTGGTG
_____PBR322 ORIGIN_____>

      5410      5420      5430      5440      5450
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTT
AAGTTCTTGAGACATCGTGGCGGATGTATGGAGCGAGACGATTAGGACAA
_____PBR322 ORIGIN_____>

      5460      5470      5480      5490      5500
ACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACT
TGGTCACCGACGACGGTCACCGCTATTCAGCACAGAATGGCCCAACCTGA
_____PBR322 ORIGIN_____>

      5510      5520      5530      5540      5550
CAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGT
GTTCTGCTATCAATGGCCTATTCCGCGTCGCCAGCCGACTGCCCCCCA
_____PBR322 ORIGIN_____>

      5560      5570      5580      5590      5600
TCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATA
AGCACGTGTGTCGGGTGGAACCTCGCTTGCTGGATGTGGCTTGACTCTAT
_____PBR322 ORIGIN_____>

      5610      5620      5630      5640      5650
CCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
GGATGTCGCACTCGATACTCTTTCGCGGTGCGAAGGGCTTCCCTCTTCC
_____PBR322 ORIGIN_____>

      5660      5670      5680      5690      5700
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGG
GCCTGTCCATAGGCCATTGCGCGTCCCAGCCTTGTCCTCTCGCGTGCTCC
_____PBR322 ORIGIN_____>

      5710      5720      5730      5740      5750
GAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTGCGGTTTCG
CTCGAAGGTCCCCCTTTCGCGACCATAGAAATATCAGGACAGCCCAAAGC
_____PBR322 ORIGIN_____>

      5760      5770      5780      5790      5800
CCACCTCTGACTTGAGCGTCGATTTTGTGATGCTCGTCAGGGGGGCGGA
GGTGGAGACTGAACTCGCAGCTAAAAACACTACGAGCAGTCCCCCGCCT
_____PBR322 ORIGIN_____>

```

5810 5820 5830 5840 5850
GCCTATGGAAAAACGCCAGCAACGCGGCCTTTTACGGTTCCTGGCCTTT
CGGATACCTTTTTCGGTTCGTTGCGCCGGAAAAATGCCAAGGACCGGAAA
_____PBR322 ORIGIN_____>

5860 5870 5880 5890 5900
TGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGT
ACGACCGGAAAACGAGTGTACAAGAAAGACGCAATAGGGGACTAAGACA

5910 5920 5930 5940 5950
GGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCC
CCTATTGGCATAATGGCGGAACTCACTCGACTATGGCGAGCGGCGTCGG

5960 5970 5980 5990 6000
GAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCA
CTTGCTGGCTCGCGTCGCTCAGTCACTCGCTCCTTCGCC'TTCTCGCGGGT

6010 6020 6030 6040
ATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTTCATTAATG
TATGCGTTTGGCGGAGAGGGGCGCGCAACCGGCTAAGTAATTAC

Figure 1C: SEQ ID 2

```

      10      20      30      40      50
CAGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAAC
GTCGTCGACCGCATTATCGCTTCTCCGGGCGTGGCTAGCGGGAAGGGTTG

      60      70      80      90     100
AGTTGCCGAGCCTGAATGGCGAATGGAATCCAGACGATTGAGCGTCAAA
TCAACGCGTCGGACTTACCGCTTACCTTAAGGTCTGCTAACTCGCAGTTT

     110     120     130     140     150
ATGTAGGTATTTCCATGAGCGTTTTTCCTGTTGCAATGGCTGGCGGTAAT
TACATCCATAAAGTTACTCGCAAAAAGGACAACGTTACCGACCGCCATTA

     160     170     180     190     200
ATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTCTTCTACTCA
TAACAAGACCTATAATGGTCGTTCCGGCTATCAAACCAAGAAGATGAGT

     210     220     230     240     250
GGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAATT
CCGTTCACTACAATAATGATTAGTTTCTTCATAACGCTGTTGCCAATTAA

     260     270     280     290     300
TGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAAC
ACGCACTACCTGTCTGAGAAATGAGCCACCGGAGTGACTAATATTTTTG

     310     320     330     340     350
ACTTCTCAGGATTCTGGCGTACCGTTCCGTCTAAAATCCCTTTAATCGG
TGAAGAGTCCTAAGACCGCATGGCAAGGACAGATTTTAGGGAAATTAGCC

     360     370     380     390     400
CCTCCTGTTTtagctcccgctctgattctaacgaggaaagcacgttatacg
ggaggacaaatcgaggcgagactaagattgctcctttcgtgcaatatgc

     410     420     430     440     450
TGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGC
ACGAGCAGTTTTCGTTGGTATCATGCGCGGGACATCGCCGCGTAATTCGCG
_____>

     460     470     480     490     500
GGCGGGTGTTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCC
CCGCCCACACCACCAATGCGCGTCGCAC TGCGGATGTGAACGGTTCGCGGG
_____F1 ORIGIN_____>

     510     520     530     540     550
TAGCGCCCGCTCCTTTCGCTTCTTCCCTTCCTTTCTCGCCACGTTTCGCC
ATCGCGGGCGGAGGAAAGCGAAAGAAGGGAAGGAAAGAGCGGTGCAAGCGG
_____F1 ORIGIN_____>

     560     570     580     590     600
GGCTTTCGCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT
CCGAAAGGGGCAGTTCGAGATTTAGCCCCCGAGGGAAATCCCAAGGCTAA
_____F1 ORIGIN_____>

```

610 620 630 640 650
 TAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGATGGTT
 ATCACGAAATGCCGTGGAGCTGGGGTTTTTTGAACTAATCCCACTACCAA
 _____ F1 ORIGIN _____>

660 670 680 690 700
 CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTG
 GTGCATCACCCGGTAGCGGGACTATCTGCCAAAAAGCGGGAACTGCAAC
 _____ F1 ORIGIN _____>

710 720 730 740 750
 GAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACT
 CTCAGGTGCAAGAAATTATCACCTGAGACAAGGTTTGACCTTGTTGTGA
 _____ F1 ORIGIN _____>

760 770 780 790 800
 CAACCCATCTCGGTCATTCTTTTGATTTATAAGGGATTTGCCGATTT
 GTTGGGATAGAGCCAGATAAGAAACTAAATATTCCTTAAACGGCTAAA

810 820 830 840 850
 CGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
 GCCGGATAACCAATTTTCTACTCGACTAAATTGTTTTTAAATTGCGCTTA

860 870 880 890 900
 TTTAACAAAATATTACGTTTACAATTTAAATATTTGCTTATACAATCTT
 AAATTGTTTTATAATTGCAAATGTAAATTTATAAACGAATATGTTAGAA

910 920 930 940 950
 CCTGTTTTTGGGGCTTTCTCATTTATCAACCGGGGTACATATGATTGACA
 GGACAAAAACCCCGAAAAGACTAATAGTTGGCCCCATGTATACTAACTGT

960 970 980 990 1000
 TGCTAGTTTTACGATTACCGTTCATCGCCTGCACTGCGCGCTCGCTCGCT
 ACGATCAAAATGCTAATGGCAAGTAGCGGACGTGACGCGGAGCGAGCGA
 _____ MUTATEDITR _____>

1010 1020 1030 1040 1050
 CACTGAGGCGCGCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCC
 GTGACTCCGCGGGGCCGTTTTCGGGCCCGCAGCCCGCTGGAACACGCGG
 _____ MUTATEDITR _____>

1060 1070 1080 1090 1100
 CGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGAAATTCACGCGT
 GCCGGAGTCACTCGCTCGCTCGCGCGTCTCTCCCTCACCTTAAGTGCGCA
 _____ MUTATEDITR _____>

1110 1120 1130 1140 1150
 GGTACGATCTGAATTCGGTACAATTCACGCGTGGTACGGCCGCGGTACCG
 CCATGCTAGACTTAAGCCATGTTAAGTGCGCACCATGCCGCGCCATGGC

1160 1170 1180 1190 1200
 GCGCGCCGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCAGTTA
 CGCGCGGCCCCCTCCGACGACCACTTATAATTGGTTCCAGTGGGGTCAAT

>Serp_enh >mTTR/promoter

```

      1210      1220      1230      1240      1250
TCGGAGGAGCAAACAGGGGCTAAGTCCACACGCGTGGTACCGTCTGTCTG
AGCCTCCTCGTTTGTCCCCGATTGAGGTGTGCGCACCATGGCAGACAGAC

```

```

      1260      1270      1280      1290      1300
CACATTTCTAGAGCGAGTGTTCGATACTCTAATCTCCCTAGGCAAGGT
GTGTAAAGCATCTCGCTCACAAGGCTATGAGATTAGAGGGATCCGTTCCA

```

```

      1310      1320      1330      1340      1350
TCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATAAT
AGTATAAACACATCCAATGAATAAGAGGAAAACAACCTGATTGAGTTATTA

```

```

      1360      1370      1380      1390      1400
CAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTT
GTCTTAGTCGTCCAAACCTCAGTCGAACCGTCCCTAGTCGTCGGACCCAA

```

>mTTR/5'/ut

```

      1410      1420      1430      1440      1450
GGAAGGAGGGGTATAAAAGCCCCCTTACCAGGAGAAGCCGTCACACAGA
CCTTCCTCCCCCATATTTTCGGGGAAGTGGTCCTCTTCGGCAGTGTGTCT

```

>MVMint

```

      1460      1470      1480      1490      1500
TCCACAAGCTCCTGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGG
AGGTGTTTCGAGGACTTCTCCATTCCCAAATTCCCTACCAACCAACCACCC

```

```

      1510      1520      1530      1540      1550
GTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTTTCA
CATAATTACAAATTAATGGACCTCGTGGACGACTTTAGTGAAAAAAGT

```

```

      1560      1570      1580      1590      1600
GGTTGGCTAGCATGCAGCGCGTGAACATGATCATGGCCGAGAGCCCCGGC
CCAACCGATCGTACGTCGCGCACTTGTACTAGTACCGGCTCTCGGGGCCG

```

_____HUFIXCOPTMT_____>

```

      1610      1620      1630      1640      1650
CTGATCACCATCTGCCTGCTGGGCTACCTGCTGAGCGCCGACTGCACCGT
GACTAGTGGTAGACGGACGACCCGATGGACGACTCGCGGCTCACGTGGCA

```

_____HUFIXCOPTMT_____>

```

      1660      1670      1680      1690      1700
GTTCTTGGAACACGAGAACGCCAACAAGATCCTGAACCGCCCCAAGCGCT
CAAGGACCTGGTGTCTTTCGGTTGTTCTAGGACTTGGCGGGGTTTCGCGA

```

_____HUFIXCOPTMT_____>

```

      1710      1720      1730      1740      1750
ACAACAGCGGCAAGCTGGAGGAGTTCGTGCAGGGCAACCTGGAGCGCGAG
TGTTGTGCGCGTTTCGACCTCCTCAAGCACGTCCCGTTGGACCTCGCGCTC

```

_____HUFIXCOPTMT_____>

```

      1760      1770      1780      1790      1800
TGCATGGAGGAGAAGTGCAGCTTCGAGGAGGCCCGCGAGGTGTTTCGAGAA

```

```

ACGTACCTCCTCTTCACGTCGAAGCTCCTCCGGGCGCTCCACAAGCTCTT
_____HUFIXCOPTMT_____>

      1810      1820      1830      1840      1850
CACCGAGCGCACCAACCGAGTTTCTGGAAGCAGTACGTGGACGGCGACCAAGT
GTGGCTCGCGTGGTGGCTCAAGACCTTCGTTCATGCACCTGCCGCTGGTCA
_____HUFIXCOPTMT_____>

      1860      1870      1880      1890      1900
GCGAGAGCAACCCCTGCCTGAACGGCGGCAGCTGCAAGGACGACATCAAC
CGCTCTCGTTGGGGACGGAAGTTGCCGCGCTCGACGTTCTCTGCTGTAGTTG
_____HUFIXCOPTMT_____>

      1910      1920      1930      1940      1950
AGCTACGAGTGCTGGTGGCCCTTCGGCTTCGAGGGCAAGAACTGCGAGCT
TCGATGCTCACGACCACGGGGAAGCCGAAGCTCCCGTTCTTGACGCTCGA
_____HUFIXCOPTMT_____>

      1960      1970      1980      1990      2000
GGACGTGACCTGCAACATCAAGAACGGCCGCTGCGAGCAGTTCTGCAAGA
CCTGCACCTGGACGTTGTAGTTCTTGCCGGCGACGCTCGTCAAGACGTTCT
_____HUFIXCOPTMT_____>

      2010      2020      2030      2040      2050
ACAGCGCCGACAACAAGGTGGTGTGCAGCTGCACCGAGGGCTACCGCCTG
TGTGCGGGCTGTTGTTCCACCACACGTCGACGTGGCTCCCGATGGCGGAC
_____HUFIXCOPTMT_____>

      2060      2070      2080      2090      2100
GCCGAGAACCAGAAGAGCTGCGAGCCCGCCGTGCCCTTCCCTGCGGCCG
CGGCTCTTGGTCTTCTCGACGCTCGGGCGGCACGGGAAGGGACGCCGGC
_____HUFIXCOPTMT_____>

      2110      2120      2130      2140      2150
CGTGAGCGTGAGCCAGACCAGCAAGCTGACCCGCGCCGAGGCCGTGTTC
GCACTCGCACTCGGTCTGGTCTGCTGACTGGGCGCGGCTCCGGCACAAGG
_____HUFIXCOPTMT_____>

      2160      2170      2180      2190      2200
CCGACGTGGACTACGTGAACAGCACCGAGGCCGAGACCATCCTGGACAAC
GGCTGCACCTGATGCACTTGTCTGCTGGCTCCGGCTCTGGTAGGACCTGTTG
_____HUFIXCOPTMT_____>

      2210      2220      2230      2240      2250
ATCACCCAGAGCACCCAGAGCTTCAACGACTTCACCCGCGTGGTGGGCGG
TAGTGGGTCTCGTGGGTCTCGAAGTTGCTGAAGTGGGCGCACCAACCGCC
_____HUFIXCOPTMT_____>

      2260      2270      2280      2290      2300
CGAGGACGCCAAGCCCGGCCAGTTCCCTGGCAGGTGGTGTGAACGGCA
GCTCCTGCGGTTCCGGCCGGTCAAGGGGACCGTCCACCACGACTTGCCGT
_____HUFIXCOPTMT_____>

      2310      2320      2330      2340      2350
AGGTGGACGCCTTCTGCGGCGGCAGCATCGTGAACGAGAAGTGGATCGTG

```

```

TCCACCTGCGGAAGACGCCGCCGTCGTAGCACTTGCTCTTCACCTAGCAC
_____HUFIXCOPTMT_____>

      2360      2370      2380      2390      2400
ACCGCCGCCCACTGCGTGGAGACCGGCGTGAAGATCACCGTGGTGGCCGG
TGGCGGCGGGTGACGCACCTCTGGCCGCACTTCTAGTGGCACCACCGGCC
_____HUFIXCOPTMT_____>

      2410      2420      2430      2440      2450
CGAGCACAAACATCGAGGAGACCGAGCACACCGAGCAGAAGCGCAACGTGA
GCTCGTGTGTAGCTCCTCTGGCTCGTGTGGCTCGTCTTCGCGTTGCACT
_____HUFIXCOPTMT_____>

      2460      2470      2480      2490      2500
TCCGCATCATCCCCACCACAACACTACAACGCCGCCATCAACAAGTACAAC
AGGCGTAGTAGGGGGTGGTGTGTATGTTGCGGCGGTAGTTGTTTCATGTTG
_____HUFIXCOPTMT_____>

      2510      2520      2530      2540      2550
CACGACATCGCCCTGCTGGAGCTGGACGAGCCCTGGTGTGAACAGCTA
GTGCTGTAGCGGGACGACCTCGACCTGCTCGGGGACCACGACTTGTTCGAT
_____HUFIXCOPTMT_____>

      2560      2570      2580      2590      2600
CGTGACCCCATCTGCATCGCCGACAAGGAGTACACCAACATCTTCCTGA
GCACTGGGGGTAGACGTAGCGGCTGTTCTCATGTGGTTGTAGAAGGACT
_____HUFIXCOPTMT_____>

      2610      2620      2630      2640      2650
AGTTTCGGCAGCGGCTACGTGAGCGGCTGGGGCCGCGTGTCCACAAGGGC
TCAAGCCGTGCGCGATGCACTCGCCGACCCCGCGCACAAAGGTGTTCCCG
_____HUFIXCOPTMT_____>

      2660      2670      2680      2690      2700
CGCAGCGCCCTGGTGTGTCAGTACCTGCGCGTGCCCTGGTGGACCGCGC
GCGTCGCGGGACCACGACGTTCATGGACGCGCACGCGGACCACCTGGCGCG
_____HUFIXCOPTMT_____>

      2710      2720      2730      2740      2750
CACCTGCCTGCTGAGCACCAAGTTCACCATCTACAACAACATGTTCTGCG
GTGGACGGACGAGTCGTGGTTCAAGTGGTAGATGTTGTTGTACAAGACGC
_____HUFIXCOPTMT_____>

      2760      2770      2780      2790      2800
CCGGCTTCCACGAGGGCGGCCGCGACAGCTGCCAGGGCGACAGCGCGCGC
GGCCGAAGGTGCTCCCGCCGGCGCTGTCGACGGTCCCGCTGTCGCCGCCG
_____HUFIXCOPTMT_____>

      2810      2820      2830      2840      2850
CCCCACGTGACCGAGGTGGAGGGCACCAGCTTCCTGACCGGCATCATCAG
GGGGTGCCTGGCTCCACCTCCCGTGGTTCGAAGGACTGGCCGTAGTAGTC
_____HUFIXCOPTMT_____>

      2860      2870      2880      2890      2900
CTGGGGCGAGGAGTGCGCCATGAAGGGCAAGTACGGCATCTACACCAAGG

```

GACCCCGCTCCTCACGCGGTACTTCCCGTTCATGCCGTAGATGTGGTTCC
 _____HUFIXCOPTMT_____>

2910 2920 2930 2940 2950
 TGAGCCGCTACGTGAAGTGGATCAAGGAGAAGACCAAGCTGACCTGGAGA
 ACTCGGCGATGCACTTGACCTAGTTCTCTTCTGGTTGCACTGGACCTCT
 _____HUFIXCOPTMT_____>

2960 2970 2980 2990 3000
 TCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC
 AGACTAGTCGGAGCTGACACGGAAGATCAACGGTCGGTAGACAACAAACG
 _____BGHPA_____>

3010 3020 3030 3040 3050
 CCGTCCCCCGTGCCTTCCCTTGACCTGGAAGGTGCCACTCCCACTGTCCT
 GGGAGGGGGCACGGAAGGAACCTGGGACCTTCCACGGTGAGGGTGACAGGA
 _____BGHPA_____>

3060 3070 3080 3090 3100
 TTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATT
 AAGGATTATTTTACTCCTTTAACGTAGCGTAACAGACTCATCCACAGTAA
 _____BGHPA_____>

3110 3120 3130 3140 3150
 CTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAA
 GATAAGACCCCCACCCACCCCGTCTGTCTGTTCCCCCTCCTAACCCCTT
 _____BGHPA_____>

3160 3170 3180 3190 3200
 GACAATAGCAGGCATGCTGGGGATCTGATAGCAGGCATGCTGGGGAGAGA
 CTGTTATCGTCCGTACGACCCCTAGACTATCGTCCGTACGACCCCTCTCT
 _____BGHPA_____>

3210 3220 3230 3240 3250
 TCGATCTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGC
 AGCTAGATCCTTGGGGATCACTACCTCAACCGGTGAGGGAGAGACGCGCG
 _____ITR_____>

3260 3270 3280 3290 3300
 TCGCTCGCTCACTGAGGCCGCGCGGCAAAGCCCGGGCGTCGGGCGACCT
 AGCGAGCGAGTGACTCCGGCGGGGCGCGTTTCGGGCGCGCAGCCCGCTGGA
 _____ITR_____>

3310 3320 3330 3340 3350
 TTGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCAGAGAGGGAGTGGCC
 AACCAGCGGGCCGGAGTCACTCGCTCGCTCGCGCGTCTCTCCCTCACC GG
 _____ITR_____>

3360 3370 3380 3390 3400
 AACCCCCCCCCCCCCCTGCATGCAGGCGATTCTCTTGTGTTGCTCCA
 TTGGGGGGGGGGGGGGGGGACGTACGTCCGCTAAGAGAACAAACGAGGT
 _____>

3410 3420 3430 3440 3450
 GACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAG

CTGAGAGTCCGTTACTGGACTATCGGAAACATCTCTGGAGAGTTTTTATC

3460 3470 3480 3490 3500
CTACCCCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATT
GATGGGAGAGGCCGTACTTAAATAGTCGATCTTGCCAACCTATAGTATAA

3510 3520 3530 3540 3550
GATGGTGATTTGACTGTCTCCGGCCTTTCTCACCCGTTTGAATCTTTACC
CTACCACTAAACTGACAGAGGCCGGAAAGAGTGGGCAAACTTAGAAATGG

3560 3570 3580 3590 3600
TACACATTACTCAGGCATTGCATTTAAATATATGAGGGTTCTAAAAATT
ATGTGTAATGAGTCCGTAACGTAAATTTTATATACTCCCAAGATTTTAA

3610 3620 3630 3640 3650
TTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAGTATTACAGGGT
AAATAGGAACGCAACTTTATTTCCGAAGAGGGCGTTTTTCATAATGTCCCA

3660 3670 3680 3690 3700
CATAATGTTTTTGGTACAACCGATTAGCTTTATGCTCTGAGGCTTTATT
GTATTACAAAAACCATGTTGGCTAAATCGAAATACGAGACTCCGAAATAA

3710 3720 3730 3740 3750
GCTTAATTTTGCTAATCTTTGCCTTGCTGTATGATTTATTGGATGTTG
CGAATTAACGATTAAAGAAACGGAACGGACATACTAAATAACCTACAAC

3760 3770 3780 3790 3800
GAATTCCGTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACA
CTTAAGGACTACGCCATAAAAGAGGAATGCGTAGACACGCCATAAAGTGT

3810 3820 3830 3840 3850
CCGCATATGCTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA
GGCGTATACCACGTGAGAGTCATGTAGACGAGACTACGGCGTATCAATT

3860 3870 3880 3890 3900
GCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGT
CGGTGCGGGCTGTGGGCGGTTGTGGGCGACTGCGCGGACTGCCGAACA

3910 3920 3930 3940 3950
CTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTG
GACGAGGGCCGTAGGCGAATGTCTGTTGACACTGGCAGAGGCCCTCGAC

3960 3970 3980 3990 4000
CATGTGTCAGAGGTTTTTCACCGTCATCACGAAACGCGCGAGACGAAAGG
GTACACAGTCTCCAAAAGTGGCAGTAGTGGCTTTGCGCGCTCTGCTTTCC

4010 4020 4030 4040 4050
GCCTCGTGATACGCCATTTTTTATAGGTTAATGTCATGATAATAATGGTT
CGGAGCACTATGCGGATAAAAATATCCAATTACAGTACTATTATTACCAA

4060 4070 4080 4090 4100
TCTTAGACGTCAGGTGGCACTTTTTCGGGGAAATGTGCGCGGAACCCCTAT
AGAATCTGCAGTCCACCGTGAAAAGCCCCCTTTACACGCGCCTTGGGGATA

4110 4120 4130 4140 4150

TTGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAAT
AACAAATAAAAAGATTATGTAAGTTATACATAGGCGAGTACTCTGTTA

4160 4170 4180 4190 4200
AACCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATT
TTGGGACTATTTACGAAGTTATTATAACTTTTCCTTCTCATACTCATAA

>

4210 4220 4230 4240 4250
CAACATTTCCGTGTGCGCCCTTATTCCCTTTTTTGCGGCATTTGCGCTTC
GTTGTAAAGGCACAGCGGAATAAGGGAAAAACGCCGTAAACGGAAGG

AMPR

>

4260 4270 4280 4290 4300
TGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATC
ACAAAAACGAGTGCGTCTTTGCGACCACTTTCATTTTCTACGACTTCTAG

AMPR

>

4310 4320 4330 4340 4350
AGTTGGGTGACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAG
TCAACCCACGTGCTCACCCAATGTAGCTTGACCTAGAGTTGTCGCCATTC

AMPR

>

4360 4370 4380 4390 4400
ATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTCCAATGATGAGCACTTT
TAGGAACCTCATAAAGCGGGGCTTCTTGCAAAAGTTACTACTCGTGAAA

AMPR

>

4410 4420 4430 4440 4450
TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAG
ATTTCAAGACGATACACCGCGCCATAATAGGGCATAACTGCGGCCCGTTC

AMPR

>

4460 4470 4480 4490 4500
AGCAACTCGGTGCGCGCATACACTATTCTCAGAACTGACTTGGTTGAGTAC
TCGTTGAGCCAGCGGCGTATGTGATAAGAGTCTTACTGAACCAACTCATG

AMPR

>

4510 4520 4530 4540 4550
TCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
AGTGGTCAGTGTCTTTTCGTAGAATGCCTACCGTACTGTCATTCTCTTAA

AMPR

>

4560 4570 4580 4590 4600
ATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTC
TACGTCACGACGGTATTGGTACTCACTATTGTGACGCCGGTGAATGAAG

AMPR

>

4610 4620 4630 4640 4650
TGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCAACAACATG
ACTGTTGCTAGCCTCCTGGCTTCCTCGATTGGCGAAAAACGTGTTGTAC

AMPR

>

4660 4670 4680 4690 4700
GGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGC

```

CCCCTAGTACATTGAGCGGAAC TAGCAACCCTTGGCCTCGACTTACTTCG
      _____
      AMPR
      _____>

      4710      4720      4730      4740      4750
CATAACAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAA
GTATGGTTTGCTGCTCGCACTGTGGTGCTACGGACATCGTTACCGTTGTT
      _____
      AMPR
      _____>

      4760      4770      4780      4790      4800
CGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAA
GCAACGCGTTTGATAATTGACCGCTTGATGAATGAGATCGAAGGGCCGTT
      _____
      AMPR
      _____>

      4810      4820      4830      4840      4850
CAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCG
GTTAATTATCTGACCTACCTCCGCCCTATTTCAACGTCCTGGTGAAGACGC
      _____
      AMPR
      _____>

      4860      4870      4880      4890      4900
CTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTG
GAGCCGGGAAGGCCGACCGACCAAATAACGACTATTTAGACCTCGGCCAC
      _____
      AMPR
      _____>

      4910      4920      4930      4940      4950
AGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC
TCGCACCCAGAGCGCCATAGTAACGTCGTGACCCCGTCTACCATTCGGG
      _____
      AMPR
      _____>

      4960      4970      4980      4990      5000
TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
AGGGCATAGCATCAATAGATGTGCTGCCCTCAGTCCGTTGATACCTACT
      _____
      AMPR
      _____>

      5010      5020      5030      5040      5050
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGT
TGCTTTTATCTGTCTAGCGACTCTATCCACGGAGTGACTAATTCGTAACCA
      _____
      AMPR
      _____>

      5060      5070      5080      5090      5100
AACTGTCTAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTT
TTGACAGTCTGGTTCAAATGAGTATATATGAAATCTAACTAAATTTTGAA
      _____>

      5110      5120      5130      5140      5150
CATTTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCAT
GTAAAAATTAAATTTTCTAGATCCACTTCTAGGAAAACTATTAGAGTA

      5160      5170      5180      5190      5200
GACCAAAATCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCG
CTGGTTTTAGGGAATTGCACTCAAAGCAAGGTGACTCGCAGTCTGGGGC

      5210      5220      5230      5240      5250
TAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATC
ATCTTTTCTAGTTTCTCTAGAAGAACTCTAGCAAAAAAGACGCGCATTAG
      _____
      PBR322 ORIGIN
      _____>

```

```

      5260      5270      5280      5290      5300
TGCTGCTTGCAAAACAAAAAACCCGCTACCAGCGGTGGTTTGTGTTGCC
ACGACGAACGTTTGTGTTTTTGGTGGCGATGGTCGCCACCAACAAACGG
_____PBR322 ORIGIN_____>

      5310      5320      5330      5340      5350
GGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAG
CCTAGTTCTCGATGGTTGAGAAAAAGGCTTCCATTGACCGAAGTCGTCTC
_____PBR322 ORIGIN_____>

      5360      5370      5380      5390      5400
CGCAGATACCAAATACTGTCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
GCGTCTATGGTTTATGACAGGAAGATCACATCGGCATCAATCCGGTGGTG
_____PBR322 ORIGIN_____>

      5410      5420      5430      5440      5450
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTT
AAGTTCTTGAGACATCGTGGCGGATGTATGGAGCGAGACGATTAGGACAA
_____PBR322 ORIGIN_____>

      5460      5470      5480      5490      5500
ACCAAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACT
TGGTCACCGACGACGGTCACCGCTATTCAGCACAGAATGGCCCAACCTGA
_____PBR322 ORIGIN_____>

      5510      5520      5530      5540      5550
CAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGT
GTTCTGCTATCAATGGCCTATTCCGCGTCGCCAGCCGACTGCCCCCCA
_____PBR322 ORIGIN_____>

      5560      5570      5580      5590      5600
TCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATA
AGCACGTGTGTCGGGTCGAACCTCGCTTGCTGGATGTGGCTTGACTCTAT
_____PBR322 ORIGIN_____>

      5610      5620      5630      5640      5650
CCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
GGATGTGCGCACTCGATACTCTTTCGCGGTGCGAAGGGCTTCCCTCTTCC
_____PBR322 ORIGIN_____>

      5660      5670      5680      5690      5700
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGG
GCCTGTCCATAGGCCATTGCGCGTCCCAGCCTTGTCCTCTCGCGTGCTCC
_____PBR322 ORIGIN_____>

      5710      5720      5730      5740      5750
GAGCTTCCAGGGGGAAACGCCCTGGTATCTTTATAGTCCTGTGCGGTTTCG
CTCGAAGGTCCCCCTTTGCGGACCATAGAAATATCAGGACAGCCCAAAGC
_____PBR322 ORIGIN_____>

      5760      5770      5780      5790      5800
CCACCTCTGACTTGAGCGTCGATTTTGTGATGCTCGTCAGGGGGGCGGA
GGTGGAGACTGAACTCGCAGCTAAAAACACTACGAGCAGTCCCCCGCCT
_____PBR322 ORIGIN_____>

```

```
      5810      5820      5830      5840      5850
GCCTATGGAAAAACGCCAGCAACGCGGCCTTTTACGGTTCCTGGCCTTT
CGGATACCTTTTTCGGGTCGTTGCGCCGGAAAAATGCCAAGGACCGGAAA
_____PBR322 ORIGIN_____>

      5860      5870      5880      5890      5900
TGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCTGATTCTGT
ACGACCGGAAAAACGAGTGTACAAGAAAGACGCAATAGGGGACTAAGACA

      5910      5920      5930      5940      5950
GGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCC
CCTATTGGCATAATGGCGGAAACTCACTCGACTATGGCGAGCGGCGTCGG

      5960      5970      5980      5990      6000
GAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCA
CTTGCTGGCTCGCGTCGCTCAGTCACTCGCTCCTTCGCCTTCTCGCGGGT

      6010      6020      6030      6040
ATACGCAAACCGCCTCTCCCGCGCGTTGGCCGATTCATTAATG
TATGCGTTTGGCGGAGAGGGGCGCGCAACCGGCTAAGTAATTAC
```

Fig. 2






Fig. 3

A



B



C





Fig. 4

A



B





Fig. 4

C



D





Fig. 4

E



F





Fig. 4

G



H




Fig. 4





Fig.4

J



K





Fig.5

A



B





Fig. 5

C



D





Fig. 6

A



B




Fig. 6

C

SEQ ID NO: 6

CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCGGGCAAAGCCCCG
 GGCCTCGGGCGACCTTTGGTCGCCCGGCCCTCAGTGAGCGAGCGAGCGCGCAGA
 GAGGGAGTGGCCAACTCCATCACTAGGGGTTCTGCGGCCGCGGTACCGGCGC
 GCCGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCCAGTTATCG
 GAGGAGCAAACAGGGGCTAAGTCCACACGCGTGGTACCGTCTGTCTGCAC
 ATTTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTTCATAT
 TTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATAATCAGAATCAG
 CAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGG
 GTATAAAAGCCCCCTTCACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCT
 GAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGNATTAATGTTTAATTACC
 TGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGGCTAGTATGCAGATCGAG
 CTGTCCACCTGCTTTTTTCTGTGCTGCTGCGGTTCTGCTTCAGCGCCAC
 CCGGCGGTACTACCTGGGCGCCGTGGAGCTGTCCTGGGACTACATGCAG
 AGCGACCTGGGCGAGCTGCCCGTGGACGCCCGGTTCCCCCCCAGAGTG
 CCCAAGAGCTTCCCCCTTCAACACCAGCGTGGTGTACAAGAAAACCTGT
 TCGTGGAGTTACCCGACCACCTGTTCAATATCGCCAAGCCCAGGCCCCC
 CTGGATGGGCCTGCTGGGCCCCACCATCCAGGCCGAGGTGTACGACACC
 GTGGTGATCACCTGAAGAACATGGCCAGCCACCCCGTGAGCCTGCACG
 CCGTGGGCGTGAGCTACTGGAAGGCCAGCGAGGGCGCCGAGTACGACG
 ACCAGACCAGCCAGCGGGAGAAAGAAGATGACAAGGTGTTCCCTGGCG
 GCAGCCACACCTACGTGTGGCAGGTGCTGAAAGAAAACGGCCCCATGGC
 CTCCGACCCCCCTGTGCCTGACCTACAGCTACCTGAGCCACGTGGACCTG
 GTGAAGGACCTGAACAGCGGCCTGATCGGCGCTCTGCTCGTCTGCCGGG
 AGGGCAGCCTGGCCAAAAGAGAAAACCCAGACCCTGCACAAGTTCATCCT
 GCTGTTCCCGTGTTTCGACGAGGGCAAGAGCTGGCACAGCGAGACAAA
 GAACAGCCTGATGCAGGACCGGGACGCCGCTCTGCCAGAGCCTGGCC
 CAAGATGCACACCGTGAACGGCTACGTGAACAGAAGCCTGCCCGGCCCTG
 ATTGGCTGCCACCGGAAGAGCGTGTACTGGCACGTGATCGGCATGGGCA
 CCACACCCGAGGTGCACAGCATCTTTCTGGAAGGGCACACCTTTCTGGT
 CCGGAACCACCGGCAGGCCAGCCTGGAAATCAGCCCTATCACCTTCCTG
 ACCGCCCAGACACTGCTGATGGACCTGGGCCAGTTCCTGCTGTTTTGCC
 ACATCAGCTCTCACCAGCACGACGGCATGGAAGCCTACGTGAAGGTGGA
 CTCTTGCCCCGAGGAACCCAGCTGCGGATGAAGAACAACGAGGAAGCC
 GAGGACTACGACGACGACCTGACCGACAGCGAGATGGACGTGGTGCGG
 TTCGACGACGACAACAGCCCCAGCTTCATCCAGATCAGAAGCGTGGCCA
 AGAAGCACCCCAAGACCTGGGTGCACTATATCGCCGCCGAGGAAGAGGA
 CTGGGACTACGCCCCCCTGGTGCTGGCCCCCGACGACAGAAGCTACAAG
 AGCCAGTACCTGAACAATGGCCCCCAGCGGATCGGCCGGAAGTACAAGA
 AAGTGCGGTTTCATGGCCTACACCGACGAGACATTCAAGACCCGGGAGGC
 CATCCAGCACGAGAGCGGCATCCTGGGCCCCCTGCTGTACGGCGAAGTG
 GCGGACACACTGCTGATCATCTTCAAGAACCAGGCTAGCCGGCCCTACA

ACATCTACCCCCACGGCATCACCGACGTGCGGCCCCCTGTACAGCAGGCG
GCTGCCCCAAGGGCGTGAAGCACCTGAAGGACTTCCCCATCCTGCCCCGGC
GAGATCTTCAAGTACAAGTGGACCGTGACCGTGGAGGACGGCCCCACCA
AGAGCGACCCCAGATGCCTGACCCGGTACTACAGCAGCTTCGTGAACAT
GGAACGGGACCTGGCCTCCGGGCTGATCGGACCTCTGCTGATCTGCTAC
AAAGAAAGCGTGGACCAGCGGGGCAACCAGATCATGAGCGACAAGCGG
AACGTGATCCTGTTGAGCGTGTTCGATGAGAACCGGTCCTGGTATCTGA
CCGAGAACATCCAGCGGTTTCTGCCCAACCCTGCCGGCGTGCAGCTGGA
AGATCCCGAGTTCAGGGCCAGCAACATCATGCACTCCATCAATGGCTAC
GTGTTGCGACTCTCTGCAGCTCTCCGTGTGTCTGCACGAGGTGGCCTACT
GGTACATCCTGAGCATCGGCGCCCCAGACCGACTTCCTGAGCGTGTTCCT
CAGCGGCTACACCTTCAAGCACAAAGATGGTGTACGAGGACACCCTGACC
CTGTTCCCTTTGAGCGGGGAGACAGTGTTTCATGAGCATGGAAAACCCCG
GCCTGTGGATTCTGGGCTGCCACAACAGCGACTTCCGGAACCGGGGGCAT
GACCGCCCTGCTGAAGGTGTCCAGCTGCGACAAGAACACCGGGCGACTAC
TACGAGGACAGCTACGAGGATATCAGCGCCTACCTGCTGTCCAAGAACA
ACGCCATCGAACCCCGGAGCTTCAGCCAGAACCCCCCGTGCTGACGCG
TCACCAGCGGGAGATCACCCGGACAACCCTGCAGTCCGACCAGGAAGAG
ATCGATTACGACGACACCATCAGCGTGGAGATGAAGAAAGAGGATTTCC
ATATCTACGACGAGGACGAGAACCAGAGCCCCAGAAGCTTCCAGAAGAA
AACCCGGCACTACTTCATTGCCGCCGTGGAGAGGCTGTGGGACTACGGC
ATGAGTTCTAGCCCCCACGTGCTGCGGAACCGGGGCCAGAGCGGCAGC
GTGCCCCAGTTCAAGAAAGTGGTGTTCAGGAATTCACAGACGGCAGCT
TCACCCAGCCTCTGTATAGAGGGCGAGCTGAACGAGCACCTGGGGCTGCT
GGGGCCCTACATCAGGGCCGAAGTGGAGGACAACATCATGGTGACCTTC
CGGAATCAGGCCAGCAGACCCTACTCCTTCTACAGCAGCCTGATCAGCT
ACGAAGAGGACCAGCGGCAGGGCGCCGAACCCCGGAAGAACTTCGTGA
AGCCCAACGAAACCAAGACCTACTTCTGGAAAGTGCAGCACCATGGC
CCCCACCAAGGACGAGTTCGACTGCAAGGCCTGGGCCTACTTCAGCGAC
GTGGATCTGGAAAAGGACGTGCACTCTGGACTGATTGGCCCACTCCTGG
TCTGCCACACTAACACCCTCAACCCCGCCACGGCCGCCAGGTGACCGT
GCAGGAATTCGCCCTGTTCTTCACCATCTTCGACGAGACAAAGTCCTGG
TACTTCACCGAGAATATGGAACGGAACCTGCAGAGCCCCCTGCAACATCC
AGATGGAAGATCCTACCTTCAAAGAGAACTACCGGTTCCACGCCATCAA
CGGCTACATCATGGACACCCTGCCTGGCCTGGTGATGGCCCAGGACCAG
AGAATCCGGTGGTATCTGCTGTCCATGGGCAGCAACGAGAATATCCACA
GCATCCACTTCAGCGGCCACGTGTTACCCGTGCGGAAGAAAAGAGTA
CAAGATGGCCCTGTACAACCTGTACCCCGGCGTGTTGAGACAGTGGAG
ATGCTGCCCAGCAAGGCCGGCATCTGGCGGGTGGAGTGTCTGATCGGC
GAGCACCTGCACGCTGGCATGAGCACCTGTTTCTGGTGTACAGCAACA
AGTGCCAGACCCCACTGGGCATGGCCTCTGGCCACATCCGGGACTTCCA
GATCACCGCCTCCGGCCAGTACGGCCAGTGGGCCCCCAAGCTGGCCAGA
CTGCACTACAGCGGCAGCATCAACGCCTGGTCCACCAAAGAGCCCTTCA
GCTGGATCAAGGTGGACCTGCTGGCCCCCTATGATCATCCACGGCATTA
GACCCAGGGCGCCAGGCAGAAAGTTCAGCAGCCTGTACATCAGCCAGTTC

ATCATCATGTACAGCCTGGACGGCAAGAAGTGGCAGACCTACCGGGGCA
ACAGCACCGGCACCCTGATGGTGTTCCTTCGGCAATGTGGACAGCAGCGG
CATCAAGCACAACATCTTCAACCCCCCATCATTGCCCCGGTACATCCGGC
TGCACCCCACTACTACAGCATTAGATCCACACTGAGAATGGAAGTGT
GGGCTGCGACCTGAACTCCTGCAGCATGCCTCTGGGCATGGAAAGCAAG
GCCATCAGCGACGCCCAGATCACAGCCAGCAGCTACTTCACCAACATGT
TCGCCACCTGGTCCCCCTCCAAGGCCAGGCTGCACCTGCAGGGGCCGGTC
CAACGCCTGGCGGCCTCAGGTCAACAACCCCAAAGAATGGCTGCAGGTG
GACTTTTCAGAAAACCATGAAGGTGACCGGCGTGACCACCCAGGGCGTGA
AAAGCCTGCTGACCAGCATGTACGTGAAAGAGTTTCTGATCAGCAGCTC
TCAGGATGGCCACCAGTGGACCCTGTTCTTTCAGAACGGCAAGGTGAAA
GTGTTCCAGGGCAACCAGGACTCCTTACCCCCCGTGGTGAAGTCCCTGG
ACCCCCCTGCTGACCCGCTACCTGAGAATCCACCCCCAGTCTTGGGT
GCACCAGATCGCCCTCAGGATGGAAGTCCTGGGATGTGAGGCCCAAGAT
CTGTACTGATGAGGATCTAGGCTCGACATGCTTTATTTGTGAAATTTGTGATG
CTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACA
ATTGCATTCATTTTATGTTTCAGGTTCAAGGGGAGGTGTGGGAGGTTTTTAAA
CTCGAGATCCACGGCCGACGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTC
TGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTGCCCCGACGCCCCG
GGCTTTGCCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGG
GCGCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATTTACACCCGA
TACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCG
GGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGC
CCGCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCCGCCGGCTTTCCCC
GTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGG
CACCTCGACCCCCAAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGGCCAT
CGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAAT
AGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCCTATCTCGGGCTATTC
TTTTGATTTATAAGGGATTTTGCCGATTTCCGGCCTATTGGTTAAAAAATGAGC
TGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATT
TTATGGTGCACCTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCC
CCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCG
GCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGA
GGTTTTACCCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACG
CCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTTCTTAGACGTCAGGTG
GCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATA
CATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATA
ATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTC
CCTTTTTTGCGGCATTTTGCCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGA
AAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACT
GGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTTC
CAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATT
GACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAAATGACT
TGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGT
AAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAAC

TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACA
ACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGA
AGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAAC
AACGTTGCGCAAACCTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAAC
AATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTC
GGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTG
GGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTAT
CGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA
CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGACC
AAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTTAATTTAAAA
GGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGT
GAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTT
CTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAAACCA
CCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTTCC
GAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTG
TAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT
CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTC
TTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAAGGCGCAGCGGTCTGGG
CTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACC
GAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAG
GGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGC
GCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGG
GTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGC
GGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTT
TGCTGGCCTTTTGCTCACATGT

Fig. 6

D

SEQ ID NO: 7

ATGCAGATCGAGCTGTCCACCTGCTTTTTTCTGTGCCTGCTGCGGTTCTGCTTCAG
 CGCCACCCGGCGGTAACCTGCGGCGCCGTGGAGCTGTCTGGGACTACATGCA
 GAGCGACCTGGGCGAGCTGCCCCGTGGACGCCCGGTTCCCCCCCAGAGTGCCCAA
 GAGCTTCCCCTTCAACACCAGCGTGGTGTACAAGAAAACCCTGTTCTGGAGTTCA
 CCGACCACCTGTTCAATATCGCCAAGCCCAGGCCCCCCTGGATGGGCCTGCTGGG
 CCCCACCATCCAGGCCGAGGTGTACGACACCGTGGTGTATCACCTGAAGAACATG
 GCCAGCCACCCCGTGAGCCTGCACGCCGTGGGCGTGAGCTACTGGAAGGCCAGC
 GAGGGCGCCGAGTACGACGACCAGACCAGCCAGCGGGAGAAAGAAGATGACAAG
 GTGTTCCCTGGCGGCAGCCACACCTACGTGTGGCAGGTGCTGAAAGAAAACGGCC
 CCATGGCCTCCGACCCCTGTGCCTGACCTACAGCTACCTGAGCCACGTGGACCT
 GGTGAAGGACCTGAACAGCGGCCTGATCGGCGCTCTGCTCGTCTGCCGGGAGGG
 CAGCCTGGCCAAAGAGAAAACCCAGACCCTGCACAAGTTCATCCTGCTGTTCCGCC
 GTGTTCCGACGAGGGCAAGAGCTGGCACAGCGAGACAAAGAACAGCCTGATGCAGG
 ACCGGGACGCCGCCTCTGCCAGAGCCTGGCCCAAGATGCACACCGTGAACGGCT
 ACGTGAACAGAAGCCTGCCCCGCCCTGATTGGCTGCCACCGGAAGAGCGTGTACTG
 GCACGTGATCGGCATGGGCACCCACCCGAGGTGCACAGCATCTTTCTGGAAGGG
 CACACCTTTCTGGTCCGGAACCCAGGCCAGGCCAGCCTGGAAATCAGCCCTATCA
 CTTTCTGACCGCCAGACACTGCTGATGGACCTGGGCCAGTTCTGCTGTTTTGC
 CACATCAGCTCTCACCAGCACGACGGCATGGAAGCCTACGTGAAGGTGGACTCTT
 GCCCCGAGGAACCCAGCTGCGGATGAAGAACAACGAGGAAGCCGAGGACTACG
 ACGACGACCTGACCGACAGCGAGATGGACGTGGTGCAGTTCCGACGACGACAACA
 GCCCCAGCTTCATCCAGATCAGAAGCGTGGCCAAGAAGCACCCCAAGACCTGGGT
 GCACTATATCGCCGCCGAGGAAGAGGACTGGGACTACGCCCCCCTGGTGCTGGC
 CCCCCGACGACAGAAGCTACAAGAGCCAGTACCTGAACAATGGCCCCAGCGGATC
 GGCCGGAAGTACAAGAAAGTGCGGTTTCATGGCCTACACCGACGAGACATTCAAGA
 CCGGGGAGGCCATCCAGCACGAGAGCGGCATCCTGGGCCCCCTGCTGTACGGCG
 AAGTGGGCGACACACTGCTGATCATCTTCAAGAACCAGGCTAGCCGGCCCTACAA
 CATCTACCCCCACGGCATCACCGACGTGCGGCCCTGTACAGCAGGCGGCTGCCC
 AAGGGCGTGAAGCACCTGAAGGACTTCCCCATCCTGCCCGGCGAGATCTTCAAGT
 ACAAGTGGACCGTGACCGTGGAGGACGGCCCCACCAAGAGCGACCCCAAGATGCC
 TGACCCGGTACTACAGCAGCTTCGTGAACATGGAACGGGACCTGGCCTCCGGGCT
 GATCGGACCTCTGCTGATCTGCTACAAAGAAAGCGTGGACCAGCGGGGCAACCAG
 ATCATGAGCGACAAGCGGAACGTGATCCTGTTGAGCGTGTTCGATGAGAACCAGG
 CCTGGTATCTGACCGAGAACATCCAGCGGTTTCTGCCCAACCCTGCCGGCGTGCA
 GCTGGAAGATCCCGAGTTCCAGGCCAGCAACATCATGCACTCCATCAATGGCTACG
 TGTTCCGACTCTCTGCAGCTCTCCGTGTGTCTGCACGAGGTGGCCTACTGGTACATC
 CTGAGCATCGGCGCCCAGACCGACTTCTGAGCGTGTCTTTCAGCGGCTACACCT
 TCAAGCACAGATGGTGTACGAGGACACCCCTGACCCTGTTCCCTTTCAGCGGCGA
 GACAGTGTTTCATGAGCATGGAAAACCCCGGCCTGTGGATTCTGGGCTGCCACAAC
 AGCGACTTCCGGAACCGGGGCATGACCGCCCTGCTGAAGGTGTCCAGCTGCGACA
 AGAACACCGGCGACTACTACGAGGACAGCTACGAGGATATCAGCGCCTACCTGCT
 GTCCAAGAACACGCCATCGAACCCCGGAGCTTCAGCCAGAACCCCCCGTGCTG
 ACGCGTCACCAGCGGGAGATCACCCGGACAACCCTGCAGTCCGACCAGGAAGAG
 ATCGATTACGACGACACCATCAGCGTGGAGATGAAGAAAGAGGATTCGATATCTA
 CGACGAGGACGAGAACCAGAGCCCCAGAAGCTTCCAGAAGAAAACCCGGCACTAC
 TTCATTGCCGCCGTGGAGAGGCTGTGGGACTACGGCATGAGTTCTAGCCCCACG

TGCTGCGGAACCGGGGCCAGAGCGGCAGCGTGCCCCAGTTCAAGAAAGTGGTGT
CCAGGAATTCACAGACGGCAGCTTCACCCAGCCTCTGTATAGAGGCGAGCTGAAC
GAGCACCTGGGGCTGCTGGGGCCCTACATCAGGGCCGAAGTGGAGGACAACATC
ATGGTGACCTTCCGGAATCAGGCCAGCAGACCCTACTCCTTCTACAGCAGCCTGAT
CAGCTACGAAGAGGACCAGCGGCAGGGCGCCGAACCCCGGAAGAACTTCGTGAA
GCCCCAACGAAACCAAGACCTACTTCTGGAAGTGCAGCACCACATGGCCCCCACC
AAGGACGAGTTGCACTGCAAGGCCTGGGCCTACTTCAGCGACGTGGATCTGGAAA
AGGACGTGCACTCTGGACTGATTGGCCCACTCCTGGTCTGCCACACTAACACCCTC
AACCCCGCCACGGCCGCCAGGTGACCGTGACGGAATTCGCCCTGTTCTTCACCA
TCTTCGACGAGACAAAGTCCTGGTACTTCACCGAGAATATGGAACGGAAGTGCAGA
GCCCCCTGCAACATCCAGATGGAAGATCCTACCTTCAAAGAGAACTACCGGTTCCA
CGCCATCAACGGCTACATCATGGACACCCTGCCTGGCCTGGTGTGGCCAGGAC
CAGAGAATCCGGTGGTATCTGCTGTCCATGGGCAGCAACGAGAATATCCACAGCAT
CCACTTCAGCGGCCACGTGTTCAACCGTGCGGAAGAAAGAGTACAAGATGGCC
CTGTACAACCTGTACCCCGGCGTGTTGAGACAGTGGAGATGCTGCCCAGCAAGG
CCGGCATCTGGCGGGTGGAGTGTCTGATCGGCGAGCACCTGCACGCTGGCATGA
GCACCCTGTTTCTGGTGTACAGCAACAAGTGCCAGACCCCACTGGGCATGGCCTC
TGGCCACATCCGGGACTTCCAGATCACCGCCTCCGGCCAGTACGGCCAGTGGGCC
CCCAAGCTGGCCAGACTGCACTACAGCGGCAGCATCAACGCCTGGTCCACCAAAG
AGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCTATGATCATCCACGGCATT
AAGACCCAGGGCGCCAGGCAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCA
TCATGTACAGCCTGGACGGCAAGAAGTGGCAGACCTACCGGGGCAACAGCACCGG
CACCCCTGATGGTGTTCCTCGGCAATGTGGACAGCAGCGGCATCAAGCACAACATCT
TCAACCCCCCATCATTGCCCGGTACATCCGGCTGCACCCCACTACAGCATT
AGATCCCACTGAGAATGGAAGTGTGGGCTGCGACCTGAACTCCTGCAGCATGC
CTCTGGGCATGGAAGCAAGGCCATCAGCGACGCCAGATCACAGCCAGCAGCTA
CTTCACCAACATGTTGCCCACCTGGTCCCCCTCCAAGGCCAGGCTGCACCTGCAG
GGCCGGTCCAACGCCTGGCGGCCTCAGGTCAACAACCCCAAAGAATGGCTGCAG
GTGGACTTTCAGAAAACCATGAAGGTGACCGGCGTGACCACCCAGGGCGTGAAAA
GCCTGCTGACCAGCATGTACGTGAAAGAGTTTCTGATCAGCAGCTCTCAGGATGGC
CACCAGTGGACCCTGTTCTTTCAGAACGGCAAGGTGAAAGTGTTCCAGGGCAACCA
GGACTCCTTCACCCCCGTGGTGAAGTCCCTGGACCCCCCTGCTGACCCGCTAC
CTGAGAATCCACCCCCAGTCTTGGGTGCACCAGATCGCCCTCAGGATGGAAGTCC
TGGGATGTGAGGCCCAGGATCTGTACTGATGA

Fig. 6
E

SEQ ID NO: 8

GGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCCAGTTATCGGAGGAGCAA
ACAGGGGCTAAGTCCAC

F

SEQ ID NO: 9

GTCTGTCTGCACATTTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAA
GGTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATAATCAGAA
TCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGG
GGTATAAAAGCCCCTTCACCAGGAGAAGCCGTC

G

SEQ ID NO: 10

AAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGNATTAATGTTTAATTACCT
GGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG

H

SEQ ID NO: 11

ATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGC
AATAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAG
GTGTGGGAGGTTTTTTAAA

Fig. 7





Fig. 8
A.




[illegible]

AGGGTGTATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG
AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCATCTCGGT
CTATTCTTTTGATTTATAAGGGATTTTGGGGATTTCCGGCCTATTGGTTAAAAAATGAGCTGATT
TAACAAAAATTTAACCGGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCC
CAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTG
TGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAG
CAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTCCGCCCATT
TCCGCCCCATGGCTGACTAATTTTTTTTATTTATGTCAGAGGCCGAGGCCGCCTCTGCCTCTGAG
CTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGA
GCTTGATATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAA
CAAGATGGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCCGGCTATGACTGG
GCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCC
GTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGG
CTATCGTGGCTGGCCACGACGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCG
GGAAGGGAGTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCT
CCTGCCGAGAAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCT
ACCTGCCCCATTTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTA CTCCGATGGAAGC
CGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTT
CGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCTGTACCCATGGCGATGCCT
GCTTGCCGAATATCATGGTGGAAAAATGGCCGCTTTTCTGGATTATCGACTGTGGCCGGCTGG
GTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCG
GCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCCGACGCGCATCG
CCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTGCAAAATGACCGACCA
AGCGACGCCCCAACCTGCCATCACGAGATTTTCGATTCCACCGCCGCTTCTATGAAAGGTTGGG
CTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGA
GTTCTTCGCCCACCCCAACTTGTTTATTGTCAGCTTATAATGGTTACAAATAAAGCAATAGCATC
ACAAATTTACAAATAAAGCATTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCA
ATGTAATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATA
GCTGTTTCCTGTGTGAATTGTTATCCGCTCACAAATCCACACAACATACGAGCCGGAAGCAT
AAAGTGTAAGCCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACT
GCCCCGTTTCCAGTCGGGAAACCTGTCTGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGG
GAGAGGCGGTTTGGCTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGT
GTTCCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCA
GGGGATAACGCAGGAAGAACAATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAA
AGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGAC
GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGA
AGCTCCCTCGTGCGCTCTCCTGTTCCGACCTGCGCGTTACCGGATACCTGTCCGCTTTCTCC
CTTCGGGAAGCGTGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCCGGTGTAGGTCGT
TCGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTTCAGCCCCGACCGCTGCGCCTTATCCGG
TAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGG
TAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAAGTGGTGGCCTA
ACTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCG
GAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTG
TTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTA
CGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAA
AAAGGATCTTACCTAGATCCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATAT
ATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCT
GTCTATTTCGTTTCATCCATAGTTGCCGTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGG
GCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATT
TATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGCTCCTGCAACTTTATCC
GCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCCGCCAGTTAATAGT
TTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGTTTGGTATGGCTT
CATTCAGCTCCGTTTCCAAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAG
CGGTTAGCTCCTTCGGTCTCCGATCGTTGTGCAAGTAAGTTGGCCGAGTGTTATCACTCAT

GGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACT
GGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCCG
GCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAA
ACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACC
CACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAA
ACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCA
TACTCTTCCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT
ATTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCC
ACCTGACGTC

Fig. 8

C.



Sequence information is provided for reference only. The coordinates are relative to the start of the minimal ITR (245bp) at 625..869. The map is not to scale.

Fig.8

D

SEQ ID NO: 13

CTAAATTGTAAGCGTTAATATTTTGTGTTAAAATTCGCGTTAAATTTTGTGTTAAATCAGCTCATTT
 TTAAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG
 GTTGAGTGTGTTCAGTTTGGAAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAA
 AGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAGTTT
 TTTGGGGTCCGAGGTGCCGTAAAGCACTAAATCGGAACCCCTAAAGGGAGCCCCCGATTTAGAG
 CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGAAGAAAGCGAAAGGAGCGG
 GCGCTAGGGCGCTGGCAAGTGTAGCGGTACGCTGCGCGTAACCACCACACCCGCCGCGCTT
 AATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTACAGGCTGCGCAACTGTTGGGAAGGGCG
 ATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATT
 AAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTGTAACACGACGGCCAGTGAGCGCG
 CTTAACCTAGAAAGATAATCATATTGTGACGTACGTTAAAGATAATCATGCGTAAATTTGAC
 GCATGTGTTTTATCGGTCTGTATATCGAGGTTTATTTATTAATTTGAATAGATATTAAGTTTTAT
 TATATTTACACTTACATACTAATAATAAATTCAACAAACAATTTATTTATGTTTATTTATTTATT
 AAAAAAAAAACAAAACTCAAAATTTCTTCTATAAAGTAACAAAACTTTATCGATAACTTCGT
 ATAATGTATGCTATACGAAGTTATagagggcggaagggacgttagggaggagcaggagagcaggagagcaggaggaac
 ggaggagGCGGCCGCGGTACCGGCGCGCGCGGGGAGGCTGCTGGTGAATATTAACCAAGGTCA
 CCCCAGTTATCGGAGGCAAAACAGGGGCTAAGTCCACACGCGTGGTACCGTCTGTCTGCAC
 ATTTCTAGAGCGAGTGTTCGATACTCTAATCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTT
 ACTTATTCTCCTTTTGTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCA
 GGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCTTCACCAGGAGAAGCCGTC
 ACACAGATCCACAAGCTCCTGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGNNATT
 AATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTCAGGTTGGCTAGTATGACAT
 CGAGCTGTCCACCTGCTTTTTTCTGTGCTGCTGCGGTTCTGCTTCAGCGCCACCCGGCGGTAC
 TACCTGGGCGCCGTGGAGCTGTCTGGGACTACATGCAGAGCGACCTGGGCGAGCTGCCCGT
 GGACGCCCCGTTCCCCCCCAGAGTGCCCCAAGAGCTTCCCTTCAACACCAGCGTGGTGTACAA
 GAAAACCCCTGTTCTGTGGAGTTACCCGACCACCTGTTCAATATCGCCAAGCCCAGGCCCCCCCTG
 GATGGGCGCTGCTGGGCCCCACCATCCAGGCCGAGGTGTACGACACCGTGGTGTATCACCTGA
 AGAATATGGCCAGCCACCCCGTGAGCCTGCACGCCGTGGGCGTGAGCTACTGGAAGGCCAGC
 GAGGGCGCCGAGTACGACGACCAGACCAGCCAGCGGGAGAAAGAGATGACAAGGTGTTCC
 CTGGCGGCAGCCACACCTACGTGTGGCAGGTGCTGAAAGAAAACGGCCCCATGGCTCCGAC
 CCCCTGTGCCTGACCTACAGCTACCTGAGCCACGTGGACCTGGTGAAGGACCTGAACAGCGGC
 CTGATCGGCGCTCTGCTCGTCTGCCGGGAGGGCAGCCTGGCCAAAGAGAAAAACCCAGACCCT
 GCACAAGTTCATCTGTGTTCCCGTGTTTCGACGAGGGCAAGAGCTGGCACAGCGAGACAA
 AGAACAGCCTGATGCAGGACCGGGACGCCGCTCTGCCAGAGCCTGGCCCCAAGATGCACACC
 GTGAACGGCTACGTGAACAGAAGCCTGCCCGGCCCTGATTGGCTGCCACCGGAAGAGCGTGTA
 CTGGCACGTGATCGGCATGGGCACACACCCGAGGTGCACAGCATCTTTCTGGAAGGGCACA
 CCTTCTGTTCCGGAACACCCGGCAGGCCAGCCTGGAAATCAGCCCTATCACCTTCCTGACCG
 CCCAGACACTGCTGATGGACCTGGGCCAGTTCTCTGCTGTTTTGCCACATCAGCTCTCACCAGC
 ACGACGGCATGGAAGCCTACGTGAAGGTGGACTCTTGCCCCGAGGAACCCAGCTGCGGATG
 AAGAACAACGAGGAAGCCGAGGACTACGACGACGACCTGACCAGACGAGATGGACGTGG
 TGCGGTTTCGACGACGACAACAGCCCCAGCTTCATCCAGATCAGAAGCGTGGCCAAAGAGCAC
 CCCAAGACCTGGGTGCACTATATCGCCGCCGAGGAAGAGGACTGGGACTACGCCCCCTGGT
 GCTGGCCCCCGACGACAGAAAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGCGGATCG
 GCCGGAAGTACAAGAAAGTGGGTTTCATGGCCTACACCGACGAGACATTCAAGACCCGGGAG
 GCCATCCAGCACGAGAGCGGCATCCTGGGCCCCCTGCTGTACGGCGAAGTGGGCGACACACT
 GCTGATCATCTTCAAGAACCAGGCTAGCCGGCCCTACAACATCTACCCCCACGGCATCACCGA
 CGTGCGGCCCCCTGTACAGCAGGCGGCTGCCAAGGGCGTGAAGCACCTGAAGGACTTCCCA
 TCCTGCCCCGCGAGATCTTCAAGTACAAGTGGACCGTGACCGTGGAGGACGCCCCACCAAG
 AGCGACCCCAGATGCCTGACCCGGTACTACAGCAGCTTCGTGAACATGGAACGGGACCTGGC

CTCCGGGCTGATCGGACCTCTGCTGATCTGCTACAAAGAAAGCGTGGACCAGCGGGGCAACC
 AGATCATGAGCGACAAGCGGAACGTGATCCTGTTTCAGCGTGTTCTGATGAGAACCCTGCTCTGGT
 ATCTGACCGAGAACATCCAGCGGTTTCTGCCAACCCCTGCCGGCGTGCAGCTGGAAGATCCCG
 AGTTCCAGGCCAGCAACATCATGCACTCCATCAATGGCTACGTGTTTCGACTCTCTGCAGCTCT
 CCGTGTGCTGTGCACGAGGTGGCCTACTGGTACATCCTGAGCATCGGCGCCAGACCGACTTCC
 TGAGCGTGTTCTTCAGCGGCTACACCTTCAAGCACAAGATGGTGTACGAGGACACCCTGACCC
 TGTTCCCTTTTCAGCGGCGAGACAGTGTTCATGAGCATGGAAAACCCCGGCCTGTGGATTCTGG
 GCTGCCACAACAGCGACTTCCGGAAACCGGGGCATGACCGCCCTGCTGAAGGTGTCCAGCTGC
 GACAAGAACACCGGCGACTACTACGAGGACAGCTACGAGGATATCAGCGCCTACCTGCTGTC
 CAAGAACAACGCCATCGAACCCCGGAGCTTCAGCCAGAACCCCCCGTGTGACGCGTCAAC
 AGCGGGAGATCACCCGGACAACCCCTGCAGTCCGACCAGGAAGAGATCGATTACGACGACACC
 ATCAGCGTGGAGATGAAGAAAGAGGATTTTCGATATCTACGACGAGGACGAGAACCAGAGCCC
 CAGAAGCTTCCAGAAGAAAACCCGGCACTACTTCATTGCCGCCGTGGAGAGGCTGTGGGACT
 ACGGCATGAGTTCTAGCCCCACGTGCTGCGGAACCGGGCCAGAGCGGCAGCGTGCCCCAG
 TTCAAGAAAGTGGTGTTCAGGAATTCACAGACGGCAGCTTCACCCAGCCTCTGTATAGAGGC
 GAGTGAACGAGCAGCTGGGGCTGCTGGGGCCCTACATCAGGGCCGAAGTGGAGGACAACAT
 CATGGTGACCTTCCGGAATCAGGCCAGCAGACCCCTACTCCTTCTACAGCAGCCTGATCAGCTA
 CGAAGAGGACCAGCGGCAGGGCGCCGAACCCCGGAAGAACTTCGTGAAGCCCAACGAAACC
 AAGACCTACTTCTGGAAAGTGACGACCCACATGGCCCCACCAAGGACGAGTTCGACTGCAA
 GGCCTGGGCTACTTCAGCGACGTGGATCTGGAAAAAGGACGTGCACTCTGGACTGATTGGCCC
 ACTCCTGGTCTGCCACACTAACACCCCTCAACCCCGCCACGGCCGCCAGGTGACCGTGCAGGA
 ATTCCGCCCTGTTCTTCACCATCTTCGACGAGACAAAGTCCCTGGTACTTCACCGAGAATATGGIA
 ACGGAACCTGCAGAGCCCCCTGCAACATCCAGATGGAAGATCCTACCTTCAAAAGAGAACTACC
 GGTTCACGCCATCAACGGCTACATCATGGACACCCCTGCCTGGCCTGGTGTATGGCCCAGGACC
 AGAGAATCCGGTGGTATCTGCTGTCCATGGGCAGCAACGAGAATATCCACAGCATCCACTTCA
 GCGGCCACGTGTTACCGTGCGGAAGAAAGAGGTACAAGATGGCCCTGTACAACCTGTAC
 CCCGGCGTGTTCGAGACAGTGGAGATGTGCCCCAGCAAGGCCGGCATCTGGCGGGTGGAGTG
 TCTGATCGGCGAGCACCTGCACGCTGGCATGAGCACCCCTGTTTCTGGTGTACAGCAACAAGTG
 CCAGACCCCACTGGGCATGGCCTCTGGCCACATCCGGGACTTCCAGATCACCGCCTCCGGCCA
 GTACGGCCAGTGGGCCCCCAAGCTGGCCAGACTGCACTACAGCGGCAGCATCAACGCCTGGT
 CCACCAAAGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCATGATCATCCACGGCA
 TTAAGACCCAGGGCGCCAGGCAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCATCATGT
 ACAGCCTGGACGGCAAGAAGTGGCAGACCTACCGGGCAACAGCACCGGCACCCCTGATGGTG
 TTCTTCGGCAATGTGGACAGCAGCGGCATCAAGCACAACATCTTCAACCCCCCATCATTTGCC
 CGGTACATCCGGCTGCACCCCACTACAGCATTAGATCCACACTGAGAATGGAAGTGTATG
 GGCTGCGACCTGAACTCCTGCAGCATGCCTCTGGGCATGGAAAGCAAGGCCATCAGCGACGC
 CCAGATCACAGCCAGCAGCTACTTCACCAACATGTTCCGCCACCTGGTCCCCCTCCAAGGCCAG
 GCTGCACCTGCAGGGCCGGTCCAACGCCTGGCGGCCCTCAGGTCAACAACCCCAAGAAATGGC
 TGCAGGTGGACTTTTCAGAAAACCATGAAGGTGACCGGCGTGACCACCCAGGGCGTGAAAAGC
 CTGCTGACCAGCATGTACGTGAAAAGAGTTTCTGATCAGCAGCTCTCAGGATGGCCACCAGTGG
 ACCCTGTTCTTTTCAGAACGGCAAGGTGAAAAGTGTTCAGGGCAACCAGGACTCCTTCACCCCC
 GTGTGAACTCCCTGGACCCCCCTGCTGACCCGCTACCTGAGAATCCACCCCCAGTCTTGG
 GTGCACCAGATCGCCCTCAGGATGGAAGTCTGGGATGTGAGGCCCAGGATCTGTACTGATG
 AGGATCTAGGCTCGACATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCAT
 TATAAGCTGCAATAAAACAAGTTAACAACAACAATTGCATTTCATTTTATGTTTCAGGTTCAAGG
 GGAGGTGTGGGAGGTTTTTTAACTCGAGACCGGTagagggcggaaggacgttaggagggaggcaggagggcag
 ggagggcaggaggaacggaggagATAACTTCGTATAATGTATGCTATACGAAGTTATGATATCTATAAC
 AAGAAAATATATATATAATAAGTTATCACGTAAGTAGAACACGAAATAACAATATAATTATC
 GTATGAGTTAAATCTTAAAGTCAAGTAAAAGATAATCATGCGTCAATTTTGACTCACGCGGTT
 GTTATAGTTCAAAATCAGTGACACTTACCGCATTGACAAGCACGCTCACGGGAGCTCCAAGC
 GCGACTGAGATGTCCTAAATGCACAGCGACGGATTTCGCGCTATTTAGAAAAGAGAGAGCAAT
 ATTTCAAGAAATGCATGCGTCAATTTTACGCAGACTATCTTTCTAGGGTTAAGCGCGCTTGGCGT
 AATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCACACAACATACG
 AGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTG

CGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCG
GCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTCCGCTTCCTCGCTCACTGACT
CGCTGCGCTCGGTTCGTTCCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGT
TATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGC
CAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCA
TCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGG
CGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCT
GTCCGCTTTCTCCCTTCGGGAAGCGTGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGT
TCGGTGTAGGTCGTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACAGCCGACCGC
TGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTG
GCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAA
GCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAG
CGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGT
CATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC
TATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACT
ACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTC
ACCGGCTCCAGATTTATCAGCAATAAACCCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC
CTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTC
GCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTC
GTTTGGTATGGCTTCATTTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCAT
GTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAAAGTAAGTTGGCCGC
AGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGA
TGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGATGCGGCGACCG
AGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTG
CTCATCATTGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCC
AGTTGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTTACTTTACCAGCGTTT
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAA
ATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCA
TGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGGCACATTT
CCCGAAAAGTGCCAC

Fig.8

E




Fig. 8

F

SEQ ID NO:14

CTAAATTGTAAGCGTTAATATTTTGTGTTAAAATTCGCGTTAAATTTTTGTGTTAAATCAGCTCATTT
TTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG
GTTGAGTGTGTTCCAGTTTGGAAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAA
AGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAGTTT
TTTGGGGTTCGAGGTGCCGTAAAGCACTAAATCGGAACCTAAAGGGAGCCCCCGATTTAGAG
CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGAAGAAAGCGAAAGGAGCGG
GCGCTAGGGCGCTGGCAAGTGTAGCGGTACGCTGCGCGTAACCACCACACCCGCCGCGCTT
AATGCGCCGCTACAGGGCGCGTCCCATTGCGCCATTACAGGCTGCGCAACTGTTGGGAAGGGCG
ATCGGTGCGGGCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATT
AAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTGTAACGACGGCCAGTGAGCGCG
CTTAACCCCTAGAAAGATAATCATATTGTGACGTACGTTAAAGATAATCATGCGTAAAAATTGAC
GCATGATAAATTCTGATAATGTATGCTATACGAAGTTATGCGGCCGCGGTACCGGCGCGCCGG
GGGAGGCTGCTGGTGAATATTAACCAAGGTACCCCAAGTTATCGGAGGAGCAACAGGGGCT
AAGTCCACACGCGTGGTACCGTCTGTCTGCACATTTCGTAGAGCGAGTGTCCGATACTCTAA
TCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATA
ATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTGGAAGGAGGG
GGTATAAAAGCCCCCTTACCAGGAGAAAGCCGTCACACAGATCCACAAGCTCCTGAAGAGGTA
AGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCGTA
AATCACTTTTTTTCAGGTTGGGCTAGCCCAACATGCAGCGCGTGAACATGATCATGGCCGAGA
GCCCCGGCCTGATCACCATCTGCCTGCTGGGCTACCTGCTGAGCGCCGAGTGCACCGTGTTC
TGGACCACGAGAACGCCAACAAAGATCCTGAACCGCCCCAAGCGCTACAACAGCGGCAAGCTG
GAGGAGTTTCGTGCAGGGCAACCTGGAGCGCGAGTGCATGGAGGAGAAGTGCAGCTTCGAGGA
GGCCCCGCGAGGTGTTTCGAGAACACCGAGCGCACCCAGGTTCTGGAAGCAGTACGTGGACG
GCGACCAGTGCAGAGCAACCCCTGCCTGAACGGCGGCAGCTGCAAGGACGACATCAACAGC
TACGAGTGTGGTGGCCCTTCGGCTTCGAGGGCAAGAACTGCGAGCTGGACGTGACCTGCAAC
ATCAAGAACGGCCGCTGCGAGCAGTTCTGCAAGAACAGCGCCGACAACAAGGTGGTGTGCAG
CTGCACCGAGGGCTACCGCTGGCCGAGAACAGAGCTGCGAGCCCCCGCTGCCCTTCC
CCTGCGGCCGCGGTGAGCGTGAGCCAGACCAGCAAGCTGACCCGCGCCGAGGCCGTGTTCCCC
GACGTGGACTACGTGAACAGCACCCGAGGCCGAGACCATCCTGGACAACATCACCCAGAGCAC
CCAGAGCTTCAACGACTTCAACCGCGTGGTGGGCGGCGAGGACGCCAAGCCCGGCCAGTTCC
CCTGGCAGGTGGTGTGAACGGCAAGGTGGACGCTTCTGCGGCGGCGAGCATCGTGAACGAG
AAGTGGATCGTGACCGCCGCCCACTGCGTGGAGACCGGCGTGAAGATCACCGTGGTGGCCGG
CGAGCACAACTCGAGGAGACCGAGCACACCGAGCAGAAGCGCAACGTGATCCGCATCATCC
CCCACCACAACTACAACGCCGCCATCAACAAGTACAACCACGACATCGCCCTGCTGGAGCTG
GACGAGCCCCCTGGTGTGAACAGCTACGTGACCCCCATCTGCATCGCCGACAAGGAGTACAC
CAACATCTTCCTGAAGTTCGGCAGCGGCTACGTGAGCGGCTGGGGCCGCGTGTCCACAAGGG
CCGCAGCGCCCTGGTGTGACGTACCTGCGCGTGGCCCTGGTGGACCGCGCCACCTGCCTGCG
CAGCACCAGTTACCATCTACAACAACATGTTCTGCGCCGGCTTCCACGAGGGCGGCCGGA
CAGCTGCCAGGGCGACAGCGGCGGCCCCACGTGACCGAGGTGGAGGGCACCAGCTTCTGA
CCGGCATCATCAGCTGGGGCGAGGAGTGCGCCATGAAGGGCAAGTACGGCATCTACACCAAG
GTGAGCCGCTACGTGAACCTGGATCAAGGAGAAGACCAAGCTGACCTAATGAAAGATGGATTT
CCAAGGTTAATTCAATTGGAATTGAAAATTAACAGCCCCCCCCCCCCCCCCCTGCAGATCTAG
AGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTCCCCCTCCCC
GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCTTCTTAATAAAATGAGGAAAT
GCATCGCATTTGTCTGAGTAGGTGTCTATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAG
GGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGACCGGTATAACTTCGTATAATGTAT
GCTATACGAAGTTATGTCATGCGTCAATTTTACGCAGACTATCTTTCTAGGGTTAAGCGCGCTTG
GCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACA
TACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTA

ATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGA
ATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGGCGCTCTCCGCTTCCTCGCTCACT
GACTCGCTGCGCTCGGTGCTTCCGCTGCGGGCAGCGGTATCAGCTCACTCAAAGGCGGTAAATA
CGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAA
AGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACG
AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC
CAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCCTGCCGCTTACCGGAT
ACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGA
CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCC
ACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT
TCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGC
TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTG
GTAGCGGTGGTTTTTTTTGTTTGCAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAA
GATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTAAAGGGATT
TTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG
GCACCTATCTCAGCGATCTGTCTATTTTCGTTTATCCATAGTTGCCTGACTCCCCGTCGTGTAGA
TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCAC
GCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAAGT
GGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGT
AGTTCGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCT
CGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCC
CATGTTGTGCAAAAAAGCGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAAGTAAGTTGGC
CGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTA
AGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGA
CCGAGTTGCTCTTGGCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAA
GTGTCATCATTGGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGA
TCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTTACCAGCG
TTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACG
GAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGT
CTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACA
TTCCCCGAAAAGTGCCAC

Fig. 8

G




Fig. 8

H

SEQ ID NO:15

CTAAATTGTAAGCGTTAATATTTTGTGTTAAAATTCGCGTTAAATTTTTGTGTTAAATCAGCTCATTT
TTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG
GTTGAGTGTGTTCAGTTTGGAAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAA
AGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAGTTT
TTTGGGGTTCGAGGTGCCGTAAAGCACTAAATCGGAACCTAAAGGGAGCCCCCGATTTAGAG
CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGAAAGCGAAAGGAGCGG
GCGCTAGGGCGCTGGCAAGTGTAGCGGTACGCTGCGCGTAACCACCACACCCGCCGCGCTT
AATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTACAGGCTGCGCAACTGTTGGGAAGGGCG
ATCGGTGCGGGCTCTTCGCTATTACGCCAGCTGCGGAAAGGGGGATGTGCTGCAAGGCGATT
AAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGCGCG
CTTAACCCCTAGAAAGATAATCATATTGTGACGTACGTTAAAGATAATCATGCGTAAAAATTGAC
GCATGATAAATTCTGATAATGTATGCTATACGAAGTTATGCGGCCGCGGTACCGGCGCGCCGG
GGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCAGTTATCGGAGGAGCAAACAGGGGCT
AAGTCCACACGCGTGGTACCGTCTGTCTGCACATTTCGTAGAGCGAGTGTCCGATACTCTAA
TCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTCAATA
ATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTGGAAGGAGGG
GGTATAAAAAGCCCCCTCACCAAGGAGAAAGCCGTCACACAGATCCACAAGCTCCTGAAGAGGTA
AGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCGTA
AATCACTTTTTTTCAGGTTGGGCTAGCCACCATGTCAGCGCGTGAACATGATCATGGCCGAGA
GCCCCGGCCTGATCACCATCTGCCTGCTGGGCTACCTGCTGAGCGCCGAGTGCACCGTGTTC
TGGACCACGAGAACGCCAACAAGATCCTGAACCGCCCCAAGCGCTACAACAGCGGCAAGCTG
GAGGAGTTTCGTGCAGGGCAACCTGGAGCGCGAGTGCATGGAGGAGAAGTGCAGCTTCGAGGA
GGCCCCGCGAGGTGTTTCGAGAACACCGAGCGCACCCAGGTTCTGGAAGCAGTACGTGGACG
GCGACCAGTGCAGAGCAACCCCTGCCTGAACGGCGGCAGCTGCAAGGACGACATCAACAGC
TACGAGTGTGGTGGCCCTTCGGCTTCGAGGGCAAGAACTGCGAGCTGGACGTGACCTGCAAC
ATCAAGAACGGCCGCTGCGAGCAGTTCTGCAAGAACAGCGCCGACAACAAGGTGGTGTGCAG
CTGCACCGAGGGCTACCGCTGGCCGAGAACAGAGCTGCGAGCCCCCGCTGCCCTTCC
CCTGCGGGCCGCGTGAGCGTGAGCCAGACCAGCAAGCTGACCCGCGCCGAGGCCGTGTTCCCC
GACGTGGACTACGTGAACAGCACCCGAGGCCGAGACCATCCTGGACAACATCACCCAGAGCAC
CCAGAGCTTCAACGACTTCAACCGCGTGGTGGGCGGCGAGGACGCCAAGCCCGGCCAGTTCC
CCTGGCAGGTGGTGTGAACGGCAAGGTGGACGCCTTCTGCGGCGGCAAGCATCGTGAACGAG
AAGTGGATCGTGACCGCCGCCCACTGCGTGGAGACCGGCGTGAAGATCACCGTGGTGGCCGG
CGAGCACAACTCGAGGAGACCGAGCACACCGAGCAGAAGCGCAACGTGATCCGCATCATCC
CCCACCACAACTACAACGCCGCCATCAACAAGTACAACCACGACATCGCCCTGCTGGAGCTG
GACGAGCCCCCTGGTGTGAACAGCTACGTGACCCCCATCTGCATCGCCGACAAGGAGTACAC
CAACATCTTCCTGAAGTTCGGCAGCGGCTACGTGAGCGGCTGGGGCCGCGTGTTCACAAGGG
CCGCAGCGCCCTGGTGTGTCAGTACCTGCGCGTGGCCCTGGTGGACCGCGCCACCTGCCTGCT
GAGCACCAGTTACCATCTACAACAACATGTTCTGCGCCGGCTTCCACGAGGGCGGCCGGA
CAGCTGCCAGGGCGACAGCGGCGGCCCCACGTGACCGAGGTGGAGGGCACCAGCTTCCTGA
CCGGCATCATCAGCTGGGGCGAGGAGTGCGCCATGAAGGGCAAGTACGGCATCTACACCAAG
GTGAGCCGCTACGTGAACCTGGATCAAGGAGAAGACCAAGCTGACCTAATGAAAGATGGATTT
CCAAGGTTAATTCAATTGGAATTGAAAATTAACAGCCCCCCCCCCCCCCCCCTGCAGATCTAG
AGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCTTCCCC
GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCTTCTTAATAAAATGAGGAAAT
GCATCGCATTTGTCTGAGTAGGTGTCTATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAG
GGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGACCGGTATAACTTCGTATAATGTAT
GCTATACGAAGTTATGCATGCGTCAATTTTACGCAGACTATCTTTCTAGGGTTAAGCGCGCTTG
GCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCACACAACA
TACGAGCCGGAAGCATAAAGTGTAAGCCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTA

ATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGA
ATCGGCCAACGCGCGGGGAGAGGCGGTTTGCCTATTGGGCGCTCTCCGCTTCCTCGCTCACT
GACTCGCTGCGCTCGGTGCTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATA
CGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAA
AGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACG
AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC
CAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCCTGCCGCTTACCGGAT
ACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTAGGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGA
CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCC
ACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT
TCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGC
TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTG
GTAGCGGTGGTTTTTTTTGTTTGCAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAA
GATCCTTTGATCTTTTCTACGGGCTGACGCTCAGTGGAACGAAAACTCACGTAAAGGGATT
TTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG
GCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGA
TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCAC
GCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAAGT
GGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGT
AGTTCGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCT
CGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCC
CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGC
CGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTA
AGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGA
CCGAGTTGCTCTTCCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAA
GTGTCATCATTGGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGA
TCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTTACCAGCG
TTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGCGGACACG
GAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGT
CTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACA
TTCCCCGAAAAGTGCCAC

Fig. 8




Fig. 8
J




Fig. 8
K

SEQ ID NO: 17

GACGGATCGGGAGATCTCCCGATCCCCATATGGTCTGACTCTCAGTACAATCTGCTCTGATGCCG
CATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTGGAGGTCGCTGAGTAGTGCGCGAGCA
AAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTT
AGGCGTTTTGCGCTGCTTCGCGCTGGAGCTAGTTATTAATAGTAATCAATTACGGGGTCATT
AGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCCGCCTGGCTG
ACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGTCAAT
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTACA
TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCCTG
GCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTC
ATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTTGAC
TCACGGGGATTTCACAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTTTTGGCACCAAAAT
CAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGT
GTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACG
CCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGATTCCGA
ATCCCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACC
GCCTATAGAGTCTATAGGCCACAAAAAATGCTTTCTTCTTTAATACTTTTTTGTATTATCTT
ATTTCTAATACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTT
TGCAACATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCAT
ATAAATATTTCTGCATATAAATTGTAAGTGTAGTAAGAGGTTTCATATTGCTAATAGCAGCTA
CAATCCAGCTACCATTTCTGCTTTTATTTATGTTGGGATAAGGCTGGATTATTCTGAGTCCAA
GCTAGGCCCTTTTGCTAATCATGTTTCATACCTCTTATCTTCTCCACAGCTCTTGGGCAACGT
GCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTGGGATTTCGAACATCGATGCCGCCA
CCATGGGAAAATCAAAAGAAATCAGCCAAGACCTCAGAAAAAGAATTGTAGACCTCCACAAG
TCTGGTTCATCCTTTGGGAGCAATTTCCCGACGCTGGCGGTACCACGTTTCATCTGTACAAACA
ATAGTACGCAAGTATAAACACCATGGGACCAACGACGCGCTCATACCGTTCAGGAAGGAGACG
CGTCTGTCTCTAGAGATGAACGTACTTTGGTGCGAAAAGTGCAAATCAATCCAGAACAAAC
AGCAAAGGACCTTGTGAAGATGCTGGAGGAAACAGGTACAAAAGTATCTATATCCACAGTAA
AACGAGTCTATATCGACATAACCTGAAAGGCCACTCAGCAAGGAAGAAGCCACTGCTCCAA
AACCAGACATAAGAAAGCCAGACTACGGTTTGCAACTGCACATGGGGACAAAGATCTAATTTT
TTGGAGAAATGTCTCTGGTCTGATGAAACAAAAATAGAACTGTTTGGCCATAATGACCATCG
TTATGTTTGGAGGAAGAAGGGGGAGGCTTGCAAGCCGAAGAACACCATCCCAACCGTGAAGC
ACGGGGGTGGCAGCATCATGTTGTGGGGGTGCTTTGCTGCAGGAGGGACTGGTAAACTTGTCC
GAATAGAAGGCATCATGGACGCGGTGCAGTATGTGGATATATTGAAGCAACATCTCAAGACA
TCAGTCAGGAAGTTAAAGCTTGGTCGCAAAATGGGTCTTCCAACACGACAATGACCCCAAGCAT
ACTTCCAAAGTTGTGGCAAAATGGCTTAAGGACAACAAAGTCAAGGTATTGGACTGGCCATC
ACAAAGCCCTGACCTCAATCCTATAGAAAAATTTGTGGGCAGAACTGAAAAAGCGTGTGCGAG
CAAGGAGGCCTACAAACCTGACTCAGTTACACCAGCTCTGTGAGGAGGAATGGGCCAAAATT
CACCCAAATTATTGTGGGAAGCTTGTGGAAGGCTACCCGAAACGTTTGACCCAAGTTAAACAA
TTTAAAGGCAATGCTACCAAATACTAGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTG
TCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTT
GTTTGGCCCTCCCCCGTGCCTTCTTGACCCTGGAAGGTGCCACTCCCACTGTCTTTCTAAT
AAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGG
GGCAGGACAGCAAGGGGGGAGGATTGGGAAAGACAATAGCAGGCATGCTGGGGATGCGGTGGG
CTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTG
TAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCA
GCGCCCTAGCGCCCGCTCCTTTCTGCTTCTTCCCTTCTTCTCGCCACGTTTCGCCGGCTTTCCC
CGTCAAGCTCTAAATCGGGGCAATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACC
CCAAAAAATTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTC

GCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACAACACT
CAACCCATCTCGGTCTATTCTTTTGATTATAAGGGATTTTGGGGATTTTCGGCCTATTGGTTA
AAAAATGAGCTGATTTAACAAAAATTTAACCGGAATTAATTCTGTGGAATGTGTGTCAAGTTAG
GGTGTGAAAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTA
GTCAGCAACCAGGTGTGGAAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAGTATGCAAAGCATGC
ATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCATCCCCCCCCCTAACTCCGCC
CAGTTCCGCCCATTTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCC
GCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCCTAGGCTTTTGC
AAAAAGCTCCCCGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCG
TTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTA
TTCCGCTATGACTGGGCACAACAGACAAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCA
GCGCAGGGGGCGCCCGTTCTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAG
GACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCTTGGCAGCTGTGCTCGAC
GTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTTGGCGGAAGTGCCGGGGCAGGATCTCCT
GTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCCGGCGGTGCA
TACCTGTGATCCCGGTACCTGCCATTCCAGACCACCAAGCGAAACATCGCATCGAGCGAGCAG
TACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCG
CGCCAGCCGAACGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCTGTG
ACCCATGGCGATGCCGTGTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCTC
GACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATT
GCTGAAGAGCTTGGCGCGGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCC
GATTCCGAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTT
CGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTTCGATTCCACCGCCGCCTT
CTATGAAAGGTTGGGCTTCGGAATCGTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGG
GGATCTCATGCTGGAGTCTTTCGCCCAACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAA
TAAAGCAATAGCATCACAAATTTACAAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTT
TGTCAAAACATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGC
GTAATCATGGTCATAGCTGTTTCCCTGTGTGAAATTGTTATCCGCTCACAAATCCACACAACATA
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAAT
TGCGTTGCGCTCACTGCCCCGTTTTCCAGTCGGGAAACCTGTCTGTGCCAGCTGCATTAATGAAT
CGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTCCGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTTCGCTGCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACG
GTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAAG
GCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAG
CATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCA
GGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCGGACCTGCCGCTTACCGGATAC
CTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCA
GTTCCGTTGTAGGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCCACC
GCTGCGCCTTATCCGGTAACATATCGTCTTGAGTCCAACCCGTAAGACACGACTTATCGCCAC
TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTC
TTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTG
AAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGT
AGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA
TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGGATTTTG
GTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTAA
TCAATCTAAAATATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCA
CCTATCTCAGCGATCTGTCTATTTTCGTTTATCCATAGTTGCCTGACTCCCCGTCTGTAGATAA
CTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT
CACC GGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGT
CCTGCAACTTTATCCGCCCTCCATCCAGTCTATTAATTTGTTGCCGGGAAGCTAGAGTAAGTAGTT
CGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTC
GTTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCAT
GTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAAGTAAGTTGGCCGC
AGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTATGCCATCCGTAAGA

TGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCG
AGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTG
CTCATCATTGGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCC
AGTTCGATGTAACCCACTCGTGACCCCACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTT
CTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAA
ATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCA
TGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGGCACATTC
CCCGAAAAGTGCCACCTGACGTC

Fig. 9




Fig. 10




Fig. 11






Fig. 12


A.



B



C



D





Fig. 12

E.



F.





Fig. 12

G.



H.





Fig. 13

A.



B.





Fig. 13

C.



D.





Fig. 14

A.



B.





Fig. 14

C.



D.






Fig. 15


A



B



C



D




Fig. 15

E





Fig. 15

F



G




Fig. 15

H






Fig. 15

J



K

